



UNIVERSIDAD DE GRANADA

Facultad de Medicina
Departamento de Pediatría

ANÁLISIS DE LOS EFECTOS A LARGO PLAZO DE LA NUTRICIÓN PRECOZ SOBRE EL NEURODESARROLLO EN LOS NIÑOS MEDIANTE TÉCNICAS DE MINERÍA DE DATOS: BASE DE DATOS NUTRIMENTHE

TESIS DOCTORAL

Hatim Azaryah

Programa de Doctorado en Medicina Clínica y Salud Pública

Granada 2020

Editor: Universidad de Granada. Tesis Doctorales
Autor: Hatim Azaryah
ISBN: 978-84-1306-710-0
URI: <http://hdl.handle.net/10481/65323>

MEMORIA PRESENTADA POR EL DOCTORANDO

HATIM AZARYAH

**PARA OPTAR AL GRADO DE DOCTOR
PROGRAMA DE DOCTORADO EN MEDICINA CLINICA Y SALUD
PÚBLICA**

Esta Tesis Doctoral ha sido dirigida por:

Prof. Dra. Dña. Cristina Campoy Folgoso

DEPARTAMENTO DE PEDIATRÍA
FACULTAD DE MEDICINA
UNIVERSIDAD DE GRANADA

"If a machine is expected to be infallible, it cannot also be intelligent."
Alan Turing

TESIS DOCTORAL

HATIM AZARYAH

FINANCIACIÓN

Los resultados presentados en esta Tesis Doctoral se han obtenido en el marco de diferentes proyectos financiados por la Unión Europea: NUTRIMENTHE EU Project, titulado: "The effect of diet on the mental performance of children (7th Framework Program – FP7/2008-2013), Contrato Nº: 212652; EARNEST EU Project titulado: "Early programming and long term consequences" (6th Framework Program – FP6/2005-2010), Contrato Nº: 007036; y parcialmente por el NUHEAL EU Project: "Nutraceuticals for a Healthier Life" - 5th Framework - Contrato Nº: QLK1-CT-1999-00888.



TESIS DOCTORAL

HATIM AZARYAH

AGRADECIMIENTOS

Puedo decir con total seguridad que la realización de este doctorado ha sido y será una de las tareas más arduas que he desempeñado, no sólo por las dificultades intrínsecas que acarrea dicha labor, sino por la necesidad de adaptarme a una línea de investigación lejana a mi formación original.

Este hecho no habría sido posible sin el apoyo moral, financiero y educativo de mi Tutora y Directora de la Tesis, la Profesora del Departamento de Pediatría de la Universidad de Granada, Cristina Campoy. Ella ha sido la artífice de éste trabajo por el constante apoyo que he recibido estos años de andadura en la interesante línea de investigación en la que se enmarca esta tesis.

En segundo lugar me gustaría agradecer a mis padres su apoyo moral e insistencia, que han supuesto en todo momento un gran estímulo a la hora de finalizar el doctorado.

Igualmente quiero mencionar de una forma muy especial a mis compañeros del Centro de Excelencia de Investigación Pediátrica EURISTIKOS, por su generosidad al ofrecerme los resultados fruto del tremendo esfuerzo realizado en la captación y seguimiento de las madres y niños durante más de 12 años, y que ha permitido que esta tesis doctoral sea una realidad. Por la ayuda constante que he

recibido de su parte en cada momento y el apoyo incondicional que me han brindado en los momentos más difíciles de esta aventura.

También quiero agradecer el apoyo recibido por el Prof. Berthold Koletzko de la Ludwig-Maximilians University of Múnich (Estudio CHOP y NUHEAL), al Prof. Tamas Decsi de la University of Pécs (Estudio NUHEAL) y al Prof. Henning Teimeier de Erasmus Medical Centre de Róterdam (Generation R). Todos ellos como responsables de los estudios CHOP, NUHEAL y Generation R en sus respectivos centros han aportado junto a sus colaboradores su trabajo, experiencia y gran conocimiento para que esta Tesis sea una realidad. Por todo ello, muchas gracias.

No puedo dejar de agradecer a las madres y niños participantes en los diferentes estudios presentados en esta Tesis Doctoral procedentes de 7 países europeos, por su paciencia y actitud desinteresada de colaboración que han manifestado durante tantos años.

Por último y no menos importante, agradecer a la Universidad de Granada que me haya brindado la oportunidad de formarme al más alto nivel. Gracias por todo.

TABLA DE CONTENIDOS

	Pág.
ABREVIATURAS.....	1
RESUMEN.....	5
INTRODUCCIÓN.....	13
Impacto de factores socio-ambientales sobre el neurodesarrollo..	18
Desarrollo del cerebro fetal.....	21
Nutrición prenatal y neurodesarrollo.....	24
Ácidos grasos poliinsaturados de cadena larga (LC-PUFAs).....	25
Ácido Fólico.....	30
Impacto de diferentes polimorfismos genéticos.....	31
Velocidad de procesamiento y desarrollo cognitivo.....	33
Nutrición y conectividad funcional.....	34
HIPÓTESIS Y OBJETIVOS.....	37
MATERIAL Y MÉTODOS.....	43
Análisis de Minería de datos.....	45
Proyecto NUTRIMENTHE.....	51
Estudio del neurodesarrollo.....	54
Estudio de la conducta.....	55
Análisis bioquímicos (NUHEAL Follow-Up).....	56
Análisis de neuroimagen (NUHEAL Follow-Up).....	58
Variables confusoras.....	60
Análisis estadístico.....	61
PUBLICACIONES.....	63
Minería de datos aplicada.....	65
Estudio 1.....	73
Estudio 2.....	95
Estudio 3.....	129
DISCUSIÓN.....	153
CONCLUSIONES.....	177
BIBLIOGRAFÍA.....	181
ANEXO.....	205

TESIS DOCTORAL

HATIM AZARYAH

TESIS DOCTORAL

HATIM AZARYAH

ABREVIATURAS

TESIS DOCTORAL

HATIM AZARYAH

ABREVIATURAS

- 5-MTHF - 5-metiltetrahidrofolato
ALA - Ácido a-linolénico
ARA - Ácido Araquidónico
CBCL - Child Behaviour Checklist
CHOP - Childhood Obesity Project
DHA - Ácido Docosahexaenoico
DMN - Red Neuronal por Defecto
EPA - Ácido Eicosapentaenoico
FO – Fish Oil (Aceite de pescado)
FPN - Red Neuronal Frontoparietal
HPG - Proyecto Genoma Humano
ICA - Análisis de Componentes Independientes
KDD - Knowledge Discovery in Databases
LA - Ácido linoleico
LC-PUFAs - Ácidos grasos poliinsaturados de cadena larga
NNB – NUTRIMENTHE Neuropsychological Battery
NUHEAL - Nutraceuticals for a Healthy Life
PCA - Análisis de Componentes Principales
SMN - Red Neuronal Sensoriomotriz
TEA - Trastornos del Espectro Autista
TDAH - Trastorno por Déficit de Atención e Hiperactividad
rs-fMRI - Resonancia Magnética Funcional en reposo

TESIS DOCTORAL

HATIM AZARYAH

RESUMEN

RESUMEN

El estado nutricional y la alimentación materna durante la gestación van a jugar un papel fundamental en el neurodesarrollo de los niños. La deficiencia de nutrientes funcionales en periodos críticos del desarrollo, puede acarrear alteraciones del desarrollo estructural y funcional del cerebro de los niños con consecuencias en el neurodesarrollo a largo plazo.

El proyecto NUTRIMENTHE ha permitido obtener una ingente cantidad de datos que ha facilitado evaluar el efecto de la dieta sobre el rendimiento mental de los niños procedentes de siete países de la Unión Europea mediante la creación de la base global NUTRIMENTHE. La base NUTRIMENTHE está compuesta por tres cohortes: a) **Proyecto NUHEAL Follow-up** (*Nutraceuticals for a Healthy Life*) – España, Alemania y Hungría; b) **Proyecto CHOP** (*Childhood Obesity Project*) – Alemania, España, Italia, Polonia y Bélgica; y, c) **Generation R** – Países Bajos.

Los niños pertenecientes a estas cohortes fueron evaluados a los 7 y 9 años de edad, mediante la NUTRIMENTHE Neuropsychological Battery (NNB), batería de tests neuropsicológicos especialmente diseñada para este fin, capaz de cubrir todo el espectro funcional del cerebro a través de una exploración por diferentes dominios cerebrales (*percepción, motricidad, atención, memoria, lenguaje, funciones ejecutivas, velocidad de procesamiento*). La NNB fue consensuada y traducida a los diferentes idiomas de los países implicados. Los problemas de desarrollo del comportamiento

también se evaluaron mediante el test Children's Behavior Checklist (CBCL) para medir los posibles problemas de comportamiento.

Además, los niños del Proyecto NUHEAL participaron en una evaluación funcional del cerebro a los 9.5 años mediante Resonancia Magnética Funcional en Reposo (rs-fMRI), que ha aportado datos de máximo interés.

Junto a los datos neuropsicológicos y de neuroimagen previamente mencionados, se obtuvieron datos correspondientes a potenciales variables confusoras, tales como: *edad materna, nivel educativo de la madre y del padre, tabaquismo durante el embarazo, edad gestacional, antropometría al nacimiento y lactancia materna durante al menos los tres primeros meses de vida,... así como datos evolutivos de las diferentes cohortes, desde el nacimiento hasta la edad de 9.5 años.*

El principal objetivo del presente estudio es el de aplicar técnicas de minería de datos y estadística avanzada a la base de datos global NUTRIMENTHE, y extraer conocimientos útiles y publicables en el ámbito de la nutrición clínica y desarrollo cerebral.

Después de preparar el conjunto de datos con técnicas de pre-procesamiento avanzadas, se aplicaron los procesos de descubrimiento de información (KDD-Knowledge Discovery in Databases) en sus dos vertientes principales: *Aprendizaje supervisado y No Supervisado.*

En el primer estudio, mediante el uso reglas de asociación sobre el conjunto de datos total de la base NUTRIMENTHE, se comprobó una relación causa-efecto entre el tabaquismo materno durante el embarazo y el desarrollo de **problemas externalizantes** de conducta en los niños en edad

escolar. No obstante, la lactancia materna durante los tres primeros meses de vida, así como el nivel educativo de los padres parecen contrarrestar los efectos nocivos del tabaquismo materno.

El segundo estudio se llevó a cabo con los datos obtenidos en el Proyecto NUHEAL; los resultados sugieren que la suplementación prenatal con FO se asoció a una mayor velocidad de procesamiento en las tareas del test CCTT-1 en los niños en edad escolar. Se comprueba que el índice AA/DHA materno en el momento del parto y la heterozigosis materna de la variante genética rs174556 de las FADS1 se asocian positivamente a la velocidad de procesamiento de los hijos a los 9 años. Por el contrario, las concentraciones de tHcy en el plasma materno en el momento del parto muestran un efecto negativo sobre la velocidad de procesamiento del niño a los 9 años.

En el tercer estudio, a los 9.5 años de edad, los niños cuyas madres recibieron suplementación prenatal con FO, mostraron una conectividad funcional débil en la red neuronal por defecto, y en las redes sensoriomotriz y frontoparietal comparadas con las muestran aquellos niños cuyas madres recibieron placebo o 5-metil-tetrahidrofolato (5-MTHF). Gracias a las técnicas de predicción y selección de características sobre la base de datos de NUHEAL, se pudo comprobar una asociación negativa entre conectividad funcional y las tareas de atención y velocidad de procesamiento en los hijos de madres suplementadas con 5-MTHF y/o placebo.

Conclusiones

1. Las técnicas de minería de datos resultan de vital importancia a la hora de descubrir conocimiento oculto en una base de datos de grandes

dimensiones, teniendo en cuenta que la adquisición de datos ha conllevado un gran esfuerzo, así como la cantidad de recursos destinados a dicha labor.

2. Gracias al uso de reglas de asociación, se justifica el hecho de que el tabaquismo materno durante la gestación puede influir en el desarrollo conductual de los niños en edad escolar, por lo que resulta de vital importancia fomentar la políticas anti-tabaco especialmente para concienciar a las mujeres en edad de concebir y embarazadas.
3. Los niños cuyas madres recibieron aceite de pescado (FO: 500 mg de DHA/día + 150 mg EPA/día) durante la gestación mostraron una mayor velocidad en la resolución de las tareas del CCTT1. El índice ácido araquidónico (ARA)/DHA materno al final de la gestación, y la heterocigosis de la variante genética rs174556 de la FADS1 ejercen un efecto beneficioso a largo plazo sobre la velocidad de procesamiento que muestran los niños a los 9 años de edad. El incremento de la Homocisteína total durante la gestación predice una menor velocidad de procesamiento cognitivo en los hijos a los 9 años de edad.
4. Gracias a la técnica de análisis de componentes independientes, la suplementación materna con FO aceite de pescado durante el embarazo parece tener efectos a largo plazo sobre sobre la conectividad funcional cerebral de los niños en edad escolar que se asocia a un mejor desarrollo del procesamiento cognitivo.

5. Se refuerza la hipótesis de la posibilidad de una programación nutricional precoz (*Early Nutrition Programming*) que determina efectos a muy largo plazo sobre el funcionamiento cerebral en los hijos.

INTRODUCCIÓN

INTRODUCCIÓN

El mundo cuenta con una ingente cantidad de datos donde la extracción de conocimiento oculto se vuelve tediosa e insostenible usando sólo técnicas de estadística clásica. De este modo nace la ciencia de datos, campo disciplinario que aprovecha los avances computacionales para desarrollar propuestas algorítmicas en la resolución de problemas de cualquier índole (Figura 1).




Figura 1. Proceso de ciencia de datos.

Gracias a la ciencia de datos se pueden realizar estudios de tal calibre como predecir la muerte cardiovascular en base al número de

latidos del corazón en intervalos de tiempo específicos [1], o ayudar a la detección precoz de células cancerígenas gracias al procesamiento de imágenes [2], entre muchas otras aplicaciones.

El Proyecto NUTRIMENTHE [3], financiado por el 7º Programa Marco de la Unión Europea, aborda cuestiones clave sobre el neurodesarrollo en la infancia y cómo la dieta puede desempeñar un papel fundamental sobre dominios cerebrales trascendentales en el desarrollo tales como la percepción, memoria, inteligencia, ansiedad, atención, funciones ejecutivas y comportamiento. Como resultado de la colaboración internacional realizada gracias al Proyecto NUTRIMENTHE, los investigadores responsables decidieron crear una nueva base de datos que recogiera información proveniente de 3 grandes estudios, a través de los cuales se pretende analizar el efecto de la dieta precoz sobre el crecimiento y neurodesarrollo de un millar de niños procedentes de siete países de la Unión Europea; las especiales características de esta base de datos donde se incluyen 2 proyectos de intervención nutricional (uno prenatal y otro postnatal) y 1 proyecto de cohorte epidemiológica, junto a la influencia cultural y de estilos de vida, hacen de la base NUTRIMENTHE una gran fuente de conocimiento sobre este tema, y constituye un reto de minería de datos merecedor de la máxima atención para este y futuros estudios.

La base de datos global NUTRIMENTHE permitirá abordar un proceso de descubrimiento de información (knowledge discovery in databases – KDD) y el correspondiente análisis inteligente de los datos, revelando patrones ocultos así como las posibles relaciones causa-efecto que se puedan detectar entre éstos. Para llegar a tal cometido, se pueden combinar técnicas tradicionales de extracción de conocimiento con propuestas recientes de la Inteligencia Artificial, dentro de la gran variedad de áreas y herramientas de minería de datos [4]. Este enfoque permitiría obtener nuevo conocimiento a partir de la base de datos que hasta la fecha solo ha sido tratada con técnicas estadísticas clásicas.

Se debe comenzar con el estudio y entendimiento del dominio del problema para identificar los posibles objetivos a analizar. Una vez definidos los objetivos, se procederá al pre-procesamiento de datos, siendo de vital importancia en el proceso KDD, ya que se centra en limpiar, transformar y eliminar ruido para la etapa posterior del análisis. El siguiente paso puede consistir en la selección de características que aporten más información útil descartando aquellas que sean redundantes. Una vez limpio el conjunto de datos, se procedería a la construcción de un modelo, paso clave en la minería de datos, proporcionando distintos enfoques a la hora de abordar un problema (Aprendizaje Supervisado y No Supervisado). El último paso sería la validación e interpretación del modelo de manera que puedan ser

entendidos por el público general. En la actualidad contamos con numerosas herramientas de libre distribución para la realización de procesos de minería de datos, siendo el lenguaje de programación R el predominante por su versatilidad y la ingente cantidad de librerías apoyada por una fuerte comunidad científica. En esta propuesta de proyecto de tesis doctoral se pretende aplicar técnicas de extracción de conocimiento, haciendo uso de técnicas de minería de datos, así como procedimientos de estadística clásica como avanzada para la base global NUTRIMENTHE, teniendo en cuenta las cohortes que la conforman. Para dicho cometido se hará uso del entorno de programación R, así como las herramientas óptimas disponibles para extraer conocimiento susceptible de ser publicado.

- **Impacto de factores socio-ambientales sobre el neurodesarrollo**

La interacción entre factores ambientales y sociales puede afectar el desarrollo conductual posterior de los niños, por lo que tiene importantes implicaciones para la salud pública y el desarrollo de políticas preventivas [5].

Factores de riesgo prenatales como el tabaquismo materno [6] y el consumo de alcohol [7] y/o estupefacientes [8] parecen tener efecto sobre el neurodesarrollo de los niños, pudiendo estar fuertemente

condicionado por otros factores como el nivel educativo de la madre, lactancia materna, así como el nivel socioeconómico de las familias [9].

Tabaquismo materno y conducta en los hijos en edad escolar

Según la Organización Mundial de la Salud (OMS), actualmente el continente europeo cuenta con la mayor proporción de fumadores de cigarrillos entre los adultos (28%) y una de las más altas entre los adolescentes, a pesar de todos los esfuerzos realizados por las entidades públicas y privadas para fomentar el abandono del hábito de fumar [10]. Si bien el consumo de tabaco predominaba anteriormente entre los hombres, la diferencia entre ambos géneros es actualmente muy pequeña (<5%) en países europeos como Dinamarca, Irlanda, Países Bajos, Noruega, Suecia y Reino Unido. Aproximadamente el 19% de las mujeres de 15 años o más fumaban tabaco en Europa según la OMS y, como motivo de preocupación, el cigarrillo representa un riesgo grave para la madre y el feto en desarrollo, siendo ahora reconocido como una causa importante de morbilidad y mortalidad infantil.

La exposición al humo del cigarrillo durante el embarazo puede perturbar el tracto respiratorio, el sistema cardiovascular y la morfología del cerebro del niño, provocando daños crónicos que pueden manifestarse posteriormente [11,12]. La mortalidad infantil perinatal, la muerte fetal, el parto prematuro, las anomalías

congénitas, el bajo peso al nacer y el lento desarrollo y crecimiento fetal son consecuencias comunes de la exposición al tabaquismo, al vapeo y la exposición pasiva al humo durante el embarazo [13–20].

Se han documentado perfiles neurocognitivos y conductuales perjudiciales de los niños en edad escolar nacidos de madres que fumaron durante el embarazo, lo que promueve la aparición temprana de síntomas psicopatológicos como el trastorno por déficit de atención con hiperactividad (TDAH) [21], comportamiento agresivo [22], trastornos del espectro autista (TEA) [23], riesgo de hipomanía[24], bajo rendimiento académico [25], así como deficiencias en el procesamiento del habla y el control de la atención [26,27]. Sin embargo, considerando la naturaleza observacional de los datos en esos estudios, parece que los resultados conductuales están vinculados de alguna manera a otros factores confusores como el género, la edad de los padres, la educación o los ingresos de los padres [28]. Además, los efectos de las características culturales y sociodemográficas de la población estudiada se consideran factores confusores [29]. Por el contrario, otros estudios apoyan la idea de que la asociación entre el tabaquismo materno durante el embarazo y el TDAH en los niños no está del todo probada [21].

• Desarrollo del cerebro fetal

La nutrición juega un papel fundamental durante los primeros 1000 días de vida (desde la concepción hasta los primeros 2 años) en el óptimo neuro-desarrollo de los niños. El cerebro humano no se puede considerar un órgano homogéneo, sino que está formado por numerosas áreas o regiones, donde cada una difiere de la otra considerando la trayectoria de desarrollo y las necesidades nutricionales. En este sentido, el neurodesarrollo fetal se considera un periodo crítico, donde deficiencias o deprivaciones de ciertos nutrientes podrían acarrear efectos duraderos o irreversibles del neurodesarrollo [30].

El comienzo de la tercera semana después de la concepción marca el inicio del período embrionario, etapa fundamental para el desarrollo del cerebro humano, dónde se forma el tubo neural (Figura 2).

Al final del período embrionario, se han establecido las estructuras básicas del cerebro y el sistema nervioso central y periférico. La producción de neuronas, o células cerebrales, comienza alrededor del día 42 después de la concepción y, en su mayoría, se completa en algún momento hacia la mitad del embarazo. A medida que se forman las neuronas, éstas se propagan a diferentes áreas del cerebro. Una vez que han alcanzado la ubicación correcta,

comienzan a formar conexiones con otras células neuronales, estableciendo redes neuronales rudimentarias.




Figura 2. Desarrollo del cerebro en el periodo pre-natal [31].

El período fetal de desarrollo prenatal marca cambios importantes en el cerebro. Este período de desarrollo comienza durante la novena semana y dura hasta el nacimiento. Los primeros sistemas y estructuras corporales establecidos en la etapa embrionaria continúan desarrollándose. El tubo neural se desarrolla en el cerebro y la médula espinal y las neuronas continúan formándose hasta su posterior migración. Las sinapsis, o las conexiones entre neuronas, también comienzan su desarrollo. Alrededor de las 28 semanas, el

cerebro comienza a madurar más rápido, con una actividad que se parece mucho a la de un recién nacido dormido.




Figura 3. Evolución temporal del neurodesarrollo. En la figura 3-A se puede apreciar la evolución temporal de los procesos claves del neurodesarrollo en el ser humano, durante la gestación y hasta los 20 años. La mayor parte del proceso de neurogénesis está completa antes de nacer, mientras la sinaptogénesis continúa tras el nacimiento hasta la adolescencia. Considerando la figura 3-B, se puede apreciar la zona ventricular y subventricular con numerosas células proliferativas (verde; marca inmunológica) que poblarán el córtex cerebral en desarrollo. Estas formarán los núcleos de las células gliales radiales (rojo/naranja; vimentin) alguna de las cuales se han marcado en negro [32].

Otro factor clave en el neurodesarrollo es la ganancia de peso cerebral. Durante el corto período de 9 meses, la célula "madre" inicial da lugar a más de 100 mil millones de células nerviosas, pesando el cerebro aproximadamente 400 g cuando nace el niño. Durante los

primeros 4 años de vida, el cerebro continúa creciendo, alcanzando el tamaño de 1200 gramos. Durante los próximos 10 a 15 años, el crecimiento del cerebro continúa, involucrando diferentes áreas cerebrales de una manera ligeramente diferente. Por ejemplo, el grosor de las diferentes regiones de la corteza cerebral cambia entre las edades de 5 y 18 años a diferentes ritmos, siendo las regiones importantes para el razonamiento, la planificación y la comunicación social las que maduran en último lugar [33].

Factores maternos, genéticos, nutricionales y ambientales pueden tener un efecto significativo sobre el desarrollo cerebral durante el periodo crítico de la vida fetal y a lo largo de los 2 primeros años de la vida.

• **Nutrición prenatal y neurodesarrollo**

Existen claras evidencias de que el factor ambiental más importante en el periodo prenatal y postnatal precoz determinante para el neurodesarrollo es la nutrición [34]. Un neurodesarrollo subóptimo implica un bajo nivel educativo y una trayectoria de una baja posición socioeconómica, que a su vez se asocia a pocas oportunidades en la vida. Una disponibilidad de nutrientes inadecuada durante la gestación se ha relacionado con enfermedades psiquiátricas, problemas de conducta, autismo y en

general alteraciones del desarrollo cognitivo. Estos efectos se asocian de forma clara a largo plazo con una reducción de la esperanza de vida y un aumento de la prevalencia de enfermedades como la depresión, esquizofrenia o el suicidio.

Nutrientes como los ácidos grasos poliinsaturados de cadena larga (LC-PUFAs), el ácido fólico y otras vitaminas del grupo B, proteínas, o minerales como el hierro son necesarios para el normal desarrollo del sistema nervioso fetal, y de forma específica para algunas regiones tan importantes como el hipocampo, cuerpo estriado, retina o la corteza cerebral, así como para establecer la arquitectura neural y los circuitos subyacentes (sinaptogénesis, poda neuronal y mielinización) que respaldan las principales funciones cerebrales [35–38].

El estado metabólico, la actividad de transporte placentario y el momento de liberación de los nutrientes influyen no solo en la cantidad sino también en la calidad de la entrega de nutrientes al feto.

✓ **Ácidos grasos poliinsaturados de cadena larga (LC-PUFAs)**

Según el número de átomos de carbono y la ausencia o presencia de dobles enlaces en su estructura química, los ácidos grasos se clasifican como: ácidos grasos saturados (AGS), ácidos grasos monoinsaturados (MUFAs), ácidos grasos poliinsaturados

(PUFAs) y ácidos grasos poliinsaturados de cadena larga (LC-PUFAs). Los ácidos grasos linoleico (LA, C18:2n-6) y α -linolénico (ALA, C18:3n-3) son esenciales, y por tanto, deben ser ingeridos a través de la dieta, y son precursores de los LC-PUFAs. La síntesis de LC-PUFAs se realiza mediante procesos de desaturación y elongación, gracias a las enzimas desaturasas (FADS1, FADS2, FADS3) y elongasas (ELOV2, ELOV5), las cuales son compartidas por ambas series de ácidos grasos poliinsaturados [31,39–42] (Figura 3).




Figura 4. Ruta metabólica de los ácidos grasos esenciales [39].

Durante mucho tiempo se ha considerado que el aporte nutricional suficiente de PUFAs es beneficioso para la salud infantil. El aporte nutricional de PUFAs de las series ω -6 y ω -3 y sus derivados de

cadena larga como el ácido araquidónico (ARA) y en especial el ácido docosahexaenoico (DHA) se considera muy importante para varias funciones fisiológicas. Entre las principales funciones de los PUFAs se encuentran regular la fluidez de la membrana celular, así como actuar como precursores de eicosanoides y docosanoides, los cuales tienen un papel importante en los procesos inflamatorios [43]. Durante la vida fetal y la infancia temprana, el DHA es necesario para el desarrollo retiniano y neuronal adecuados [44], reflejado por la acumulación masiva de DHA en la retina y cerebro fetales durante el embarazo[45]. En años recientes, el interés de la investigación se ha volcado en la optimización del suministro fetal de DHA por la ingesta materna de suplementos de DHA durante el embarazo y la lactancia. Además de la importancia de la ingesta nutricional de AGPI, ha surgido evidencia de una variación interindividual considerable en la capacidad de cómo los ácidos grasos ω-6 y ω-3 se procesan endógenamente mediante la ruta de desaturación/elongación [46] De manera breve, el ácido linoleico y el ácido α-linolénico obtenidos de la dieta se convierten en ácidos grasos de cadena más larga gracias a la elongación de la cadena de carbonos del ácido graso y la inserción de enlaces dobles (es decir, desaturación) mediante esta vía, descrita por Sprecher [47].

Recientemente, los estudios de asociación genética han demostrado que los antecedentes genéticos son muy importantes

para la composición de PUFAs en los tejidos humanos. Así, los polimorfismos en los genes que codifican las desaturasas de ácidos grasos o FADS determinan la eficiencia con la cual los PUFAs se metabolizan endógenamente para producir los ácidos grasos poliinsaturados de cadena larga (LC-PUFAs). Los hallazgos recientes sobre interacción entre genes y nutrición sugieren que estos polimorfismos modulan el efecto de la ingesta nutricional de ácidos grasos sobre fenotipos complejos como la evolución cognitiva y el riesgo de asma en niños.

Los ácidos grasos son moléculas implicadas en una amplia gama de procesos biológicos que incluyen, entre otros, la señalización celular, la regulación de las respuestas inmunitarias y el control de la expresión de una variedad de genes [48]. Por tanto, son moléculas esenciales para el mantenimiento de la salud y el bienestar, y alteraciones en su composición pueden dar lugar a distintas disfunciones fisiológicas.

Debido a la inmadurez fisiológica del feto, los niveles de PUFA dependen casi exclusivamente del suministro materno. La ingesta dietética materna debería incluir una amplia gama de ácidos grasos, con diferentes efectos en el metabolismo materno y fetal. La mayoría de los estudios realizados durante el embarazo y la lactancia se centran en el papel estructural de los LC-PUFAS. Los LC-PUFA son esenciales para la síntesis de fosfolípidos de la membrana celular.

Además, los derivados de éstos desempeñan un papel crucial en la señalización y son necesarios para la función celular normal.

Varios estudios también han explorado el efecto de los PUFA en el desarrollo del tejido adiposo, pero los datos no son concluyentes. El desequilibrio entre la ingesta materna de PUFA n-6 y n-3, en lugar del consumo de PUFA n-6 o n-3 per se, durante el embarazo parece influir negativamente en el desarrollo del tejido adiposo fetal [49,50].

Los AGPI-CL son a su vez importantes mediadores de la expresión génica, mediante la activación de los receptores proliferadores peroxisomales (PPARs), controlando la expresión de genes involucrados tanto en el metabolismo de los lípidos y de la glucosa como en la adipogénesis [48,51]. Los PUFAs y sus metabolitos de cadena larga como el DHA y el AA, son esenciales para un desarrollo adecuado del cerebro, aunque Los ácidos grasos poliinsaturados de larga cadena (AGPI-CL) de la serie n-3, y especialmente el DHA, han demostrado ser críticos para el crecimiento y el neurodesarrollo, habiéndose comprobado cambios estructurales en el cerebro, en concreto una relación directa con el tamaño del núcleo caudado [52]. En el estudio ALSPAC se observado que una baja ingesta de AGPI-CL n-3 durante la gestación incrementa el riesgo de tener puntuaciones subóptimas del coeficiente de inteligencia (IQ) en la expresión verbal, alteraciones de la conducta pro-social, menor desarrollo psicomotor en la manipulación fina, problemas de comunicación y bajos niveles de desarrollo social [53]. Igualmente, se

ha demostrado que la incidencia de bajo peso para la edad de gestación disminuye con el incremento de la ingesta de pescado por la embarazada, lo que también se asocia a un mejor desarrollo visual. Varios estudios han sugerido beneficios de la suplementación materna de LC-PUFAs durante el embarazo sobre el desarrollo neurológico de los hijos. Los niños cuyas madres recibieron suplementos de LC-PUFAs desempeñaron significativamente mejor que el grupo de placebo con respecto al dominio de la comunicación cognitiva a las edades de 4 y 6 meses [54], coordinación de ojos y manos a los 2.5 años [55], y atención sostenida en 5 años [56]. Sin embargo, también hay estudios que no apreciaron ninguna asociación entre el suministro materno de LC-PUFA durante el embarazo y el desarrollo neurológico a las edades de 18 meses [57] y 5 [58] y 12 años [59].

✓ **Ácido Fólico (5-MTHF)**

Existe evidencia científica de que la suplementación materna durante las primeras 12 semanas de embarazo no solo previene los defectos del tubo neural [60], sino que también tienen un papel crucial en la apoptosis, la neurogénesis y el desarrollo óptimo del sistema nervioso [61,62].

La deficiencia cerebral de ácido fólico (5-MTHF) podría estar asociada con una alteración del transporte de folato, lo que podría conducir a la atrofia de las regiones fronto-temporales y la

desmielinización periventricular, como se ha observado en algunos estudios de neuroimagen [63][64][65].

Sin embargo, los efectos a largo plazo de la suplementación prenatal con ácido fólico más allá de las 12 semanas de gestación sobre el neurodesarrollo no están determinados, estando en discusión el tiempo de suplementación, la dosis y los potenciales efectos combinados al aportarlo junto a otros micronutrientes. De hecho, algunos estudios epidemiológicos [36] y un seguimiento previo del proyecto NUHEAL [66] han demostrado que la suplementación prenatal con ácido fólico mejora la atención sostenida en los niños a los 8 años de edad.

✓ **Impacto de Polimorfismos Genéticos en el neurodesarrollo**

El contenido de LC-PUFAs en los tejidos depende de dos factores, la ingesta dietética y los procesos metabólicos de desaturación y elongación (controlado por los polimorfismos genéticos) a partir de los precursores. En este sentido, se ha demostrado que las enzimas δ-5 y δ-6 desaturasas, codificadas en los genes FADS1 y FADS2, son esenciales para el metabolismo de ácidos grasos y pueden influir en la síntesis de los LC-PUFAs. Recientemente, se ha sugerido que las variantes genéticas de las FADS y ELOVs de las madres durante el embarazo, van a influir directamente sobre el

suministro de LC-PUFAs hacia el feto, pudiendo afectar su óptimo desarrollo cerebral [67].

El metabolismo de 1 carbono está mediado por diferentes nutrientes dadores de grupos metilo (ácido fólico, vitamina B12, vitamina B6, vitamina B2 o colina), donde dos ciclos principales se entrelazan: la biosíntesis del ADN y el ciclo de metilación, habiéndose comprobado la implicación de estos nutrientes en los procesos de metilación del ADN y de las histonas [68]. El ácido fólico participa en procesos biosintéticos y epigenéticos que facilitan la síntesis y metilación de ácidos nucleicos y proteínas. Se han identificado diferentes variaciones en los polimorfismos genéticos de la metiltetrahidrofolato reductasa (MTHFR), enzima implicada en la absorción de ácido fólico y su metabolismo [69], siendo el MTHFR 677 C/T el más importante en términos de prevalencia e impacto [70]; el genotipo 677 C/T se asocia a una reducción de la actividad enzimática del 60%, determinando un aumento de la homocisteína y reacciones de metilación (epigenéticas) [71]. El alelo materno MTHFR 677 T se ha descrito como un predictor independiente de un peor desarrollo neurológico infantil a los 24 meses de edad, mientras que los genotipos MTHFR 677 C/T del niño no se asociaron con el neurodesarrollo infantil [72]. Se ha sugerido que la variación genética materna en el metabolismo del ácido fólico durante el embarazo puede programar las trayectorias del desarrollo neurológico en los

hijos [72], en concreto, las variantes del gen materno MTHFR 677 T/T (rs1801133 C/T), CBS rs2234715 GT+TT y COMT AA (rs4680 G/A) se asociaron con un trastorno mental y con un mayor riesgo de autismo en los niños, coincidiendo con niveles más altos de homocisteína [73].

- **Velocidad de procesamiento y desarrollo cognitivo.**

La velocidad del procesamiento de la información es un proceso esencial para la función cognitiva de orden superior, incluyendo funciones básicas como la memoria o las funciones ejecutivas [74]. Este proceso cognitivo se puede definir como el tiempo necesario para mover información de una neurona a la siguiente [75], o la rapidez con la que una persona puede realizar las operaciones mentales necesarias para completar una tarea [76]. En este caso, la velocidad de procesamiento está altamente relacionada con la mielinización intacta, crucial para la integración de información a través de redes neuronales distribuidas espacialmente. Además, la asociación entre la integridad de la materia blanca y la velocidad de procesamiento en las tareas cognitivas se ha establecido en la bibliografía [77,78].

• **Nutrición y conectividad funcional**

A pesar de la relevancia de la suplementación nutricional en la estructura del cerebro, se sabe poco sobre los efectos de la suplementación materna con LC-PUFAS y/o ácido fólico en la conectividad funcional del cerebro de los niños.

Las imágenes por resonancias magnéticas funcionales en reposo (rsfMRI) se usan en el trazado cerebral para evaluar las interacciones regionales que ocurren cuando no se está realizando una tarea explícita. Esta técnica se basa en el hecho de que el flujo sanguíneo cerebral y la activación neuronal están acoplados; dicho de otro modo, cuando se activa un área del cerebro, también aumenta el flujo sanguíneo a esa región (BOLD – Blood-Oxygen-Level Dependant).

La conectividad funcional es la conexión entre regiones del cerebro que comparten propiedades funcionales. Se puede definir como la correlación temporal entre eventos neurofisiológicos espacialmente remotos, expresada como desviación de la independencia estadística a través de estos eventos en áreas y grupos neuronales distribuidos [79].

Las principales redes o áreas que nos podemos encontrar en un análisis de rs-fMRI son (Figura 5):




Figura 5. Principales RSN identificadas por los siguientes estudios: (a) Biswal et al. (1995), (b) Beckamnn et al. (2005), (c) De Luca et al. (2006), (d) Damoiseaux et al. (2006), (e) Salvador et al. (2005), and (f) Van den Heuvel et al. (2008).

✓ Red Neuronal por Defecto (Default Mode Network - DMN)

La red de modo por defecto es una red de regiones del cerebro que están activas cuando un individuo está despierto y en reposo [80]. Se considera un sistema cerebral interconectado y anatómicamente definido que se activa preferentemente cuando las personas se concentran en tareas internas como soñar despierto, visualizar el futuro y recuperar recuerdos [81]. Se correlaciona negativamente con los sistemas cerebrales que se centran en señales visuales externas. Es una de las redes más estudiadas presentes durante el estado de reposo y es una de las redes más fáciles de visualizar [82].

✓ **Red Neuronal Sensoriomotora (*Sensorimotor Network - SMN*)**

La red sensorimotora es una de las más extensas, incluyendo numeroso procesos. El SMN incluye regiones somatosensoriales (post-central gyrus) y motoras (pre-central gyrus), extendiéndose a las áreas motoras suplementarias [83]. Numerosos trabajos han sugerido que esta red se activa durante las tareas motoras, como el golpeteo de los dedos [84], lo que indica que estas regiones pueden implicar un estado premeditado que prepara al cerebro para realizar y coordinar una tarea motora [83]. La disfunción en el SMN está implicada en varios trastornos neuropsiquiátricos.

✓ **Red Neuronal Frontoparietal (*Frontoparietal Network - FPN*)**

Es una red cerebral compuesta principalmente por la corteza prefrontal dorsolateral y la corteza parietal posterior [85], alrededor del surco intraparietal [86]. Dicha red esta involucrada en la atención sostenida, la resolución de problemas complejos y la memoria de trabajo [87].

HIPÓTESIS Y OBJETIVOS

HIPÓTESIS Y OBJETIVOS

La aplicación de procesos de minería de datos en el campo de la biomedicina está ocupando un papel central en el ámbito científico con múltiples propuestas algorítmicas y aplicaciones. La hipótesis de partida es el potencial de estos algoritmos para el procesamiento de datos imperfectos, el aprendizaje en sus dos vertientes (Supervisado y No supervisado) y la validación de los resultados obtenidos mediante análisis de estadística clásica y avanzada, presentando como aplicación práctica el análisis de la base de datos global de NUTRIMENTHE.

El objetivo general del presente proyecto de tesis es aplicar metodologías de procesamiento de datos en el ámbito de la nutrición y neurodesarrollo aplicados al proyecto NUTRIMENTHE. Para ello se hará uso de las técnicas más avanzadas de minería de datos aprovechando el hecho de que la información incluida en la base de datos es susceptible de ser convertida en conocimiento útil y de amplio interés para la comunidad científica.

Los análisis realizados han permitido la extracción de conocimiento oculto, aprovechando los enormes esfuerzos y recursos dedicados para obtener la ingente cantidad de datos de difícil manejo proporcionados por la base de datos NUTRIMENTHE, así como

las cohortes que lo conforman (NUHEAL, CHOP y Generation R). La minería de datos aporta un nuevo enfoque de análisis exploratorio, destacando los factores que más impacto tienen sobre las variables objetivo previamente seleccionadas, pudiendo estar ocultos al análisis estadístico convencional.

Los objetivos específicos propuestos son los siguientes:

1. Revisión bibliográfica de las técnicas de pre-procesamiento, selección de características, Subgroup Discovery y técnicas de minería de datos en general que deban ser utilizadas en el análisis inteligente de datos asociado a la base de datos NUTRIMENTHE.
2. Aplicación de técnicas de pre-procesamiento en general y selección de características en particular para determinar las variables más relevantes en la base de datos considerando diferentes hipótesis asociadas a los estudios de nutrición y neurodesarrollo infantil.
3. Diseño y aplicación de modelos de minería de datos para la predicción de variables de interés, la extracción de subgrupos (Subgroup Discovery) y la extracción de información y patrones ocultos mediante reglas de asociación.
4. Desarrollar estudios de investigación relacionados con los resultados previamente validados con análisis estadísticos.

4.1. Extracción de conocimiento de la Base Global NUTRIMENTHE.

Análisis de los efectos del tabaquismo materno sobre el desarrollo de la conducta en los hijos a la edad escolar.

4.2. Análisis con modelos de efectos mixtos para analizar los efectos de la suplementación prenatal con aceite de pescado y/o 5-metiltetrahidrofolato (5-MTHF) sobre la velocidad de procesamiento.

4.3. Análisis de componentes independientes y técnicas exploratorias de minería de datos para determinar los efectos de la suplementación prenatal con aceite de pescado y/o 5-MTHF sobre la conectividad funcional del cerebro en situación de reposo (*resting state*) y su significado clínico en niños de 10 años de edad.

MATERIAL Y MÉTODOS

MATERIAL Y MÉTODOS

- **Análisis de Minería de datos**

El proceso general de extracción de conocimiento de una base de datos está expuesto en la figura 6.




Figura 6. Proceso de extracción de conocimiento de una base de datos

El primer paso sería establecer las hipótesis de partida teniendo en cuenta los datos sin procesar que tenemos a nuestra disposición. El siguiente paso sería la recolección de datos para su posterior pre-procesamiento. Una vez que los datos estén limpios y estandarizados, se puede tomar dos caminos alternativos. Selección de características

junto a Subgroup discovery o crear modelos de predicción basados en aprendizaje supervisado o No supervisado. El siguiente paso (sea cual fuere el camino escogido anteriormente) es la validación de los resultados obtenidos usando las métricas pertinentes para cada algoritmo usado, así como técnicas de estadística clásica para validar nuestros resultados.

Adaptación del proceso de minería de datos a la base de datos NUTRIMENTHE.

- 1) **Establecimiento de hipótesis iniciales.** En nuestro caso sería el efecto de la dieta prenatal y otros factores disponibles en la NGDB en el neurodesarrollo de los niños.
- 2) **Recolección de datos.** La base de datos global de NUTRIMENTHE estará compuesta por 3 cohortes distintas (CHOP, NUHEAL y Generation R), incluyendo un total de un millar de niños con datos imperfectos, donde se han obtenido datos sobre el desarrollo cognitivo y de la conducta. Resulta de vital importancia analizar, recodificar y estandarizar las distintas bases de datos para permitir un análisis posterior fiable.
- 3) **Pre-procesamiento de datos:** Una vez fusionada la base de datos, será prioritario realizar un proceso de pre-procesamiento de datos, ya que las técnicas de minería de datos son sensibles a la calidad de la información sobre la que se pretende extraer conocimiento [88]. Los datos tomados en el proyecto de NUTRIMENTHE pueden

contener inconsistencias, errores, o de forma más genérica, no estar preparados para una etapa posterior de minería de datos. Gracias al pre-procesamiento de datos, se pueden adaptar los datos para cumplir las expectativas de entrada de cualquier algoritmo de aprendizaje. Entre los posibles técnicas que ofrece el pre-procesamiento de datos nos podemos encontrar con [88]:

- Limpieza y estandarización de datos.
- Imputación de valores perdidos si procede.
- Identificación de anomalías.
- Selección y generación de instancias.

4) **Selección de características.** Una de las tareas más complejas a la hora de aplicar técnicas clásicas de estadística para la base de NUTRIMENTHE es el número de variables con las que cuenta (aproximadamente dos mil, si consideramos todas y cada una de las variables antropomórficas en distintos intervalos de tiempo, así como datos provenientes de la cohorte NUHEAL>1000). Si consideramos cada una de ellas independientemente de las otras, solo podríamos conducir análisis parciales limitando la capacidades para verificar las hipótesis. La minería de datos proporciona mecanismos para reducir el número de variables concentrándose solo en aquellas que ofrezcan la misma o más cantidad de información útil [89], como es el caso de PCA, ICA, FS y por ello, hemos destacado esta técnica de forma independiente, debido a

la importancia que tendrá al abordar el análisis de esta base de datos.

✓ **Análisis de Componentes Independientes**

Los Análisis de Componentes Independientes (ICA) se llevaron a cabo utilizando el Análisis Probabilístico de Componentes Independientes [90], similar a la implementación de MELODIC (Descomposición Lineal Exploratoria Multivariante en Componentes Independientes) Versión 3.14, parte de FSL. Los datos pre-procesados se blanquearon y proyectaron en un sub-espacio de 40 dimensiones mediante el análisis probabilístico de componentes principales. Los cuarenta componentes se comprobaron e identificaron visualmente. Los componentes que representan artefactos conocidos como movimiento, ruido de alta frecuencia o pulsación venosa [91,92] o aquellos que no se encuentran principalmente en la materia gris [93] fueron identificados y no tomados en cuenta en los siguientes análisis. Se descartaron catorce componentes por el motivo anterior; y las veintiséis redes de estado en reposo (RSN) restantes se etiquetaron basándose en la superposición con los atlas estructurales corticales y subcorticales de Harvard-Oxford disponibles en FSL.

- 5) **Obtención y verificación de hipótesis parciales.** En la mayoría de los casos la hipótesis general a probar resulta ser la más interesante, y a

la vez la más difícil de verificar. Sin embargo, podemos coincidir en el hecho de que a mayor número de variables, mayor es la complejidad a la hora definir la relación entre variables secundarias y variables objetivo definiendo quién es quién en la base de datos. La minería de datos proporciona técnicas como el Subgroup Discovery [94], diseñado específicamente para la extracción de grupos de interés asociadas a una clase, capaz de generar nuevas hipótesis describiendo las características del subgrupo donde se hace cierta la nueva hipótesis. Éste nuevo enfoque permite rediseñar la hipótesis inicial para un proceso de verificación más riguroso. Por ejemplo, si queremos probar la hipótesis de que la suplementación materna de ácido fólico durante la gestación aumenta los efectos a largo plazo sobre la atención de los hijos, Subgroup Discovery nos proporcionaría los factores implicados en la confirmación de dicha hipótesis.

6) **Aprendizaje supervisado**, capaz de resolver problemas específicos teniendo un conjunto de variables explicativas y una variable objetivo [95]. Podemos encontrarnos con dos grandes variantes dependiendo del tipo de la variable objetivo.

a. **Clasificación**, cuando la variable objetivo Y es discreta (número finito de valores) pudiendo dividir el conjunto de toda la población en clases en función de Y .

b. **Regresión**, siendo la variable objetivo Y de tipo continuo.

7) **Aprendizaje no supervisado**, que no necesita información acerca de una variable objetivo, basándose sólo en las variables conocidas. Se abordará el uso de dos tipos de técnicas:

- a. **Clustering**, método capaz de seleccionar grupos de individuos acorde a unas características, que en conjunción con el Subgroup Discovery, podría proporcionarnos información relevante a la hora de caracterizar los grupos donde se cumpla una condición específica.
- b. **Reglas de asociación**, proceso por el cual se descubren relaciones entre variables de la forma causa-efecto [96]. En el caso del estudio de los datos de la base global NUTRIMENTHE, dicha idea podría proporcionarnos información acerca de la cadena causa-efecto para diagnosticar ciertas condiciones.

8) **Validación**. Una vez obtenidos los resultados en la etapa anterior, el siguiente paso sería comprobar la veracidad/calidad de dichos resultados, mediante validación cruzada. En esta etapa se selecciona aleatoriamente una parte del conjunto de datos llamado training, y el resto, llamado conjunto test, que se usaría para validar dicho modelo.

En la tabla 1 aparece un resumen de los paquetes disponibles R que mejores resultados nos dieron con la base de datos NUTRIMENTHE,

teniendo en cuenta siempre la fiabilidad y procedencia de los dichos paquetes (repositorio CRAN oficial de R).

Tabla 1. Algoritmos de pre-procesamiento y aprendizaje con mejor resultado para la base de datos NUTRIMENTHE.

FASE	TIPOS	PAQUETES R
PRE-PROCESAMIENTO DE DATOS	Limpieza de datos	caret[97]
	Imputación de valores perdidos	caret,MICE[98]
	Identificación de valores extremos	caret
SELECCIÓN DE CARACTERÍSTICAS	Selección de instancias	caret
	Selección de predictores	randomForest[99]
	Importancia relativa	relaimpo[100]
	Subconjunto de variables con máxima ganancia	WGCNA[101]
SUBGROUP DISCOVERY	Importancia absoluta	BORUTA[102]
	SDIGA	SDEFSR[103]
	MESDIF	SDEFSR
	NMEEF-SD	SDEFSR
Aprendizaje Supervisado	FuGePSD	SDEFSR
	RandomForest	randomForest
	Xgboost	caret
Aprendizaje No Supervisado	CART	caret
	Clustering	kmeans[104]
	Reglas de Asociación	arules[105]

- **Proyecto NUTRIMENTHE**

Los datos de este estudio provienen del Proyecto NUTRIMENTHE 7FP UE ("El efecto de la dieta en el rendimiento mental de los niños", GA n.º 212652, www.nutritmenthe.eu), descrito anteriormente en [3]. Se ha conseguido establecer la Base de datos global NUTRIMENTHE (NGDB) uniendo los conjuntos de datos de tres Cohortes de

seguimiento europeas: el estudio *Nutraceuticals for a Healthy Life* (NUHEAL-Follow Up) [106] (Alemania, Hungría y España), el estudio *Childhood Obesity Project* (CHOP) [107] (Bélgica, Alemania, Italia, Polonia y España), y el estudio Generation R [108] (Países Bajos) . Después de combinar las variables comunes de los tres estudios, se formó una nueva base de datos con un total de un millar niños con datos imperfectos que fueron evaluados mediante un procedimiento neuropsicológico común a los 8 – 9.5 años de edad.

✓ **COHORTE NUHEAL Follow-UP (n=147)**

NUHEAL es un ensayo multicéntrico, randomizado, doble ciego, factorial 2x2 controlado por placebo, diseñado para evaluar los efectos de los n-3 LC-PUFA y la suplementación con 5-metil-tetrahidrofolato (5-MTHF) durante la segunda mitad del embarazo en desarrollo infantil. Las mujeres fueron reclutadas antes de las 20 semanas de gestación y fueron asignadas aleatoriamente a cuatro grupos diferentes. Desde la semana 20 hasta el parto, recibieron un suplemento diario consistente en Fish Oil (1) {FO: 500 mg de ácido docosahexanoico (DHA) + 150 mg de ácido eicosapentaenoico (EPA)}, (2) 400 µg de 5-MTHF, (3) ambos, o (4) Placebo, junto con vitaminas y minerales siguiendo las recomendaciones europeas para

mujeres embarazadas. Para mas información sobre la cohorte, consúltese [106].

✓ **COHORTE CHOP (n=525)**

El Programa de Obesidad Infantil de la UE (CHOP) se dedicó a estudiar si la relación proteínas/grasas provista en la fórmula infantil y los alimentos complementarios tiene efectos duraderos sobre los riesgos de padecer obesidad. Dicho estudio permitió, por primera vez, realizar un ensayo de intervención multicéntrico en recién nacidos, para estudiar si la alimentación con fórmulas infantiles, que difieren en su nivel de proteínas de la leche, podrían estar asociados con el riesgo posterior de obesidad infantil. El ensayo se llevó a cabo en cinco países (España, Alemania, Bélgica, Italia y Polonia) con diferentes ingestas habituales de proteínas (bajas y altas concentraciones) para probar la hipótesis de que una ingesta temprana de proteínas se asocia con el crecimiento infantil y el riesgo posterior de obesidad infantil.

✓ **COHORTE Generation R (n=200)**

Generation R es un estudio de cohorte prospectivo desde la vida fetal hasta la edad adulta en una población urbana holandesa multiétnica [108]. El estudio está diseñado para identificar las causas ambientales

y genéticas tempranas del crecimiento, desarrollo y salud normales y anormales desde la vida fetal hasta la edad adulta. Eventualmente, los resultados del Estudio Generación R deben contribuir al desarrollo de estrategias para optimizar la salud y la atención médica de las mujeres embarazadas y los niños.

• **Estudio del Neurodesarrollo**

El desarrollo neurocognitivo de los niños se evaluó mediante la NUTRIMENTHE Neuropsychological Battery (NNB), una batería neuropsicológica integral desarrollada específicamente para el proyecto NUTRIMENTHE [109]. El NNB consta de quince pruebas cognitivas para evaluar siete dominios neuropsicológicos diferentes: velocidad de procesamiento, percepción, motricidad, memoria, atención, lenguaje y funciones ejecutivas, que se describen brevemente en la Tabla 2. [109]

Table 2. NUTRIMENTHE Neuropsychological Battery description

Domain	Function	Test
Memory	Visual Episodic Memory	Recall of Object Test (ROT)
	Verbal Memory	Rey Auditory Verbal Learning Test (RAVLT)
Attention	Sustained & Focused Attention	Continuous Performance Test (CPT)
	Spatial Attention	Pair Cancellation test (W-M)
Motor	Visio-Motor Coordination	Grooved Pegboard Test (GPT)
Perception	Visio-Perceptual Integration	Hooper Visual Organization Test (HVOT)
Language	Semantic Fluency	Categorical Fluency Test (F-A-S-Animals)
	Verbal Comprehension	Token test II (NEPSY-II)
Processing Speed	Processing Speed	Symbol Digit Modalities Test (SDMT)
Executive Functions	Impulsivity/Inhibition	Stroop Color & Word Test
	Update	Reversal Digits Subtest
	Flexibility/Shifting	Matrix Analogies test - (K-ABC-II)
	Decision Making	Children's Color Trail Test (CCTT)
		Hungry Donkey Task (HDT)

• Estudio de la conducta

El CBCL/6-18 (Child Behavior Checklist) [110] es una medida derivada empíricamente, altamente válida, basada en observaciones directas de los padres para proporcionar información sobre el comportamiento y los problemas emocionales de sus hijos, traduciendo los resultados a una puntuación.

El CBCL proporciona un índice (T-Score) del estado social y de comportamiento de los niños en relación con otros niños de la misma edad y sexo. Se obtienen once ítems provenientes del CBCL: tres

escalas totales (internalización, externalización y problemas totales) y ocho escalas individuales (quejas somáticas, abstinencia/depresión, ansiedad/depresión, rebeldía, agresividad, sociales, pensamiento y atención).

Se ha dicotomizado cada CBCL T-Score en dos clases: 1) Sujetos normales con un T-Score por debajo del percentil 60 para cualquier escala CBCL individual y por debajo del percentil 65 para la escala CBCL total. 2) Patología clínica para aquellos con una puntuación T igual o superior al percentil 60 para una escala de CBCL individual, e igual o superior al percentil 65 para la escala de CBCL total, como se detalla en [110].

- **Análisis Bioquímicos (NUHEAL Follow-up)**

- ✓ **Análisis de ácidos grasos (maternos y en el cordón umbilical)**

Para establecer las concentraciones de ácidos grasos en los fosfolípidos del plasma , se ha seguido el procedimiento descrito en [111] . Brevemente, la sangre se centrifugó a 3500 ppm x g durante 10 min a temperatura ambiente. A continuación, se extrajo el plasma y se almacenó a -80°C. La extracción de lípidos del plasma se realizó según el método de Kolarovic y Fournier [112]. El análisis de los ácidos grasos a partir de fosfolípidos en plasma se realizó mediante

cromatografía gas-líquido de alta resolución. Las condiciones durante el análisis y los estándares utilizados están establecidos en [113]. Los resultados se expresaron como porcentajes en peso (% en peso) de todos los ácidos grasos cuantificados.

✓ **Análisis de ácido fólico**

El análisis de ácido fólico en plasma se llevó a cabo mediante un ensayo microbiológico utilizando una cepa de *Lactobacillus casei* resistente al cloranfenicol, como se describió anteriormente [114]. Los coeficientes de variación interensayo e intraensayo fueron inferiores al 11%.

✓ **Análisis de homocisteína**

Las concentraciones de homocisteína total (tHcy) se analizaron mediante inmunoensayo polarizado por fluorescencia con en el autoanalizador IMx [115]. La preparación de la muestra y las condiciones cromatográficas se realizaron como se describió anteriormente [116]. Las intensidades de fluorescencia se midieron con excitación a 385 nm y emisión a 515 nm.

✓ **Selección de SNP**

El genotipado de polimorfismos de un solo nucleótido (SNP) del grupo de genes FADS se realizó con el método iPLEX (Sequenom, San Diego, CA, EE. UU.) Mediante el método de espectrometría de masas

de ionización-tiempo de vuelo con desorción láser asistida por matriz (MALDI-TOF MS, Mass Array, Sequenom), de acuerdo con las instrucciones del fabricante. El control de calidad de genotipado estándar incluyó un 10% de muestras duplicadas y negativas. La tasa de discordancia de genotipado fue inferior al 0,3%. La selección de SNP para los siguientes análisis se realizó calculando el Pairwise Linkage Disequilibrium.

✓ **MTHFR 677 C/T**

Se obtuvieron muestras de ADN a partir de la sangre materna y del cordón en el momento del parto. Dichas muestras se genotiparon para la variante 677 C/T de metilentetrahidrofolato reductasa (MTHFR) mediante PCR, con enzimas de restricción y separación de fragmentos de ADN por electroforesis como se describió previamente [115]. Se seleccionó MTHFR 677 C>T por su alta relevancia clínica en humanos debido a la asociación del genotipo TT con altas concentraciones de homocisteína en plasma [117].

- **Análisis de Neuroimágen (NUHEAL Follow-up)**

- ✓ **Adquisición y pre-procesamiento de imágenes (NUHEAL Follow-Up)**

Los datos de resonancia magnética funcional se recopilaron con un sistema 3T Philips Intera Achieva (Philips Medical Systems, Eindhoven, Países Bajos) equipado con una bobina de cabezal de matriz en fase de ocho canales. Se adquirió una secuencia de imágenes ecoplanares (EPI) ponderadas en T2* con los siguientes parámetros: tiempo de repetición (TR) = 2000 ms; tiempo de eco (TE) = 30 ms; ángulo de giro = 78°; campo de visión = 230 x 230 mm; número de slices = 23; dimensión del voxel = 3 x 3 x 4 mm; espacio, 1 mm. Las imágenes estructurales también se obtuvieron como una secuencia de eco-gradiente turbo ponderada en T1 isotrópica en el plano sagital (TR = 8,3 ms; TE = 3,8 ms; ángulo de giro = 8 °; FOV = 240 x 240 mm; número de cortes = 160; grosor del corte = 1 mm; dimensión del voxel = 1 x 1 x 1 mm). Antes del pre-procesamiento, el movimiento durante la adquisición se estimó utilizando la herramienta de realineación implementada en el software de mapeo paramétrico estadístico (SPM8) (Departamento de Neurología Cognitiva de Wellcome, Instituto de Neurología, Queen Square, Londres). Los sujetos con parámetros de movimiento superiores a 3 mm o 3 grados fueron excluidos del procesamiento y análisis posteriores.

El pre-procesamiento de rsfMRI se realizó con la biblioteca software (FMRIB) (v5.0.9, FSL, <http://fsl.fmrib.ox.ac.uk/fsl/fslwiki>). Los pasos previos al procesamiento incluyeron la eliminación de los diez primeros volúmenes, filtrado temporal de paso alto (120 s), corrección

de movimiento con la herramienta MCFLIRT, extracción del cerebro con BET (Smith, 200), suavizado espacial con un núcleo gaussiano de FWHM = 8 mm, registro en una plantilla estándar ponderada en T1 utilizando FSL-Linear Registration Tool (FLIRT) con 12 grados de libertad (DOF) y finalmente re-muestreo a una resolución de 4 mm.

- **Variables confusoras**

- ✓ **Base Global NUTRIMENTHE**

Se encontraron un conjunto de variables comunes entre las tres cohortes y se agregaron al presente análisis: País de origen, Cohorte, Edad materna (años) al parto, Edad gestacional al parto (semanas), Estado civil, Nivel educativo materno, Nivel educativo paterno, Sexo del niño, medidas antropométricas al nacer (peso (kg), altura (cm) y perímetro cefálico (cm)), y Lactancia materna al menos durante los primeros tres meses.

- ✓ **NUHEAL**

En conjunción con las variables previamente expuestas, la cohorte NUHEAL follow-up cuenta con más variables confusoras, como es el caso de los ácidos grasos, genotipado y resonancias magnéticas previamente establecidas.

• Análisis estadístico

Los resultados descriptivos se expresaron como medias \pm desviación estándar para las variables continuas o porcentajes para las variables categóricas, después de evaluar la normalidad de éstas con el test de Kolmogorov-Smirnov o Shapiro-Wilk, dependiendo del tamaño de la muestra. Las diferencias en las características de la población entre los grupos de estudio se analizaron mediante el test t de Student o ANOVA para variables continuas o la prueba de Chi cuadrado para variables categóricas.

Para evaluar el effect size de la muestra, se ha hecho uso del coeficiente d de Cohen, siguiendo cuidadosamente la regla general, donde $d \leq 0.2$ se consideró como "pequeño", $d \leq 0.5$ como "mediano" y $d \geq 0.8$ como tamaño de efecto "grande" [118].

Para analizar los efectos que podrían tener las variables confusoras, se realizaron modelos de regresión logística y de modelos mixtos en un procedimiento paso a paso para ajustar los posibles factores confusores que mostraban diferencias estadísticamente significativas ($p < 0,05$) entre los grupos de estudio.

Para los datos de resonancias magnéticas, se implementó un método de regresión dual en FSL [119], seguido de pruebas t de dos grupos, para comparar mapas cerebrales entre los grupos de estudio. Se crearon mapas cerebrales estadísticos específicos del sujeto y se

colapsaron en un archivo 4D para cada RSN. En la primera etapa del método de regresión dual, los componentes espaciales generados durante el análisis ICA se regresaron con los RSN de cada sujeto para dar un conjunto de puntos de tiempo específicos del sujeto para cada componente. En la segunda etapa, esos puntos de tiempo se regresaron a los datos rs-fMRI para obtener mapas cerebrales espaciales específicos del sujeto para cada componente. Seguidamente, esos mapas cerebrales específicos del sujeto se usaron para comparar cada red cerebral entre grupos. Estas comparaciones se probaron a nivel de vóxels para determinar las diferencias entre los grupos mediante pruebas de permutación no paramétrica (5000 permutaciones) [120]. Para cada RSN, los mapas estadísticos resultantes tenían un umbral en $p < 0,05$.

Se realizaron correlaciones de Pearson y Spearman entre las puntuaciones de RSN y las pruebas de NNB, teniendo en cuenta la normalidad de las variables.

Tanto el análisis estadístico como los análisis de minería de datos se desarrollaron bajo el entorno y lenguaje de desarrollo R. Las ventajas principales que conlleva son: La inmensurable cantidad de paquetes de código abierto disponibles así como la rapidez de aplicar técnicas potentes de extracción de conocimiento.

TESIS DOCTORAL

HATIM AZARYAH

PUBLICACIONES

PUBLICACIONES

- **Minería de datos aplicada**

Partimos de la hipótesis de que la alimentación precoz pueda tener efecto en el neurodesarrollo y conducta de los niños de la NGDB. Para poder hacer uso de las técnicas de minería de datos, el conjunto de datos que tenemos a nuestra disposición tiene que cumplir con una serie de estándares de calidad. Por ejemplo, el problema de los valores extremos u outliers tiene fácil solución ya que los últimos algoritmos de modelado en inteligencia artificial se encuentran tan avanzados que son capaces de ajustar el error automáticamente. En el caso de selección de instancias, nos puede ayudar a maximizar el resultado objetivo que se desee, seleccionando el subconjunto de muestras que mejor satisfaga una hipótesis, aunque para datos clínicos lo más aconsejable es usar toda la muestra. El principal problema que nos encontramos en el pre-procesamiento de datos en la NGDB fue la gran cantidad de valores perdidos o incompletos; ya que los algoritmos de aprendizaje supervisado o no supervisado necesitan que los datos estén completos para una predicción fiable. El problema reside en que algunos casos, el

porcentaje de valores perdidos supera el 70 %, perdiendo el valor de esa variable por completo. Cuando la perdida de datos esta entre un 15 y un 30 %, mejor calidad tendrá el algoritmo de imputación de datos. El mejor algoritmo de imputación de valores perdidos en el caso de NUTRIMENTHE fue MICE (Multiple Imputations by Chained Equations), cuyo propio nombre indica, se basa en la parametrización de las variables en polinomios de X grado, donde X tiende a ser el número de variables con las que cuenta nuestro conjunto de datos. La principal ventaja de este algoritmo de datos reside en su robustez y fiabilidad, mientras que su principal desventaja es el tiempo de ejecución exponencial que depende del tamaño muestral (82 horas para una población de 872 individuos y 450 variables).

El siguiente paso fue hacer un análisis exploratorio (Aprendizaje NO Supervisado) poco convencional, usando las reglas de asociación como arma principal. Las reglas de asociación permiten de una forma simple, mostrar todas las relaciones causa y efecto intrínsecas en la base de datos. El único requisito metodológico es que la totalidad de las variables estén discretizadas. Se basa en métricas de soporte y confianza, relacionadas básicamente con las veces que se repite la regla o transacción en el conjunto de datos. No se encontró ninguna regla que relacionase la dieta prenatal con alguna variable de neurodesarrollo o conducta, en cambio la relación causa-efecto que

más aparecía estaba relacionada con problemas de conducta Externalizantes y el tabaquismo perinatal.

*Smoking During Pregnancy=Yes --> CBCL_ExternalProblems=Borderline/Pathologic
{support = 0.95 , confidence=0.91, lift=0.99}*

A partir de este resultado, se comprobó en la bibliografía la certeza de esta afirmación, y por consiguiente se desarrolló el manuscrito "**Maternal smoking during pregnancy and child behavior problems: A multicenter study from the NUTRIMENTHE EU Project**", que aparece en la sección Estudio 1.

El hecho de que no haya ninguna asociación directa entre alimentación precoz y neurodesarrollo para la base de datos global NUTRIMENTHE, se decidió seguir explorando la base de forma separada por cohortes. Se descubrió que la cohorte NUHEAL Follow-up contenía gran cantidad de información oculta susceptible de ser extraída con técnicas de minería de datos. Gracias otra vez a las reglas de asociación, se descubrieron las siguientes relaciones causa-efecto:

*AA/DHA ratio = >p75 --> SDMT = >p75
{support = 0.94 , confidence=0.92, lift=0.98}*

AA/DHA ratio = >p75 --> CCTT-1(sc) = >p25
{support = 0.91 , confidence=0.92, lift=0.98}

Se puede apreciar en las dos reglas que el ratio de concentraciones AA/DHA por encima del percentil 75 (previamente discretizado en los percentiles 25,50 y 75) estaba relacionado con ambas pruebas pertenecientes al dominio de velocidad de procesamiento (SDMT = Symbol Digit Modalities test y CCTT = Children Color Trails Test).

A partir de este resultado, se comprobó en la bibliografía la certeza de esta afirmación, y por consiguiente se desarrolló el manuscrito “**Long-chain polyunsaturated fatty acids, homocysteine at birth and fatty acid desaturase gene cluster polymorphisms are associated with children’s processing speed up to age 9 years.**”, que aparece en la sección Estudio 2.

En relación, se partió desde la hipótesis inicial de que la suplementación prenatal con LC-PUFAS y/o 5-MTHF tendría un efecto sobre el conectoma cerebral de los niños; por lo que este estudio estará limitado al proyecto NUHEAL con un total de 57 niños finales que realizaron las sesiones de resonancia.

Después de realizarse los análisis de neuroimagen, implicando el análisis de componentes independientes, doble regresión, y re-agrupación de nuestros grupos en FO (FO o FO + 5-MTHF, n=33) y No-

FO (5-MTHF o placebo, n=24), se decidió estudiar las posibles relaciones vigentes entre las puntuaciones de las resonancias y el resto de variables que aparecen en la base de datos de NUHEAL. Aunque este estudio tenga solo 57 niños, contamos con un total de 1000 variables, incluyendo numerosas características basales, (al contrario que ocurrió con el proyecto NUTRIMENTHE), concentraciones de LC-PUFAS en la madre e hijo en diversos tiempos, parámetros antropomórficos, NNB, CBCL, etc..

En minería de datos, gracias a la selección de características, podemos depurar la base de datos seleccionando sólo los parámetros de interés que nos satisfagan. En el caso presente, se ha dividido la población en FO y NO-FO, y en cada grupo se ha seleccionado como variable objetivo las regiones del conectoma con diferencias significativas entre los dos grupos:

- DMN - Angular Gyrus
- SMN - Postcentral Gyrus, Precentral Gyrus (L&R) y Putamen
- FPN - Angular Gyrus

Una vez seleccionadas las variables objetivo, se crearan modelos de aprendizaje (regresión-randomForest) incluyendo todas las variables predictoras disponibles en la base total de NUHEAL para intentar predecir el curso de la variable objetivo en cuestión. El hecho de haber elegir este algoritmo en concreto recae en su simplicidad y facilidad a la hora de entrenar y ajustar un modelo, como

consecuencia es de los algoritmos de aprendizaje más famosos y usados.

En la tabla 3, se reflejan los resultados de dichos modelos.

Tabla 3. Modelos randomForest para cada RSN significativa

RSN	Area	RMSE	MAE	R ²
Default Mode Network	Angular gyrus	12.14	121.20	0.62
	Postcentral Gyrus	17.52	145.21	0.87
	Precentral Gyrus L	17.54	114.2	0.52
	Precentral Gyrus R	5.23	85.21	0.91
Sensorimotor Network	Putamen	11.02	114.30	0.67
	FrontoParietal Network	Angular Gyrus	7.52	170.44
				0.89

RSN = Resting state Network, RMSE = Root mean squared error, MAE = Mean absolute error, R² = R-squared, BOLD = very high R²

Tanto el Postcentral y Precentral R Gyrus pertenecientes a la red SMN, así como el Angular gyrus, de la red FPN tuvieron como resultado una R² bastante elevada, indicando que las variables explicativas o predictoras son capaces de describir en más de un 90 % las variables objetivo previamente mencionadas.

Se ha usado la función Importance, que viene con el paquete randomForest de R para calcular las 5 características que más se asocian a cada variable objetivo y descubrir, de entre el conjunto

ingente de datos que proporciona NUHEAL, los factores que mejor influyen sobre las puntuaciones de las RSN.

Las variables que más influyen sobre la activación del Postcentral Gyrus (SMN), Precentral R Gyrus (SMN) y Angular gyrus (FPN) se pueden apreciar en la tabla 4.

Se ha descubierto que el CT hits (Cancellation Test, perteneciente a la NNB - Dominio de atención) tiene un alto índice de participación en la activación de las tres RSN, así como el SDMT (perteneciente a la NNB - Dominio de velocidad de procesamiento) se asociaba fuertemente también al Angular Gyrus de la FPN.

Gracias a estos resultados, se consiguió descubrir que la activación del conectoma humano se correlacionaba negativamente con el rendimiento en atención y velocidad de procesamiento, y prueba de ella es artículo “**Effects of Maternal Fish Oil and/or 5-MethylTetrahydrofolate Supplementation during Pregnancy on Offspring Brain Resting-State at 10 Years Old: A Follow-Up Study from the NUHEAL Randomized Controlled Trial**”, publicado en Septiembre del 2020.

Tabla 4. Selección de características para RSN significativa.

Postcentral Gyrus (SMN)		Precentral R Gyrus (SMN)		Angular Gyrus (FPN)	
Variables Importantes	%IncMSE	Variables Importantes	%IncMSE	Variables Importantes	%IncMSE
CT Hits (NNB)	55.32	CT Hits (NNB)	49.52	SDMT hits (NNB)	35.32
Índice n6/n3 (semana 30 de gestación)	7.45	IMC materno (40 sem)	8.25	CT hits (NNB)	31.51
Ácido araquidónico (cordón umbilical)	2.55	K-ABC test	3.99	Homocigoto menor SNP rs174556	4.32
Educación de la Madre	1.26	APGAR 5'	1.22	Ácido α-linolénico (cordón umbilical)	3.52
Perímetrocefálico (12 meses)	0.98	IMC al nacimiento	0.95	País de Origen - Alemania	0.75

%IncMSE = porcentaje que incrementa el error cuadrático medio si quitamos la variable del modelo

ESTUDIO 1

“Maternal smoking during pregnancy and child behavior problems: A multicenter study from the NUTRIMENTHE EU Project.”

Hatim Azaryah, José Antonio García-Santos, Francisco J. Torres-Espínola, Berthold Koletzko, Miguel Pérez-García, Cristina Campoy.

DRAFT submitted - Under review

Maternal smoking during pregnancy and child behavior problems: A multicenter study from the NUTRIMENTHE EU Project.

3

4 Hatim Azaryah^{1,3}, José Antonio García-Santos^{1,2,3}, Francisco J. Torres-Espínola^{1,3},
5 Berthold Koletzko⁵, Miguel Pérez-García¹⁰, Cristina Campoy^{1,2,3,10,11}.

6

7 ¹Department of Paediatrics, School of Medicine, University of Granada, Spain.

² Instituto de Investigación Biosanitaria ibsGRANADA, Health Sciences Technological Park, Granada, Spain.

³ EURISTIKOS Excellence Centre for Paediatric Research, University of Granada, Spain.

12 ⁵ Division of Metabolism and Nutritional Medicine, Dr. von Hauner Children's Hospital, LMU
13 - Ludwig Maximilians-University of Munich Medical Centre, Munich, Germany.

¹⁰ Mind, Brain and Behaviour Research Centre-CIMCYC, University of Granada, Spain.

¹¹ CIBERESP: National Network of Research in Epidemiology and Public Health.
¹² Institute Carlos III, Madrid, Spain.

18

19

20 Corresponding Author:

21 Prof Cristina Campoy, MD, PhD.

22 Department of Paediatrics. School of Medicine. University of Granada

23 Ayda. de la Investigación. 11 – 18016 Granada. Spain.

24 e-mail: ccampos@uqr.es

25

26 ABSTRACT

27 *Background*

28 Maternal smoking may alter child development harming different organs and systems such
29 lungs, cardiovascular system or brain structure and function; these effects may increase the
30 risk to develop chronic non-communicable diseases later in life, including mental disorders. In
31 the present study, a possible association between maternal smoking during pregnancy and
32 later behavioral problems in the offspring at school age (7 – 8 years old) was investigated.

33 *Methods*

34 A total of 818 children who participated in the NUTRIMENTHE project were included in the
35 present observational study. Data comes from three well-established Europeans cohorts
36 (CHOP, Generation R and NUHEAL), including information from six countries: Germany, The
37 Netherlands, Poland, Italy, Belgium and Spain. Mothers were divided in two groups: perinatal
38 Smokers (n=167) and Non-Smokers (n=651). All children were assessed at age 7 - 8 with the
39 Child Behaviour Checklist (CBCL).

40 *Results*

41 Children born to non-smokers mothers shown consistently lower T score (range from 49 to
42 49.5) than those born to the smoking mothers group (range from 51 to 54) in Total, Internalizing
43 and Externalizing continuous CBCL scales. After categorizing outcomes in Normal and
44 Borderline/Clinical pathology, and including potential confounders (cohort, country of origin,
45 parental education, and breastfeeding at three months) in the adjusted analyses, only
46 externalizing problems remained statistically significant (OR: 2.03; 95% CI: 1.23-3.11, p-
47 value=0.012).

48 *Conclusions*

49 These results support previously reported effects about maternal smoking during pregnancy
50 and offspring behaviour; in general, children born to non-smokers mothers showed fewer
51 behavioural problems during childhood. However, country of origin, parental educational level
52 and breastfeeding at 3 months seems to modify the effect of maternal smoking during perinatal
53 period on children behavioral development. Tobacco control efforts and reduce smoking rates,
54 has the potential to prevention and mitigation of perinatal risk factors-related childhood
55 behavioral problems, as well as the associated long-lasting health consequences.

56 **Keywords:** Maternal smoking, pregnancy, CBCL, NUTRIMENTHE, Children Behavior.

57

58 **BACKGROUND**

59 Interaction between genetic, environmental and social factors may affect later behavioral
60 development in children, which has major implications for public health and policy
61 development. According to the World Health Organization (WHO), Europe has currently the
62 highest proportion of cigarette smokers among adults (28%) and one of the highest among
63 adolescents, despite all the efforts made by public and private entities to encourage smoking
64 cessation [1]. While tobacco use was previously predominant among men, difference between
65 both genders is currently very small (<5%) in European countries such as Denmark, Ireland,
66 the Netherlands, Norway, Sweden and United Kingdom. Some 19% of women aged 15 and
67 above smoked tobacco in the WHO European Region [1] and, as a matter of concern, cigarette
68 poses serious risk to the mother and her developing fetus, being now recognized as an
69 important cause of child morbidity and mortality. Cigarette smoke exposure during pregnancy
70 can perturb child's respiratory tract, cardiovascular system and brain morphology, leading to
71 chronic damage that can manifest later in life [2, 3]. Perinatal infant mortality, stillbirth, preterm
72 birth, congenital anomalies, lower birth weight and slow fetal development and growth, are
73 common consequences of exposure to maternal smoking, use of smokeless tobacco during
74 pregnancy and of second-hand smoke exposure [4–11].

75 Detrimental neurocognitive and behavioral profiles of school-aged children born to mothers
76 who smoked during pregnancy have been documented, promoting early appearance of
77 psychopathological symptoms such as attention deficit hyperactivity disorder (ADHD) [12],
78 aggressive behavior [13], autism spectrum disorders (ASD) [14], risk of hypomania [15], low
79 academic achievements [16], as well as speech-processing and attention control deficits [17,
80 18]. However, considering the observational nature of data in those studies, it appears that
81 behavioral outcomes are linked somehow to other confounding factors such as gender,
82 parental age, parental education or parental income [19]. Moreover, effects of cultural and
83 sociodemographic characteristics of the population studied are considered confounding factors
84 [20]. Conversely, other studies support the idea that association between maternal smoking
85 during pregnancy and offspring ADHD reflects unmeasured confounding [12].

86 The goal of the present study is to investigate a plausible association between maternal
87 smoking during pregnancy and behavioral profile of children at 7 - 8 years old, evaluated

88 through the Childhood Behavior Checklist (CBCL). The analysis was performed involving
89 mother-child pairs from six different European countries, taking into account potential effects of
90 various confounding factors collected through the NUTRIMENTHE research project

91 **METHODS**

92 **Study setting**

93 This is a descriptive cross-sectional study which data comes from the NUTRIMENTHE 7FP EU
94 Project, previously described in [21]. Within NUTRIMENTHE EU Project (*"The Effect of Diet on*
95 *the Mental Performance of Children"*, GA no. 212652, www.nutrimenthe.eu) framework, the
96 NUTRIMENTHE Global Database (NGDB) was established joining the data sets from three
97 different follow-up European cohorts, the Childhood Obesity Project (CHOP) study (Belgium,
98 Germany, Italy, Poland and Spain), the Generation R study (The Netherlands) and the
99 Nutraceuticals for a Healthy Life (NUHEAL) study (Germany, Hungary and Spain). Description
100 of participants of these cohorts has been published elsewhere [22–24]. After combining the
101 common variables from the three studies, a new cohort was formed with a total of 1050 children
102 who were assessed using a common neuropsychological procedure; all data sets from these
103 children were included in the NGDB [20].

104 **Participants**

105 Some 818 healthy children from six European countries whose mothers fully completed the
106 Child Behavior Checklist questionnaire were included in the present analysis: 129 Spanish and
107 German children from the “Nutraceuticals for a Healthier Life (NUHEAL)” [24]; 509 children
108 from Germany, Spain, Poland, Italy and Belgium participating in the EU Childhood Obesity
109 Programme (CHOP) [22]; and 180 children from the Generation R epidemiological study in The
110 Netherlands [23]. Due to significant drop-out rate, participants from Hungary were excluded
111 from further analysis.

112 **Study variable and sample size**

113 Maternal smoking was self-reported and harmonized to derive a dichotomous variable as ‘Yes’
114 and ‘No’ for maternal smoking during pregnancy, encompassing a period extended before,
115 during and after pregnancy. From the 818 children, some 651 were born to mothers who did

116 not smoke during pregnancy and 167 children whose mothers were smokers. For the sample
117 size calculation, r package “pwr” was used. Considering a standard deviation of 0.5,
118 significance level of 0.05 and a desired power of 80%, we need a minimum sample size of 63
119 for each group.

120 **Outcomes**

121 The Child Behavior Checklist (CBCL/6-18) [26] is an empirically derived measure, highly
122 reliable and valid test, based on direct observations from parents to provide information about
123 behavior and emotional problems of their children, and translating the results into a score.

124 The CBCL provides an index (T-score) of the children's social and behavioral status relative to
125 other children of the same age and gender. Each CBCL T-Score were categorized in two
126 classes: 1) Normal subjects with a T-Score below percentile 60 for any single CBCL scale and
127 below percentile 65 for total CBCL scale. 2) Borderline/Clinical pathology for those with a T-
128 Score equal or above percentile 60 for single CBCL scale, and equal or above percentile 65 for
129 total CBCL scale, as detailed elsewhere [27]. Eleven items are obtained from the CBCL
130 checklist: three *total scales* (Internalizing, Externalizing and Total problems) and eight *single*
131 *scales* (Somatic Complaints, Withdrawn/Depressed, Anxiety/Depression, Rule Breaking,
132 Aggressive Behaviors, Social (child dependent, lonely, jealous, clumsy, among others),
133 Thought, and Attention Problems). CHOP children were evaluated at 8 years, those from
134 Generation R at 7 years and those participating in the NUHEAL study at 7·5 years [20].

135 **Confounding variables**

136 A set of common variables were found between the three cohorts and added to the
137 present analysis: Country of origin, Cohort , Maternal Age (years) at delivery, Gestational Age
138 at delivery (weeks), Marital Status, Maternal Educational level, Paternal Educational level, Child
139 gender, anthropometrical measures at birth (weight (kg), height (cm) and head circumference
140 (cm)),and Breastfeeding at least for the first three months.

141 **Statistical analysis**

142 Descriptive results were expressed as means ± standard deviation (SD) or percentages, after
143 assessing normal distribution of variables with Kolmogorov–Smirnov test. Differences in

144 population characteristics considering maternal smoking habit as study groups were analyzed
145 by Student's t-test for continuous variables, or Chi square test for categorical variables.

146 In order to study differences in behavioral performance among children born to mothers who
147 smoked against those born to non-smokers mothers, both descriptive and one-way ANOVA
148 analysis were conducted using smoking during pregnancy (Yes or No) as the independent
149 factor, and CBCL T scores as continuous dependent variables. To evaluate size effect of
150 maternal smoking during pregnancy on each CBCL T score, Cohen's d coefficient analysis was
151 performed, following carefully the general "rule of thumb", where $d \leq 0.2$ was considered as
152 "small", $d \leq 0.5$ as "medium" and $d \geq 0.8$ as "large" effect size [28, 29].

153 To analyze effects of maternal smoking during pregnancy on each CBCL scale, logistic
154 regression models were then performed in a step by step procedure to adjust for those
155 potential confounders which showed statistically significant differences ($p < 0.05$) between
156 smokers and non-smokers mother groups. Statistical models were as follows: 1) unadjusted; 2)
157 adjusted by cohort and country of origin (Model 1); 3) Model 1 plus maternal and paternal
158 educational level (Model 2); 4) Model 2 plus breastfeeding at least during three months (Model
159 3). Statistical analysis were conducted using statistical software R version 3.4 (The R Project for
160 Statistical Computing, <https://www.r-project.org/>).

161 **Ethical consideration**

162 The three studies were performed in line with the Declaration of Helsinki II Principles [25], and
163 the procedures were authorized by the Ethical Committees of all centers involved in each
164 country. All families were properly informed about the types of procedures and signed a written
165 consent prior to their inclusion in the study.

166 **RESULTS**

167 **Study participants**

168 Our observational study included 818 mother-children pairs who fully answered CBCL
169 questionnaires. Baseline characteristics of subjects involved are detailed in **Table 1**. Total
170 number of smoking mothers was 167 (20.42%), whereas number in the non-smoking group
171 was 651 (79.58%). There were no statistically significant differences ($p > 0.05$) between groups

172 regarding maternal age at pregnancy, gestational age at delivery and child gender, neither in
 173 newborn weight, length or head circumference at birth. Nevertheless, there were statistically
 174 significant differences regarding breastfeeding at three months: women who had never smoked
 175 were more likely to continue maternal breastfeeding than smoker mothers ($p<0.0001$). The
 176 majority of the current study population were married or living with a partner, regardless of
 177 smoking status ($p=0.08$). Concerning maternal educational level, non-smokers group had a
 178 predominance of high (higher education) and medium (secondary education) educational level,
 179 whereas smokers group had between medium and low education (primary or no education)
 180 status ($p<0.0001$). Considering paternal education, a high proportion of the fathers had medium
 181 or low educational level in the smoking group, while educational level was almost equivalent
 182 through the three educational categories in the non-smoking group ($p<0.0001$). Statistically
 183 significant differences between groups regarding cohort and country of origin were detected
 184 ($p<0.0001$).

185

186

187

188

189

190

191

192

193

194

195

196 **Table 1.** General characteristics of the population participating in the study.

197

		Non Smokers Mothers (n=651)	Smokers Mothers (n=167)	P
Country of origin	Spain	205 (31.49)	86 (51.49)	<0.0001
	Germany	76 (11.67)	15 (8.98)	
	Italy	73 (11.21)	24 (14.37)	
	The Netherlands	179 (27.50)	1 (0.60)	

	Poland	67 (10.29)	34 (20.36)	
	Belgium	51 (7.83)	7 (4.19)	
	NUHEAL	106 (16.28)	23 (13.77)	
Cohort	CHOP	366 (56.22)	143 (85.63)	<0.0001
	Generation R	179 (27.50)	1 (0.60)	
Maternal Age (years) at delivery		31.46±4.80	30.41±5.70	0.28
Gestational Age at delivery (weeks)		39.81±1.54	39.65±1.37	0.43
Marital Status	Married/Living together	545 (94.45)	112 (90.32)	0.08
	Single/No partner	32 (5.55)	12 (9.68)	
Maternal Educational level	High	317 (48.99)	31 (18.56)	<0.0001
	Medium	284 (43.89)	93 (55.69)	
	Low	46 (7.11)	43 (25.74)	
Paternal Educational level	High	229 (37.36)	21 (8.40)	<0.0001
	Medium	207 (33.77)	85 (29.11)	
	Low	177 (28.87)	59 (25.00)	
Child gender	Girl	342 (52.53)	78 (46.71)	0.15
	Boy	309 (47.47)	89 (53.29)	
Newborn weight at birth (kg)		3.45±0.35	3.31±0.32	0.32
Newborn length at birth (cm)		51.02±2.82	50.54±2.55	0.51
Newborn HC at birth (cm)		34.72±1.50	34.52±2.01	0.12
Breastfeeding from birth (at least during 3 months)	Yes	314 (52.42)	26 (19.85)	<0.0001
	No	285 (47.58)	105 (80.15)	

198 Data are expressed as n (%) or media ±SD. HC: head circumference. P from t and Chi-square test Bold =
 199 Significance. CHOP: Childhood Obesity Project; NUHEAL: Nutraceuticals for a Healthy Life.

200
 201 **Effects of smoking during pregnancy on CBCL outcomes in children of 7.5 and 8 years.**

202 Analysis of CBCL T scores in children born to smoking mothers vs. non-smoking mothers are
 203 shown in **Table 2**. Children born to non-smoking mothers shown consistently lower CBCL T
 204 scores (between 49 and 49.5) than children born to smoking mothers (between 51 and 54),
 205 which generally correlates with fewer behavioural problems.

206 There were significant differences ($p<0.05$) in almost all CBCL scales, except for Thought
 207 problems ($p=0.16$, $d=0.13$) and Social problems ($p=0.066$, $d=0.17$), where no differences were
 208 found between groups. The majority of scales showed a medium-small effect size between
 209 smoking and non-smoking groups on CBCL scale outcomes (between 0.21 and 0.54).

210 **Table 2.** Differences on CBCL T scores between children's born to smokers and non-smokers
 211 mothers.

CBCL Scale	Non Mothers	Smokers Mothers	d	P
Anxious/Depressed	49.31±9.93	52.65±9.76	0.34	<0.0001
Withdrawn/Depressed	49.55±9.62	51.60±11.07	0.21	<0.01
Somatic complaints	49.49±9.72	51.93±10.85	0.24	<0.001
Social problems	49.50±10.02	51.14±9.24	0.17	0.066
Thought problems	49.61±9.59	50.86±10.67	0.13	0.16
Attention problems	48.90±9.51	54.20±10.59	0.54	<0.0001
Rule breaking behavior	49.40±9.86	51.65±10.24	0.23	<0.01
Aggressive behavior	49.32±9.65	52.42±10.40	0.35	<0.0001
Internalizing Problems	49.39±9.96	52.26±9.70	0.31	<0.0001
Externalizing Problems	49.28±9.66	52.63±10.43	0.35	<0.0001
Total Problems	49.14±9.64	53.10±10.28	0.41	<0.0001

212 Results are expressed as Mean±SD; P = p value from one way ANOVA; d from Cohen's effect size. Bold =
 213 Significance.
 214


215 Next, differences in the percentage of children categorized at or above Borderline/Clinical
 216 Range for the CBCL Scales regarding Internalizing, Externalizing and Total problems were
 217 studied. As shown in **Figure 1**, children born to smoking mothers shown these kind of
 218 behavioral disturbances more frequently compared to children born to mothers who never
 219 smoked ($p<0.05$).

220

221

222

223 Figure 1. Percentage of children at or above the borderline/clinical range for CBCL scales in
 224 internalising, externalising or total problems according to maternal smoking status during pregnancy. P
 225 = p-value from Chi-square test.



226

227 **Associations between CBCL T scores scales and potential confounders**

228 Subsequently, strength of association between CBCL T scores and mothers smoking status
 229 was examined, via multiple logistic regression analysis (**Table 3**). Statistical significant
 230 differences were found in Internalizing, Externalizing and Total Problems (p=0.041, p=0.004,
 231 p=0.001, respectively), as well as in the Thought and Attention Problems and Somatic
 232 complaints scales (p=0.029, p=0.017, p=0.003, respectively) in the unadjusted model. After
 233 adjusting by cohort and country of origin (Model 1), effect of maternal smoking during
 234 pregnancy remained significant on Thought, Attention and Externalizing Problems (p=0.029,
 235 p=0.017, p=0.013, respectively). The inclusion of maternal and paternal educational level as
 236 confounders in the Model 2, results in a loss of significance in relation to Thought Problems,
 237 but kept it for Attention and Externalizing Problems (p=0.029, p=0.021, respectively). In Model
 238 3, which comprised also breastfeeding at least during 3 months as confounding factor,
 239 significant differences were detected for Thought Problems (p=0.024) and Externalizing
 240 Problems scale (p=0.012). A trend of significance in Total Problems outcome, although
 241 marginal, was also detected in this Model 3 (p=0.057).

242

Table 3. Effects of maternal smoking on categorical CBCL outcomes considering potential confounders.

CBCL Scale	Unadjusted model (n=818)		MODEL 1 (n=818)		MODEL 2 (n=777)		MODEL 3 (n=777)
	OR (CI 95%)	P	OR (CI 95%)	P	OR (CI 95%)	P	
Anxious/Depressed	1.29 (0.75-2.13)	0.331	0.81 (0.39-1.32)	0.068	1.03 (0.49-1.71)	0.799	1.17 (0.62-2.72)
Withdrawn/Depressed	1.48 (0.81-2.59)	0.182	1.28 (0.66-2.12)	0.411	0.98 (0.51-1.97)	0.332	1.21 (0.68-2.74)
Somatic complaints	1.52 (0.84-5.65)	0.003	1.05 (0.52-2.12)	0.311	1.37 (0.68-2.61)	0.271	1.31 (0.68-2.74)
Social problems	0.86 (0.44-1.57)	0.629	0.79 (0.39-1.42)	0.611	0.71 (0.32-1.11)	0.621	0.83 (0.38-1.88)
Thought problems	1.98 (1.04-3.72)	0.034	2.08 (0.99-3.61)	0.029	1.65 (0.88-3.05)	0.098	2.37 (1.20-4.56)
Attention problems	2.81 (1.41-4.56)	0.001	1.79 (1.13-2.87)	0.017	1.81 (0.99-3.01)	0.029	1.35 (0.68-2.94)
Rule breaking behavior	1.17 (0.66-2.01)	0.577	1.27 (0.74-2.02)	0.302	1.25 (0.67-1.98)	0.598	0.98 (0.48-2.48)
Aggressive behavior	1.66 (0.91-2.93)	0.08	1.56 (0.79-3.01)	0.112	1.47 (0.69-2.89)	0.198	1.77 (0.98-3.56)
Internalizing Problems	1.56 (1.01-2.37)	0.041	1.42 (0.71-1.65)	0.501	1.55 (0.82-1.96)	0.311	1.41 (0.68-2.74)
Externalizing Problems	1.87 (1.20-2.86)	0.004	1.82 (1.02-2.94)	0.013	1.86 (1.01-2.69)	0.021	2.03 (1.20-3.86)
Total Problems	2.01 (1.3-3.09)	0.001	1.49 (0.81-2.02)	0.069	1.59 (1.02-2.29)	0.071	1.77 (1.02-3.09)

243
244

Logistic regression analysis of CBCL scores according to maternal smoking status during pregnancy, adjusted by: Model 1: Country of origin and 1+ Maternal and Paternal Educational Level; Model 3: Model 2+ Breastfeeding at least for 3 months. OR = Odds Ratio, CI= Confidence Interval, P

DISCUSSION

The main goal of this observational study was to investigate a potential association between maternal smoking and behavioral profile of European children at 7 - 8 years old, assessed through CBCL questionnaires in a multicenter cohort, involving mother-children pairs from the NUTRIMENTHE project. Overall, results show that children born to smoking mothers have higher risk of Externalizing behavioral problems after adjusting for confounding variables (cohort and country of origin, maternal and paternal educational level, and breastfeeding at least during three months) than children born to non-smoker mothers. Childhood internalizing/externalizing problems seems to be predictive of later negative adolescent and adult behavioral, emotional, cognitive, and physical health outcomes [30]. Internalizing problems refer to inwardly focused negative behaviors such as anxiety, depression, and somatic symptoms, while externalizing problems refer to outwardly focused negative behaviors such as hyperactivity, aggression, disruptive conduct, and substance use [31, 32].

It is also worth to mention that parental education and breastfeeding from birth at least for three months seems to modulate effects of maternal smoking on Thought and Attention problems respectively, in children at 7 - 8 years of age. It is well established the protective role of breastfeeding on children internalizing, externalizing behavioral problems and low intelligence in childhood [33].

Our results are in agreement with other previously published studies [34-36], which found behavioral problems in children exposed to maternal smoking during pregnancy. Conduct and behavioral disorders have been found frequently associated with prenatal tobacco exposure, in children as young as 18–24 months, and in older children (6–16 years old) [37]. However, other researchers have reported no causal association between maternal smoking during pregnancy and ADHD, using twin studies, in vitro fertilization cohorts or genetic epidemiology approaches [38, 39], which support the idea that association between maternal smoking during pregnancy and offspring ADHD is not due to causal intrauterine effects, but reflects unmeasured confounding [12]. Other authors suggest that effect of smoking on behavior is small and less important than found in previous studies, and influence may be due to time-stable familial factors, such as environmental and genetic factors [40]. On the other hand, other researchers

have found changes in superior frontal and parietal cortices and smaller global brain volumes in children aged 6 to 8 years who were prenatally exposed to tobacco, even after adjustment for socioeconomic confounding factors [41].

Nevertheless, there is a wide consensus about the pernicious effects of tobacco smoke during pregnancy, which occurs in the context of a set of socioeconomic circumstances that place the child at increased developmental risk, but may not be causally related to the children's behavior [35].

The statistical association of maternal smoking with children behavioral problems could be strongly confounded by sociodemographic characteristics. It has been previously reported that mothers who smoke during their pregnancies are on average of lower income status and have less education [42]. In the current study, the smoker group mothers also shows between medium and low educational level, while non-smoking mothers have higher level of education. Moreover, country of origin has been previously reported as a factor that should be considered an important confounder in studies measuring neuropsychological performance [20] having in mind always the strong relationship that prevail with behavior outcomes.

On the other hand, systematic review of genetically informative studies, suggest that minimal evidence exist to support a causal effect on offspring ADHD or conduct problems of maternal smoking during pregnancy. Moreover, much evidence suggest associations reflect familial confounding and passive gene-environment correlation [38].

Some limitations of the study have to be acknowledged: there are no available data regarding paternal smoking status. Maternal smoking habit was based only on questionnaires. No data were available regarding mothers' smoking duration, nor number of cigarettes smoked per day. This may imply a risk of misclassification, and excludes the possibility of assessing a possible dose-response relationship. On the other hand, smoking habit period encompass an extended period (before, during and after pregnancy), thereby limiting conclusions to the whole perinatal time. Some researchers have pointed out that children exposed prenatally to tobacco were more likely to exhibit abnormal behaviors compared to children exposed only during postnatal period [43], thus emphasizing that gestation is a critical period in the development of behavioral disorders. Another limitation of the current study is that no data about possible maternal psychological problems were available, which could affect maternal perception of their children,

nor the influence of familiar social background. In that sense, depression and psychopathological problems are more common in mothers who smoked during pregnancy than non-smoker mothers [44], and mothers who smoke during pregnancy are on average of lower educational level and income status [42]. Regarding Generation R cohort, it was previously reported [35] a higher percentage of smoking mothers (21.7%) in this population, while participants of the Generation R cohort in the current study show a lower percentage of smoking mothers. However, sensitivity analyses excluding children from Generation R study were performed, and results obtained did not change current study conclusions.

In summary, our results point out to a higher risk of Borderline/Clinical pathological Externalizing Problems in children at 7 - 8 years of age, born to smoking mothers, even after adjusting for confounding variables. In addition, the effect of smoking during pregnancy considering Thought and Attention Problems scales, seems to be conditioned by parental educational level and breastfeeding at three months respectively. Other confounding factors could not be discarded to influence the effects of tobacco smoking in child neurodevelopment. Therefore, it is important to reinforce tobacco control efforts and reduce smoking rates, including pregnant women and households with young children, as effects of tobacco smoke in child growth has been reported. Understanding this phenomenon has the potential to facilitate recognition, prevention, and mitigation of perinatal risk factors-related childhood behavioral problems, as well as the associated long-lasting negative health consequences.

DECLARATIONS

Ethics approval and consent to participate

All studies involved in the current analysis ("Nutraceuticals for a Healthier Life (NUHEAL)" [24], EU Childhood Obesity Programme (CHOP) [22]; and the Generation R epidemiological study [23]), were performed in line with the Declaration of Helsinki II Principles [25], and the procedures were authorized by the Ethical Committees of all centers involved in each country. All families were properly informed about the types of procedures and signed a written consent prior to their inclusion in the study.

Consent for publication

Not applicable.

Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available due to nature of the information that could compromise research participant privacy/consent, but are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

The studies reported herein have been carried out with financial support from the European Commission 7th Framework Programme (FP7/2008-2013) under Grant Agreement (GA) 212652 (NUTRIMENTHE Project "*The Effect of Diet on the Mental Performance of Children*", www.nutrimenthe.eu). Further support was received from European Union research projects EarlyNutrition, FP7 KBBE-2011-1 (GA 289346) and Horizon2020 DynaHEALTH (GA 633595) and Lifecycle-733206, the European Research Council Advanced Grant META-GROWTH ERC-2012-AdG-no.322605, European Joint Programming Initiative Project NutriPROGRAM. Further support was provided by German Ministry of Education and Research, Berlin (Grant Nr. 01 GI 0825), German Research Council (Ko912/12-1 and INST 409/224-1 FUGG), US National Institutes of Health, the Government of Norway, and different healthcare and nutrition companies, predominantly as part of publically funded research projects supported by the European Commission. Those funding sources had no role in the design of this study or any role during its execution, analyses, interpretation of the data, or decision to submit results.

Authors' contributions

CC designed, coordinated the study and reviewed the manuscript. HA, MGB and JAGS analyzed data and written the draft. All the remaining co-authors contributed deeply in data acquisition, results interpretation, review and final manuscript editing. All authors read and approved the final manuscript.

Acknowledgements

We thank all the children and families which generously have accepted to participate in the NUTRIMENTHE EU Project for their precious collaboration. Authors would like to thank also researchers in the different subprojects for their invaluable collaboration.

The results reported in this article are likely to be included in the Doctoral Thesis of Hatim Azaryah at the University of Granada (Spain), in the context of the PhD Program in Epidemiology and Public Health.

REFERENCES

1. WHO. World Health statistics 2018: Monitoring Health for the SDGs. World Health Organization. 2018.
2. Ekblad M, Korkeila J, Lehtonen L. Smoking during pregnancy affects foetal brain development. *Acta Paediatr* 2015;104(1):12-8. doi: 10.1111/apa.12791.
3. Bandera G, Martelli A, Landi M, Moretti F, Betti F, Radaelli G, et al. Short and long term health effects of parental tobacco smoking during pregnancy and lactation: a descriptive review. *J Transl Med* 2015;13:327. doi: 10.1186/s12967-015-0690-y.
4. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: A systematic analysis and implications. *Lancet* 2012;379(9832):2162-72. doi: 10.1016/S0140-6736(12)60820-4.
5. Flenady V, Koopmans L, Middleton P, Frøen JF, Smith GC, Gibbons K, et al. Major risk factors for stillbirth in high-income countries: A systematic review and meta-analysis. *Lancet* 2011;377(9774):1331-40. doi: 10.1016/S0140-6736(10)62233-7.
6. Leonardi-Bee J, Smyth A, Britton J, Coleman T. Environmental tobacco smoke and fetal health: Systematic review and meta-analysis. *Arch Dis Child Fetal Neonatal Ed* 2008;93(5):F351-61. doi: 10.1136/adc.2007.133553.
7. Pineles BL, Hsu S, Park E, Samet JM. Systematic review and meta-analyses of perinatal death and maternal exposure to tobacco smoke during pregnancy. *Am J Epidemiol* 2016;184(2):87-97. doi: 10.1093/aje/kwv301.
8. Zhang K, Wang X. Maternal smoking and increased risk of sudden infant death syndrome: A meta-analysis. *Leg Med (Tokyo)* 2013;15(3):115-21. doi: 10.1016/j.legalmed.2012.10.007.
9. Gupta PC, Subramoney S, Sreevidya S. Smokeless tobacco use, birth weight, and gestational age: population based, prospective cohort study of 1217 women in Mumbai, India. *BMJ* 2004;328(7455):1538. doi: 10.1136/bmj.38113.687882.EB.
10. Inamdar AS, Croucher RE, Chokhandre MK, Mashyakhy MH, Marinho VCC. Maternal smokeless tobacco use in pregnancy and adverse health outcomes in newborns: A systematic review. *Nicotine Tob Res* 2015;17(9):1058-66. doi: 10.1093/ntr/ntu255.
11. Duby JC, Langkamp DL. Another Reason to Avoid Second-Hand Smoke. *J Pediatr* 2015;167(2):224-5. doi: 10.1016/j.jpeds.2015.04.049.
12. Gustavson K, Ystrom E, Stoltenberg C, Susser E, Surén P, Magnus P, et al. Smoking in Pregnancy and Child ADHD. *Pediatrics* 2017;139(2):e20162509. doi: 10.1542/peds.2016-2509.
13. Malanchini M, Smith-Woolley E, Ayorech Z, Rimfeld K, Krapohl E, Vuoksimaa E, et al. Aggressive behaviour in childhood and adolescence: the role of smoking during pregnancy, evidence from four

twin cohorts in the EU-ACTION consortium. *Psychol Med* 2019;49(4):646-654. doi: 10.1017/S0033291718001344.

14. Grossi E, Migliore L, Muratori F. Pregnancy risk factors related to autism: an Italian case-control study in mothers of children with autism spectrum disorders (ASD), their siblings and of typically developing children. *J Dev Orig Health Dis* 2018;9(4):442-449. doi: 10.1017/S2040174418000211.

15. Mackay DF, Anderson JJ, Pell JP, Zammit S, Smith DJ. Exposure to tobacco smoke in utero or during early childhood and risk of hypomania: Prospective birth cohort study. *Eur Psychiatry* 2017;39:33-39. doi: 10.1016/j.eurpsy.2016.06.001.

16. Kristjansson AL, Thomas S, Lilly CL, Thorisdottir IE, Allegrante JP, Sigfusdottir ID. Maternal smoking during pregnancy and academic achievement of offspring over time: A registry data-based cohort study. *Prev Med* 2018;113:74-79. doi: 10.1016/j.ypmed.2018.05.017.

17. Key APF, Ferguson M, Molfese DL, Peach K, Lehman C, Molfese VJ. Smoking during pregnancy affects speech-processing ability in newborn infants. *Environ Health Perspect* 2007;115(4):623-9. doi: 10.1289/ehp.9521.

18. Motlagh MG, Sukhodolsky DG, Landeros-Weisenberger A, Katsovich L, Thompson N, Scahill L, et al. Adverse effects of heavy prenatal maternal smoking on attentional control in children with ADHD. *J Atten Disord* 2011;15(7):593-603. doi: 10.1177/1087054710374576.

19. Behl M, Rao D, Aagaard K, Davidson TL, Levin ED, Slotkin TA, et al. Evaluation of the association between maternal smoking, childhood obesity, and metabolic disorders: a national toxicology program workshop review. *Environ Health Perspect*. 2013;121(2):170-80. doi: 10.1289/ehp.1205404.

20. Pérez-García M, Luna JDD, Torres-Espínola FJ, Martínez-Zaldívar C, Anjos T, Steenweg-de Graaff J, et al. Cultural effects on neurodevelopmental testing in children from six European countries: an analysis of NUTRIMENTHE Global Database. *Br J Nutr* 2019;122(s1):S59-S67. doi: 10.1017/S0007114517000824.

21. Anjos T, Altmäe S, Emmett P, Tiemeier H, Closa-Monasterolo R, Luque V, et al. Nutrition and neurodevelopment in children: Focus on NUTRIMENTHE project. *Eur J Nutr* 2013;52(8):1825-42. doi: 10.1007/s00394-013-0560-4.

22. Koletzko B, Von Kries R, Closa R, Escribano J, Scaglioni S, Giovannini M, et al. Lower protein in infant formula is associated with lower weight up to age 2 y: A randomized clinical trial. *Am J Clin Nutr* 2009;89(6):1836-45. doi: 10.3945/ajcn.2008.27091.

23. Jaddoe VWV, Mackenbach JP, Moll HA, Steegers EAP, Tiemeier H, Verhulst FC, et al. The Generation R Study: Design and cohort profile. *Eur J Epidemiol* 2006;21(6):475-84. doi: 10.1007/s10654-006-9022-0.

24. Krauss-Etschmann S, Shadid R, Campoy C, Hostler E, Demmelmair H, Jiménez M, et al. Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: A European randomized multicenter trial. *Am J Clin Nutr* 2007;85(5):1392-400. doi: 10.1093/ajcn/85.5.1392.

25. World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects. *JAMA* 2013;310(20):2191-4. doi: 10.1001/jama.2013.281053.

26. Achenbach TM, Becker A, Döpfner M, Heiervang E, Roessner V, Steinhausen HC, et al. Multicultural assessment of child and adolescent psychopathology with ASEBA and SDQ instruments: Research findings, applications, and future directions. *J Child Psychol Psychiatry* 2008;49(3):251-75. doi: 10.1111/j.1469-7610.2007.01867.x.

27. Achenbach TM, Rescorla LA. The Achenbach system of empirically based assessment. In: Forensic Uses of Clinical Assessment Instruments. 2nd Ed. 2013.
28. Cohen J. Statistical power analysis for the behavioral sciences. 2nd Ed. 1988.
29. Durlak JA. How to select, calculate, and interpret effect sizes. *J Pediatr Psychol* 2009;34(9):917-28. doi: 10.1093/jpepsy/jsp004.
30. Tien J, Lewis GD, Liu J. Prenatal risk factors for internalizing and externalizing problems in childhood. *World J Pediatr*. 2019 Oct 15. doi: 10.1007/s12519-019-00319-2.
31. Liu, J. Childhood externalizing behavior: theory and implications. *J Child Adolesc Psychiatr Nurs*. 2004;17(3):93–103. doi: 10.1111/j.1744-6171.2004.tb00003.x.
32. Achenbach TM, Ivanova MY, Rescorla LA, Turner LV, Althof RR. Internalizing/externalizing problems: review and recommendations for clinical and research applications. *J Am Acad Child Adolesc Psychiatry*. 2016;55(8):647–56. doi: 10.1016/j.jaac.2016.05.012.
33. Park S, Kim BN, Kim JW, Shin MS, Yoo HJ, Cho SC. Protective effect of breastfeeding with regard to children's behavioral and cognitive problems. *Nutr J* 2014;13(1):111. doi: 10.1186/1475-2891-13-111.
34. Martin RP, Dombrowski SC, Mullis C, Wisenbaker J, Huttunen MO. Smoking during pregnancy: Association with childhood temperament, behavior, and academic performance. *J Pediatr Psychol* 2006;31(5):490-500. doi: 10.1093/jpepsy/jsj041.
35. Roza SJ, Verhulst FC, Jaddoe VW V, Steegers EAP, Mackenbach JP, Hofman A, et al. Maternal smoking during pregnancy and child behaviour problems: The generation R study. *Int J Epidemiol* 2009;38(3):680-9. doi: 10.1093/ije/dyn163.
36. Cornelius MD, De Genna NM, Leech SL, Willford JA, Goldschmidt L, Day NL. Effects of prenatal cigarette smoke exposure on neurobehavioral outcomes in 10-year-old children of adolescent mothers. *Neurotoxicol Teratol* 2011;33(1):137-44. doi: 10.1016/j.ntt.2010.08.006.
37. Ross EJ, Graham DL, Money KM, Stanwood GD. Developmental consequences of fetal exposure to drugs: What we know and what we still must learn. *Neuropsychopharmacology*. 2015;40(1):61-87. doi: 10.1038/npp.2014.147.
38. Rice F, Langley K, Woodford C, Davey Smith G, Thapar A. Identifying the contribution of prenatal risk factors to offspring development and psychopathology: What designs to use and a critique of literature on maternal smoking and stress in pregnancy. *Dev Psychopathol*. 2018;30(3):1107–28. doi: 10.1017/S0954579418000421.
39. Langley K, Heron J, Smith GD, Thapar A. Maternal and paternal smoking during pregnancy and risk of ADHD symptoms in offspring: testing for intrauterine effects. *Am J Epidemiol*. 2012;176(3):261–8. doi: 10.1093/aje/kwr510.
40. Obel C, Olsen J, Henriksen TB, Rodriguez A, Järvelin MR, Moilanen I, et al. Is maternal smoking during pregnancy a risk factor for hyperkinetic disorder?--Findings from a sibling design. *Int J Epidemiol*. 2011;40(2):338–45. doi: 10.1093/ije/dyq185.
41. El Marroun H, Tiemeier H, Franken IHA, Jaddoe VWV, van der Lugt A, Verhulst FC, et al. Prenatal Cannabis and Tobacco Exposure in Relation to Brain Morphology: A Prospective Neuroimaging Study in Young Children. *Biol Psychiatry* 2016;79(12):971-9. doi: 10.1016/j.biopsych.2015.08.024.

42. Cornelius MD, Leech SL, Goldschmidt L. Characteristics of persistent smoking among pregnant teenagers followed to young adulthood. *Nicotine Tob Res* 2004;6(1):159-69. doi: 10.1080/14622200310001656975.
43. Rückinger S, Rzehak P, Chen CM, Sausenthaler S, Koletzko S, Bauer CP, et al. Prenatal and postnatal tobacco exposure and behavioral problems in 10-year-old children: Results from the GINI-plus prospective birth cohort study. *Environ Health Perspect* 2010;118(1):150-4. doi: 10.1289/ehp.0901209.
44. Godleski SA, Eiden RD, Schuetze P, Colder CR, Huestis MA. Tobacco exposure and maternal psychopathology: Impact on toddler problem behavior. *Neurotoxicol Teratol*. 2016;57:87–94. doi: 10.1016/j.ntt.2016.07.003.

ESTUDIO 2

“Long-chain polyunsaturated fatty acids, homocysteine at birth and fatty acid desaturase gene cluster polymorphisms are associated with children’s processing speed up to age 9 years.”

Cristina Campoy, **Hatim Azaryah**, Francisco José Torres-Espínola , Cristina Martínez-Zaldívar , José Antonio García-Santos , Berthold Koletzko , and Miguel Pérez-García.

DRAFT submitted - Under review

1 **Long-chain polyunsaturated fatty acids,**
2 **homocysteine at birth and fatty acid desaturase**
3 **gene cluster polymorphisms are associated with**
4 **children's processing speed up to age 9 years.**

5
6 **Cristina Campoy** ^{1,2,3,4,5*}, **Hatim Azaryah** ^{1,2,4}, **Francisco José Torres-Espínola**
7 ^{1,2,5}, **Cristina Martínez-Zaldívar** ^{1,2}, **José Antonio García-Santos** ^{1,2,4}, **Berthold**
8 **Koletzko** ⁶, and **Miguel Pérez-García** ^{12,13}.

9
10 ¹ EURISTIKOS Excellence Centre for Paediatric Research, Biomedical Research Centre,
11 University of Granada, 180016 Granada, Spain; ccampoy@ugr.es (C.C.);
12 rifappstudio@gmail.com (H.A.); fitespinola@yahoo.es (F.J.T-E.); mcriszald@ugr.es (C.M-Z.);
13 joseantonio_gsantos@outlook.es (J.A.G-S.)

14 ² Department of Paediatrics, School of Medicine, University of Granada, Avda. Investigación
15 11, 180016 Granada, Spain.

16 ³ Spanish Network of Biomedical Research in Epidemiology and Public Health (CIBERESP),
17 Granada's node, Institute of Health Carlos III, 28029 Madrid, Spain.

18 ⁴ Instituto de Investigación Biosanitaria de Granada (Ibs-GRANADA), Health Sciences
19 Technological Park, 18012 Granada, Spain

20 ⁵ Instituto de Neurociencias "Doctor Olóriz", Health Sciences Technological Park, 18012
21 Granada, Spain

22 ⁶ Ludwig-Maximilians-Universität München, Dr. von Hauner Children's Hospital,
23 University of Munich Hospitals, 80337 Munich, Germany;
24 hans.demmelmaier@med.uni-muenchen.de (H.D.); gudrun.haile@med.uni-muenchen.de
25 (G.H.); peter.rzehak@med.uni-muenchen.de (P.R.);
26 Berthold.koletzko@med.uni-muenchen.de (B.K.)

27 ¹² Mind, Brain and Behaviour International Research Centre (CIMCYC), University of
28 Granada, 18011 Granada, Spain; mperezg@ugr.es (M. P-G.)

29 ¹³ Spanish Network of Biomedical Research Centre on Mental Health (CIBERSAM), Granada's
30 node, Institute of Health Carlos III, 28029 Madrid, Spain

31
32 * Correspondence: ccampoy@ugr.es; Tel.: +34 629-308-695

33
34 Received: date; Accepted: date; Published: date

35

36

37

38

39 **Abstract:** Both pre- and early postnatal supplementation with docosahexaenoic acid
40 (DHA), arachidonic acid (AA) and folate have been related to many neural processes,
41 but its long-term effects on later neural function remain unclear. We evaluated the
42 long-term effects of maternal prenatal supplementation with fish-oil (FO),
43 5-methyltetrahydrofolate (5-MTHF), placebo or FO+5-MTHF, as well as the role of
44 fatty acid desaturase (*FADS*) gene cluster polymorphisms, on their offspring's
45 processing speed at later school age. This study was conducted in 143 NUHEAL
46 children at 7.5 and 9 years old. Processing speed tasks were assessed using *Symbol*
47 *Digit Modalities Test (SDMT)*, *Children Color Trails Test (CCTT)* and *Stroop Color and*
48 *Word Test (SCWT)*. Long-chain polyunsaturated fatty acids, folate and total
49 homocysteine (tHcy) levels were determined at delivery from maternal and cord
50 blood samples. *FADS* and methylenetetrahydrofolate reductase (*MTHFR*) 677C>T
51 genetic polymorphisms were analyzed. Multivariate linear and mixed effects logistic
52 regression models were performed. There were significant differences in processing
53 speed performance among children at different ages ($p<0.001$). However, type of
54 prenatal supplementation had no effect on processing speed in children up to 9 years.
55 Secondary exploratory analyses indicated that children born to mothers with higher
56 AA/DHA ratio at delivery ($p<0.001$) and heterozygotes for *FADS1* rs174556 ($p<0.05$)
57 showed better performance in processing speed at 9 years. Negative associations
58 between processing speed scores and maternal tHcy levels at delivery were found.
59 Our findings suggest speed processing development in children up to 9 years could be
60 related to maternal factors, including AA/DHA and tHcy levels, and their genetic
61 background, mainly *FADS* polymorphism. These considerations support that
62 maternal prenatal supplementation should be quantitatively adequate and
63 individualized to obtain better brain development and mental performance in the
64 offspring.

65 **Keywords:** Long-chain polyunsaturated fatty acids, folate, prenatal
66 supplementation, processing speed, neurodevelopment, *FADS* gene, children.
67

68 **1. Introduction**

69 The speed of information processing is an essential basis for higher order
70 cognitive function, including memory or executive functions [1]. This cognitive
71 process can be defined as the time required to move information from one neuron to
72 the next [2], or how quickly a person can perform the mental operations needed to
73 complete a task [3]. Then, processing speed is highly related to intact myelination,
74 which is important for the integration of information across spatially distributed
75 neural networks. Moreover, the association between white matter integrity and
76 processing speed in cognitive tasks has been consistently established [4,5].
77

78 Long-chain polyunsaturated fatty acids (LC-PUFAs) and folic acid play an
79 important role in brain development, particularly during fetal and early postnatal life
80 [6,7]. Interestingly, their effects on neurodevelopment depend of the timing of

81 occurrence and brain needs for particular nutrients at that time [8]. For instance,
82 essential fatty acids (FA) deficiencies during the first year of life lead to severe
83 impairments in synapse formation and myelination [9], which may have negative
84 effects on processing speed tasks later in life [10].
85

86 LC-PUFAs, particularly docosahexaenoic acid (DHA, 22:6 *n*-3) and arachidonic
87 acid (AA, 20:4 *n*-6) are incorporated into the brain in relatively large amounts during
88 the pre- and postnatal growth spurt [11-13]. However, due to a limited capacity in the
89 fetus and neonate for PUFAs elongation and desaturation, tissue deposition of DHA
90 and AA strongly depends on the pre-formed LC-PUFAs supply via the placenta and
91 postnatal diet [14]. On the other side, PUFAs composition is also clearly related to
92 polymorphisms in the fatty acid desaturase (*FADS*) gene cluster [15]. There is
93 evidence that dietary LC-PUFAs supply in early life may modulate information
94 processing [12,16], cognitive and visual development [17,18], as well as early mental
95 and motor skills development [6,19]. Recently, higher maternal DHA status has been
96 also related to better performance in language and short-term memory in the offspring
97 [20]. Moreover, early availability of *n*-6 PUFAs, mainly AA, during pre- and postnatal
98 periods has been positively associated to cognitive performance and mental function
99 in later childhood [21-23].
100

101 In addition, folate intake before and during pregnancy is also essential for normal
102 brain development, differentiation and cognitive performance [24-27]. Thus, maternal
103 folate deficiency causes structural brain abnormalities during fetal development and
104 poor childhood cognitive ability [26], while maternal folate supplementation in
105 pregnancy improves neurological development and may reduce the prevalence of
106 autism spectrum disorders in their offspring [24,28].
107

108 Having in mind that LC-PUFAs and folate play key roles in synaptogenesis,
109 synapse maturation and myelination, it seems clear that dietary intake of both
110 nutrients may have effects on processing speed [2]. Long-term effects of nutritional
111 interventions on processing speed have been classically evaluated using perceptual
112 speed tasks [29], but further studies evaluating specific neuropsychological domains
113 are still missing [6,30]. Therefore, our main objective was to evaluate the potential role
114 of LC-PUFAs and total homocysteine (functional marker of folate status) at delivery, as
115 well as maternal *FADS* polymorphisms, on children's processing speed at 7.5 and 9
116 years.
117

2. Materials and Methods


2.1. Study Design and Subjects

119 This is a follow-up study of the NUHEAL (*Nutraceuticals for a Healthier Life*) trial,
120 registered at www.ClinicalTrials.gov, Identifier NTC01180933. Detailed study design,
121 subject recruitment, and population characteristics have been described elsewhere
122 [31,32]. Briefly, NUHEAL project is a multicenter, randomized, double-blind,

123 placebo-controlled trial in healthy pregnant women from Munich, Pécs and Granada.
 124 Pregnant women were assigned by blockwise randomization to receive either a
 125 modified fish-oil (FO) preparation [500 mg DHA + 150 mg eicosapentaenoic acid
 126 (EPA)/day], 5-methyl-tetrahydrofolate (5-MTHF) (400 µg/day), a combination of both
 127 supplements (FO+5-MTHF), or placebo, from gestational week 20 until delivery.
 128 Detailed information on sociodemographic data and course of pregnancy together
 129 with maternal blood samples were collected at 20 and 30 weeks of pregnancy and at
 130 delivery; additionally, cord blood samples were also obtained.

131 Of 270 women participating in NUHEAL study until giving birth, 152 mothers
 132 agreed to participate in the follow-up for their offspring at 7.5 and 9 years of age.
 133 Processing speed tasks were entirely performed in 143 NUHEAL children, from
 134 which 38 were born to mothers who received FO, 29 whose mothers were
 135 supplemented with 5-MTHF, 36 born to mothers supplemented with FO+5-MTHF,
 136 and 40 children whose mothers received placebo during pregnancy (**Figure 1**).

137 The follow-up study protocols were approved by the Ethical Committees from all
 138 centers involved in the study. Written informed consent was obtained from parents of
 139 all participating children at study entry and at each follow-up.



140
 141 **Figure 1. Flowchart of NUHEAL participants up to 9 years.** FO: fish-oil; 5-MTHF:
 142 5-methyltetrahydrofolate. ^a 4 participants who did not meet the inclusion criteria : 2
 143 women weighed >92 kg, 1 of whom used commercial FO preparations; 2 women
 144 regularly consumed FO preparations. ^b 41 participants did not complete the study:
 145 noncompliance (n=2), relocation (n=1), aversion to or bad taste of the supplement
 146 (n=9), loss of contact (n=2) and unknown reasons (n=27). ^b 133 participants lost to
 147 follow up at 7.5 years: relocation (n=3), loss of contact (n=74), infants born
 148 prematurely (n=4), congenital left-side anophthalmus (n=1), craniosynostosis (n=1),
 149 left-side deafness (n=1), unwillingness to continue (n=50). ^d Processing speed tasks
 150 were not entirely performed in 16 participants at 9 years

151 2.2. *Neuropsychological assessment*

152 NUTRIMENTHE Neuropsychological Battery (NNB) was used to evaluate the
153 whole spectrum of neuropsychological functioning in children aged 7.5-9 years,
154 including processing speed tasks such as *Symbol Digit Modalities Test (SDMT)*, *Children*
155 *Color Trails Test (part 1) (CCTT-1)* and *Stroop Color and Word Test (SCWT)* [33].

156 The *Symbol Digit Modalities Test (SDMT)* was used to assess
157 information-processing speed and attention [34]. This test requires individuals to
158 write the correct number under the corresponding symbol according to a key code
159 specified on the top of the page, which links different meaningless geometric symbols
160 with numbers 1 through 9. The participant is given 90 s to complete the task. Number
161 of correctly identified symbols (hits) is recorded as score.

162 The *Children Color Trails Test (CCTT)* is an individually administered
163 neuropsychological instrument which consists of two parts used to evaluate sustained
164 visual attention, sequencing, psychomotor speed (part-1), and cognitive flexibility
165 (part-2). This test requires the connection of one set of encircled numbers (1-25) in
166 ascending order. Current study used only the part 1 of this test, which even numbers
167 are printed in a yellow background while odd numbers are printed in a pink
168 background. The final score is the time (in seconds) taken to complete part-1 of the
169 *CCTT* [35].

170 Finally, Golden's version of the *Stroop Color and Word Test (SCWT)* was used to
171 evaluate cognitive flexibility, selective attention, cognitive inhibition and information
172 processing speed [36]. There are three components to this task. First, participants are
173 asked to read aloud color words (blue, green and red) printed in black ink. Second, the
174 child is asked to say the colors of "XXXX" printed in blue, green or red. Finally, the
175 child is asked to name the ink color of color words (blue, green or red) printed in
176 incongruent colors as quickly and accurately as possible in 45 seconds time. As
177 consequence, this test produces three direct scores: *the word-reading (WR)* score, *the*
178 *color-naming (CN)* score, and *the color-word (CW)* score, respectively [37]. The increase
179 in time taken to perform the CW test compared with the WR and CN tests is called
180 color-word interference effect or Stroop effect, which is considered as the main
181 dependent variable for SCWT test [38]. CW score is associated to attention
182 development, and for this reason has not been taken into account in the current study.

183 2.3. *Fatty acid analyses in maternal and umbilical cord plasma phospholipids*

184 Procedures of analysis for FA determinations in plasma phospholipids have been
185 described in detail elsewhere [31,32]. Briefly, blood was centrifuged at 3500xg for 10
186 min at room temperature within 2 h. Plasma was thereafter removed and stored at
187 -80°C. Lipid extraction from plasma was performed according to the method of
188 Kolarovic and Fournier [39]. Analysis of FA methyl esters from plasma phospholipids
189 was performed by high-resolution capillary gas-liquid chromatography. Conditions

190 during the analysis and standards used were described elsewhere [40]. Results were
191 expressed as weight percentages (wt %) of all quantified FA.

192 *2.4. Folate analysis*

193 Analysis of plasma folate was carried out by microbiological assay using a
194 chloramphenicol resistant strain of *Lactobacillus casei*, as previously described [41].
195 Inter and intra-assay coefficients of variation were below of 11%.

196 *2.5. Total homocysteine*

197 Total homocysteine (tHcy) concentrations were assayed by fluorescence
198 polarized immunoassay on the IMx autoanalyser [42]. Sample preparation and
199 chromatographic conditions were performance as described previously [43]. The
200 fluorescence intensities were measured with excitation at 385 nm and emission at 515
201 nm.

202 *2.6. SNP selection and genotyping*

203 Genotyping of single-nucleotide polymorphisms (SNPs) from *FADS* gene cluster
204 was performed with the iPLEX method (Sequenom, San Diego, CA, USA) by means of
205 matrix-assisted laser desorption ionization-time of flight mass spectrometry method
206 (MALDI-TOF MS, Mass Array, Sequenom), according to the manufacturer's
207 instructions. Standard genotyping quality control included 10% duplicate and
208 negative samples. Genotyping discordance rate was below 0.3%. SNP selection for
209 following analyses is showed in **Supplemental Methods (Supplemental Figure 1 and**
210 **Supplemental Tables 1-3).**

211 *2.7. MTHFR 677 C/T polymorphism*

212 Genomic DNA was prepared from maternal and umbilical cord blood samples
213 obtained at delivery. DNA samples were genotyped for the
214 methylenetetrahydrofolate reductase (*MTHFR*) 677 C/T variant by polymerase chain
215 reaction (PCR), restriction enzyme digestion, and DNA fragment separation by
216 electrophoresis as described previously [42]. *MTHFR* 677 C>T was selected for its high
217 clinical relevance in humans due to the association of TT genotype with high plasma
218 homocysteine concentrations [44].

219 *2.8. Statistical Analysis*

220 Using standard approaches, power for the current study was calculated, setting α
221 value as 0.05 and β value as 0.2. Different intervention groups (FO, 5-MTHF and
222 FO+5-MTHF) were grouped and compared with placebo group for processing speed
223 tasks, including *SDMT*, *CCTT* and *SCWT*, in children at 7.5 years old. A statistical
224 power of 80% was obtained for selected tasks in aforementioned population
225 (**Supplemental Table 4**). "PowerEQTL v 0.1.3" (R software) was also used to calculate

226 the statistical power for our genetic study; except for *FADS2* rs174570 and *FADS3*
227 rs2727271, a statistical power of 90% was obtained for analyzed SNPs (**Supplemental**
228 **Figure 2 and Supplemental Table 5**).

229 A descriptive analysis of quantitative variables were performed using summary
230 measures (*mean, standard deviation, standard error of the mean, centiles, median,*
231 *interquartile or amplitude ranges*), meanwhile frequency distribution was used for
232 qualitative variables. Comparisons among different groups of treatment (FO,
233 5-MTHF, both or placebo) were made using one-way ANOVA for continuous
234 variables or χ^2 test for categorical variables. In order to verify the underlying
235 hypothesis of one-way ANOVA (variance's homogeneity and normality), Box-Cox
236 transformation was computed when considered necessary. When one-way ANOVA
237 resulted significant, Bonferroni test post-hoc was applied.

238 A multivariate multiple linear regression model was adjusted in order to analyze
239 independent effects of different covariates and confounders, including maternal age,
240 maternal education level, maternal smoking, maternal BMI, mode of delivery,
241 gestational age and child's sex. Those confounders with a significant level of $p<0.05$
242 were included in the final models for the multivariate analyses. Variables of
243 processing speed obtained from *SDMT*, *CCTT-1* and *SCWT* tests were considered as
244 dependent variables. Due to hierarchical structure resulted from processing speed
245 evaluation in children at 7.5 and 9 years, a multivariate linear model was computed
246 using mixed-effects logistic regression models, where children were considered as
247 level one and each of two time points measures were fixed as second level. Time (7.5
248 years and 9 years) was used as fixed effects factor. Logistic regression mixed model
249 was used when dependent variables were dichotomized (below or above third
250 quartile), in which case the measure of the effect was the suitable odds ratio with
251 corresponding confidence interval. Interactions between groups of prenatal
252 supplementation and confounders were analyzed in each multivariate analysis
253 performed, but significant differences were not observed (**Supplemental Tables 5 and**
254 **6**).

255 All statistical analyses were performed using the statistical package STATA 12.1
256 (Stata Corp, College Station, TX). *P* values <0.05 were considered as statistically
257 significant

258 **3. Results**

259 *3.1. Background and baseline characteristics of the NUHEAL study participants*

260 The baseline characteristics of the mothers whose children were evaluated at 7.5
261 and 9 years of age are shown in **Table 1**. No difference between prenatal
262 supplementation groups were observed in those descriptive variables analyzed prior
263 or during pregnancy, including maternal age, BMI at 20 and 30 weeks of pregnancy,
264 hematocrit at 30 weeks of pregnancy, parity, smoking during pregnancy, gravidity

265 risk at 20 weeks of pregnancy, high maternal education, family status or gestational
 266 age at delivery. Moreover, we analyzed maternal biochemical parameters at delivery.
 267 As expected, plasma levels of folate were significantly higher in those mothers who
 268 received 5-MTHF or FO+5-MTHF supplementation during pregnancy ($p<0.001$).
 269 However, type of prenatal supplementation had no effect on maternal AA/DHA ratio
 270 and tHcy levels.

271 **Table 1.** General characteristics of the studied population

	FO (n=38)	5-MTHF (n=29)	FO+5-MTHF (n=36)	Placebo (n=40)	<i>p</i>
Maternal age (years) ¹	28.81 ± 5.25	30.70 ± 5.68	29.56 ± 4.32	30.71 ± 3.90	NS
BMI (kg/m ²) ¹					
20 weeks	26.03 ± 3.62	24.92 ± 2.45	25.28 ± 2.77	24.74 ± 2.28	NS
30 weeks	28.52 ± 3.91	26.87 ± 2.43	27.23 ± 2.86	26.91 ± 2.29	NS
Hematocrit (%) at 30 weeks ¹	33.85 ± 3.73	32.61 ± 5.14	33.37 ± 2.58	33.13 ± 2.75	NS
Parity [n (%)]					NS
0	23 (60.5%)	23 (79.3%)	28 (93.3%)	28 (70%)	
≥1	3 (7.9%)	3 (12.5%)	2 (5.5%)	4 (10%)	
Smoking in pregnancy [Yes= n (%)]	7 (18.4%)	5 (17.2%)	7 (19.4%)	4 (10%)	NS
Gravidity risk at 20 weeks [n (%)]					NS
No risk factors	6 (15.8%)	6 (20.7%)	8 (22.2%)	11 (27.5%)	
≥1 risk factors	18 (47.4%)	18 (62.1%)	22 (61.1%)	21 (52.5%)	
High Maternal education [n (%)]	8 (21.05%)	8 (27.58%)	14 (38.89%)	10 (25%)	NS
Family Status Pregnancy [n (%)]					NS
Single	8 (21.1%)	8 (27.4%)	1 (2.7%)	10 (25%)	
Partnership	23 (60.5%)	23 (44.8%)	29 (80.6%)	29 (72.5%)	
Gestational Age (weeks) ¹	38.90 ± 1.51	38.75 ± 1.62	38.73 ± 2.06	39.43 ± 1.43	NS
AA/DHA ^{1,2}	0.90 ± 0.38	1.13 ± 0.54	0.97 ± 0.42	1.14 ± 0.63	NS
Plasma Folate (μg/L) ^{1,2}	6.17 ± 4.33	12.10 ± 5.55	13.46 ± 5.78	6.06 ± 0.82	<0.001
tHcy (μmol/L) ^{1,2}	7.08 ± 2.83	6.29 ± 2.81	6.93 ± 3.09	6.78 ± 2.39	NS

272 ¹: Values expressed as mean ± standard deviation; ²: Values obtained from mothers at delivery.
 273 5-MTHF: 5-methyltetrahydrofolate; AA: arachidonic acid; DHA: docosahexaenoic acid; FO:
 274 fish-oil; tHcy: total homocysteine. n=number of cases; p: level of significance from one-way
 275 ANOVA for continuous variables or χ^2 test for categorical variables. Noted that there are
 276 missing values for some descriptive variables.

277 3.2. Processing speed task of the NUHEAL children at 7.5 and 9 years old

278 As shown in **Table 2**, no significant statistical differences were found among the
 279 type of prenatal supplementation in all analyzed processing speed tasks at 7.5 years,
 280 except for CCTT-1 test. In fact, children born to mothers who were supplemented with
 281 5-MTHF during pregnancy showed a decrease in the timing to solve CCTT-1 ($p=$
 282 0.017). Moreover, there were no differences between type of prenatal supplementation

283 and processing speed tasks at 9 years old. In general, we observed that children aged 9
 284 years had better processing speed than those aged 7.5 years in terms of higher scores
 285 and less time to solve *CCTT-1* test.

286 **Table 2.** Descriptive analysis of processing speed evaluation in the NUHEAL children at 7.5 and
 287 9 years

		FO	5-MTHF	FO+5-MTHF	Placebo		p	
Children at 7.5 y	n	Mean ± SD	n	Mean ± SD	n	Mean ± SD	n	Mean ± SD
SDMT – hits	36	23.56 ± 7.62	28	22.61 ± 6.87	34	22.38 ± 5.27	41	24.66 ± 6.38
CCTT-1 (sc)	36	100.44 ± 39.27	28	87.85 ± 30.05	34	96.56 ± 34.48	41	99.88 ± 50.77
STROOP Test – hits -1 (Word-reading)	37	59.49 ± 17.72	28	61.82 ± 11.66	34	57.68 ± 16.34	41	59.34 ± 16.41
STROOP Test – hits -2 (Color-naming)	37	38.97 ± 7.77	28	42.14 ± 7.26	34	42.18 ± 9.36	41	41.95 ± 8.41
Children at 9 y								
SDMT – hits	33	31.42 ± 6.66	26	30.00 ± 7.16	28	30.25 ± 7.73	37	33.76 ± 8.60
CCTT-1 (sc)	33	57.60 ± 17.13	28	67.99 ± 23.16	28	73.61 ± 24.73	37	66.58 ± 25.99
STROOP Test – hits -1 (Word-Reading)	34	70.53 ± 12.69	28	71.54 ± 10.29	28	72.32 ± 8.71	37	73.62 ± 9.65
STROOP Test – hits -2 (Color-Naming)	34	48.26 ± 7.58	28	49.32 ± 9.49	28	50.61 ± 8.57	37	51.41 ± 7.94

288 5-MTHF: 5-methyltetrahydrofolate; CCTT-1: Children Color Trails Test; FO: fish-oil;SDMT:
 289 Symbol Digit Modalities Test. n= number of cases; p: level of significance obtained for χ^2 test;
 290 Bold: $p < 0.05$.

291

292 3.3. Prenatal predictors of processing speed in children up to 9 years


293 3.3.1. Symbol Digit Modalities Test (**SDMT**) Hits

294 Type of prenatal supplementation had no long-term effects on **SDMT** hits in
 295 children at 7.5 and 9 years, after adjusting for *maternal blood parameters, mother's genetic*
296 polymorphisms and lifestyle variables in pregnancy (**Table 3**). However, we observed an
 297 age-dependent increase in **SDMT** hits; in fact, children at 9 years showed an increase
 298 of 10.72 points in the mean of hits [(95% CI: 7.98-13.47); $p < 0.001$] compared to
 299 children at 7.5 years. Moreover, each unit of increase in maternal AA/DHA ratio at
 300 delivery predicted an increase of 8.80 points in the mean of **SDMT** hits [(95% CI:
 301 3.61-13.99); $p = 0.001$]. Conversely, higher maternal weight gain between 20 and 30
 302 weeks of pregnancy (dBMI) [(95% CI:-1.25 - -0.02); $p = 0.043$] and maternal tHcy [(95%
 303 CI: -1.02 - -0.002); $p = 0.049$] were associated with a decrease of 0.63 and 0.52 points in
 304 the mean of **SDMT** hits, respectively.

305 Further logistic regression analysis, characterizing those children aged 9 years
 306 having hits above P75, showed that maternal AA/DHA ratio at delivery was the best
 307 predictor to obtain higher number of *SMDT* hits [OR: 30.46 (95% CI: 3.68-252.0); $p=$
 308 0.002] (**Table 6**). This probability is also increased in those children whose mothers
 309 had a high educational level ($p= 0.013$) or were heterozygote for *FADS1* rs174556 ($p=$
 310 0.014). However, maternal tHcy at delivery reduced the odds of placing children aged
 311 9 years above the P75, with a probability of 0.71 to obtain less hits per each unit
 312 ($\mu\text{mol/L}$) of increase of tHcy [OR: 0.71 (95% CI: 0.56-0.89); $p= 0.003$].

313

314



315

316 **Figure 2. Effects of prenatal supplementation on CCTT-1 test in**
 317 **children at 7.5 and 9 years.** Level of significance was obtained from
 318 ONE-WAY ANOVA. * Significant differences at 7.5 years and 9 years
 319 were observed in time spent (s) to solve the CCTT-1 test between
 320 children whose mothers were supplemented with FO ($p= 0.0001$),
 321 5-MTHF ($p= 0.0113$) or both treatments (FO+5MTHF) ($p= 0.038$) during
 322 pregnancy .5-MTHF: 5-Methyltetrahydrofolate; CCTT-1: Children's
 323 Color Trails Test; FO: fish-oil.

324

325

326

327

328
329**Table 3.** Effect of selected cofounders on the Symbol Digit Modalities Test (**SDMT**) hits in the NUHEAL children

Variables	Categories	b	CI (95%)		p
			LCL	UCL	
Prenatal Supplementation	FO	1.60	-2.45	5.64	0.439
	5-MTHF	-3.02	-7.06	1.03	0.144
	FO+5-MTHF	-0.08	-4.52	4.69	0.972
	Placebo	0	-----	-----	-----
Time point	7.5y	0	-----	-----	-----
	9y	10.72	7.98	13.47	<0.001
Study Group * Time point	FO * 9y	-2.40	-6.67	1.86	0.269
	5-MTHF * 9y	-2.28	-6.57	2.01	0.299
	FO+5-MTHF * 9y	-1.50	-5.82	2.82	0.497
	Placebo * 9y	0	-----	-----	-----
Maternal Age		0.22	-0.04	0.48	0.100
Maternal Education Level	None + Primary	0	-----	-----	-----
	Secondary or >	1.47	-1.02	3.96	0.248
Smoking	No	0	-----	-----	-----
	Yes	2.08	-1.01	5.18	0.188
dBMI (kg/m2)		-0.63	-1.25	-0.02	0.043
Mode of delivery	Spontaneous	0	-----	-----	-----
	Forceps	1.73	-2.55	6.02	0.427
	Vacuum	-2.65	-6.85	1.56	0.217
	Cesarean section	0.17	-2.43	2.77	0.898
Gestational Age		0.44	-0.27	1.16	0.228
Sex	Girls	0	-----	-----	-----
	Boys	-1.00	3.21	1.21	0.373
AA/DHA ratio ^{1,2}		8.80	3.61	13.99	0.001
FADS1 rs174556 polymorphism		1.24	-0.51	3.01	0.165
Plasma Folate (μg/L) ¹		0.11	-0.16	0.37	0.439
tHcy (μmol/L) ¹		-0.52	-1.02	-0.002	0.049
MTHFR 677 C/T polymorphism		-0.47	-2.10	1.16	0.574

330 1: values obtained from mothers at delivery; 2:fatty acids measured as % of total fatty acids; 5-MTHF:
331 5-Methyltetrahydrofolate; AA: Arachidonic acid; b: Regression coefficient; CI: Confidence Interval;
332 dBMI: difference of body mass index between 20 and 30 weeks of pregnancy; DHA: Docosahexaenoic
333 acid; FADS: Fatty acid desaturase; FO: Fish-oil; LCL: lower confidence limit; MTHFR:
334 Methyl-tetrahydrofolate reductase; tHcy: total homocysteine; UCL; upper confidence limit. p=level of
335 significance obtained from multivariate multiple linear regression model; Bold: p<0.05

336 3.3.2. Children Color Trails Test (**CCTT-1**)

337 No statistically significant differences in elapsed time for **CCTT-1** at 7.5 and 9
338 years were found among groups of prenatal supplementation after adjustment for
339 selected confounders (*maternal blood parameters, maternal FADS1 polymorphism and*
340 *pregnancy and lifestyle characteristics*). Independently of prenatal supplementation,
341 children aged 9 years showed a decrease in the timing spent to solve the task
342 compared to their results at the previous examination at age 7.5 years ($p < 0.001$) (**Table**
343 **4**).

344 After considering the interaction between age and prenatal supplementation, we
345 observed that decrease in time elapsed was higher in those children whose mothers
346 were supplemented with FO during pregnancy ($p = 0.0001$), 5-MTHF ($p = 0.0113$) or
347 FO+5-MTHF ($p = 0.038$) (**Figure 2**), but not in the placebo group.

348 As shown in **Table 4**, other selected cofounders had also a significant effect on the
349 time required to complete **CCTT-1** test. In fact, vacuum delivery determined an
350 increase in the time elapsed of 24.77 s for the task ($p = 0.010$) compared to those
351 children whose mothers had an uncomplicated spontaneous delivery. Moreover,
352 smoking during pregnancy had also a negative effect on the child's **CCTT-1** hits,
353 increasing the time of solving this task in 23.43 s ($p = 0.001$). Finally, we observed that
354 maternal AA/DHA ratio at delivery was a significant factor determining less timing to
355 solve the **CCTT-1** task of their offspring up to 9 years (-27.87 s, $p = 0.019$). Positive
356 association between maternal AA/DHA ratio and **CCTT-1** was also determined after
357 logistic regression analysis, and characterizing those children aged 9 years with
358 elapsed time of solving the **CCTT-1** below the P25 [OR: 18.53 (95% CI: 2.13-160.9); $p =$
359 0.008] (**Table 6**). Shorter solving times were also observed in those children born to
360 mothers who were heterozygote for *FADS1* rs174556 [OR: 2.75 (95% CI: 1.02-7.39; $p =$
361 0.045].

362

363

364

365

366

367

368

369

370 **Table 4.** Associations between interest cofounders and Children Color Trails Test (**CCTT-1**) Hits
 371 in the NUHEAL children at school age

Variables	Categories	<i>b</i>	CI (95%)		<i>p</i>
			LCL	UCL	
Prenatal Supplementation	FO	-12.69	-31.22	5.84	0.180
	5-MTHF	-8.43	-27.01	10.14	0.373
	FO+5-MTHF	-15.25	-36.34	5.83	0.156
	Placebo	0	-----	-----	-----
Time point	7.5y	0	-----	-----	-----
	9y	-34.12	-46.92	-21.10	<0.001
Study Group * Time point	FO * 9y	-13.57	-33.42	6.28	0.180
	5-MTHF * 9y	16.41	-3.55	36.38	0.107
	FO+5-MTHF * 9y	15.28	-5.04	35.61	0.141
	Placebo * 9y	0	-----	-----	-----
Maternal Age		-0.80	-1.97	0.38	0.183
Maternal Education Level	None + Primary	0	-----	-----	-----
	Secondary or >	-7.92	-19.22	3.38	0.170
Smoking	No	0	-----	-----	-----
	Yes	23.43	9.43	37.44	0.001
dBMI (kg/m2)		-0.62	-3.41	2.18	0.666
Mode of delivery	Spontaneous	0	-----	-----	-----
	Forceps	-5.91	-25.07	13.24	0.545
	Vacuum	24.77	6.01	43.53	0.010
	Cesarean section	2.66	-9.15	14.47	0.659
Gestational Age		3.22	-0.05	6.49	0.054
Sex	Girls	0	-----	-----	-----
	Boys	6.06	-3.98	16.10	0.237
AA/DHA ratio ^{1,2}		-27.87	-51.13	-4.61	0.019
FADS1 rs174556 polymorphism		-7.15	-15.15	0.86	0.080
Plasma Folate (μg/L) ¹		-0.26	-1.47	0.95	0.674
tHcy (μmol/L) ¹		-1.06	-2.39	1.27	0.371
MTHFR 677 C/T polymorphism		0.37	-7.04	7.78	0.922

372 1: values obtained from mothers at delivery; 2: fatty acids measured as % of total fatty acids;
 373 5-MTHF: 5-Methyltetrahydrofolate; AA: Arachidonic acid; b: Regression coefficient; CI:
 374 Confidence Interval; dBMI: difference of body mass index between 20 and 30 weeks of
 375 pregnancy; DHA: Docosahexaenoic acid; FADS: Fatty acid desaturase; FO: Fish-oil; LCL:
 376 lower confidence limit; MTHFR: Methyl-tetrahydrofolate reductase; tHcy; total homocysteine;
 377 UCL; upper confidence limit. p= level of significance obtained from multivariate multiple linear
 378 regression model; Bold: p <0.05

379 3.3.3. Stroop Color and Word Test (*SCWT*)

380 We analyzed the influence of prenatal supplementation and other selected
381 cofounders on the information processing speed using Stroop Color and Word test
382 and its obtained scores: Word-Reading (*WRST*) and Color-Naming (*CNST*).

383 Similarly to initial descriptive evaluation, further adjusted analysis for selected
384 cofounders did not show statistically significant differences between different types of
385 prenatal supplementation in the number of *WRST* hits obtained by children at 7.5 and
386 9 years (**Table 5**). However, independently of maternal supplementation during
387 pregnancy, children at 9 years showed an increase of 15.37 points in the number of hits
388 for *WRST* ($p < 0.001$) respect to children at 7.5 years. In relation to other cofounders
389 considered in the model, boys showed 4.93 less hits than girls solving the task ($p =$
390 0.019). Moreover, we also observed that each increment of one unit ($\mu\text{mol/L}$) of
391 maternal tHcy at delivery predicted that their offspring had 1.09 less hits by average
392 solving the task ($p = 0.025$). Further logistic regression analysis, characterizing those
393 children aged 9 years which hits of solving the *WRST* test below the P50, determined
394 that maternal tHcy at delivery had a negative influence on this test [OR: 0.69 (95% CI:
395 0.51-0.93); $p = 0.015$] (**Table 6**).

396 When analyzing the effects of both prenatal supplementation and child's age on
397 *CNST*, similar results to those mentioned above were found. In fact, cofounder
398 adjustment analysis did not show statistical differences between different groups of
399 prenatal supplementation in the number of hits obtained by NUHEAL children at 7.5
400 and 9 years. Once again, there was an increase of *CNST* hits at 9 years compared to 7.5
401 years ($p < 0.001$), but this effect was independent of type of supplementation during
402 pregnancy (**Table 5**). Interestingly, we observed that each increment of one unit of
403 AA/DHA ratio in maternal blood at delivery determined that their offspring had 6.55
404 more hits by average solving the *CNST* ($p = 0.034$) (**Table 5**). After logistic regression
405 analysis, we observed that maternal age positively influenced the likelihood for
406 children aged 9 years to be above the P75 to solve *CNST* test ($p = 0.039$), but maternal
407 tHcy level at delivery reduced this probability ($p = 0.005$) (**Table 6**).

408

409

410

411

412

413

414
415**Table 5.** Analysis of the influence of selected cofounders on the Word-Reading Stroop Test (WRST) and Color-Naming Stroop Test (CNST) in the NUHEAL children

Variables	Categories	b	Word-Reading Stroop Test (WRST)-hits			Color-Naming Stroop Test (CNST)-hits			
			CI (95%)		p	CI (95%)		p	
			LCL	UCL		LCL	UCL		
Prenatal Supplementation	FO	4.02	-3.25	11.30	0.278	0.85	-3.91	5.62	0.726
	5-MTHF	1.09	-6.16	8.35	0.768	-1.97	-6.74	2.81	0.419
	FO+5-MTHF	-1.33	-9.70	7.01	0.754	2.46	-2.97	7.90	0.374
	Placebo	0	-----	-----	-----	0	-----	-----	-----
Time point	7.5y	0	-----	-----	-----	0	-----	-----	-----
	9y	15.37	11.20	19.55	<0.001	10.00	6.80	13.21	<0.001
Study Group * Time point	FO * 9y	-3.09	-9.55	3.37	0.348	-1.02	-5.95	3.92	0.686
	5-MTHF * 9y	-6.35	-12.80	0.11	0.054	-1.89	-6.86	3.06	0.453
	FO+5-MTHF * 9y	-2.21	-8.82	4.39	0.511	-2.52	-7.57	2.53	0.328
	Placebo * 9y	0	-----	-----	-----	0	-----	-----	-----
Maternal Age		-0.30	-0.85	0.24	0.279	0.046	-0.26	0.35	0.769
Maternal Education Level	None + Primary	0	-----	-----	-----	0	-----	-----	-----
	Secondary or >	2.32	-2.33	6.98	0.328	-0.44	-3.37	2.50	0.768
Smoking	No	0	-----	-----	-----	0	-----	-----	-----
	Yes	5.58	-0.20	11.35	0.058	1.47	-2.17	5.11	0.430
dBMI (kg/m2)		-0.46	-1.54	0.73	0.485	-0.57	-1.29	0.16	0.126
Mode of delivery	Spontaneous	0	-----	-----	-----	0	-----	-----	-----
	Forceps	2.00	-5.96	9.98	0.621	3.12	-1.87	8.11	0.221
	Vacuum	1.85	-5.86	9.55	0.639	-0.771	-5.65	4.10	0.756
	Cesarean section	-0.18	-5.04	4.66	0.939	1.91	-1.15	4.98	0.222
Gestational Age		-0.28	-1.62	1.06	0.683	0.32	-0.53	1.17	0.466
Sex	Girls	0	-----	-----	-----	0	-----	-----	-----
	Boys	-4.93	-9.06	-0.81	0.019	-1.86	-4.48	0.74	0.161
AA/DHA ratio ^{1,2}		8.15	-1.47	17.78	0.097	6.55	0.50	12.60	0.034
FADS1 rs174556 polymorphism		-1.47	-4.78	1.83	0.382	-1.07	-3.15	1.01	0.315
Plasma Folate (μg/L) ¹		0.24	-0.26	0.74	0.343	0.28	-0.03	0.60	0.079
tHcy (μmol/L) ¹		-1.09	-2.04	-0.14	0.025	-0.47	-1.07	0.14	0.129
MTHFR 677 C/T polymorphism		2.61	-0.43	5.65	0.093	-0.39	-2.32	1.53	0.688

¹: values obtained from mothers at delivery; ²:fatty acids measured as % of total fatty acids; 5-MTHF: 5-Methyltetrahydrofolate; AA: Arachidonic acid; b: Regression coefficient; CI: Confidence Interval; dBMI:

416
417

418 difference of body mass index between 20 and 30 weeks of pregnancy; DHA: Docosahexaenoic acid; *FADS*:
 419 Fatty acid desaturase; FO: Fish-oil; LCL: lower confidence limit; *MTHFR*: Methyl-tetrahydrofolate
 420 reductase; tHcy: total homocysteine; UCL: upper confidence limit. *p*= level of significance obtained from
 421 multivariate multiple linear regression model; Bold: *p*<0.05

422

423 **Table 6.** Logistic regression analysis after characterizing children aged 9 years of age below P75,
 424 P50 or P25 for Symbol Digit Modalities Test (*SDMT*), Children Color Trails Test (*CCTT-1*) and
 425 *STROOP* Test

	Maternal AA/DHA	<i>FADS1 rs174556</i>		Maternal tHcy	Maternal High Education	Maternal age
		1	2			
<i>SDMT</i> - hits p75						
Contrast	30.46	3.31	1.43	0.71	3.63	1.04
95% CI	(3.68, 252.0)	(1.28,	(0.31, 6.55)	(0.56, 0.89)	(1.32, 9.98)	(0.94, 1.14)
<i>p</i> -value	0.002	8.56)	0.64	0.003	0.013	0.446
						0.014
<i>CCTT-1 (sc) p25</i>						
Contrast	18.53	2.75	4.95	1.03	2.03	1.03
95% CI	(2.13, 160.9)	(1.02,	(0.91,	(0.85, 1.26)	(0.71, 5.77)	(0.93, 1.14)
<i>p</i> -value	0.008	7.39)	27.07)	0.733	0.184	0.587
				0.065		
<i>STROOP</i> Test – hits						
1						
(Word-reading) p50	3.73	0.63	1.67	0.69	1.47	0.95
Contrast	(0.31, 44.28)	(0.19,	(0.22,	(0.51, 0.93)	(0.44, 4.85)	(0.84, 1.08)
95% CI	0.297	2.03)	12.85)	0.015	0.529	0.440
<i>p</i> -value		0.439	0.624			
<i>STROOP</i> Test – hits						
2						
(Color-naming) p75	21.70	0.28	0.67	0.51	0.69	1.20
Contrast	(0.88,	(0.07,	(0.07, 6.48)	(0.32, 0.81)	(0.17, 2.76)	(1.01, 1.42)
95% CI	534.97)	1.16)	0.733	0.005	0.602	0.039
<i>p</i> -value	0.06	0.08				

426 1= Heterozygous, 2 = Homozygous minor; AA: arachidonic acid; CCTT-1: Children Color Trails
 427 Test; DHA: Docosahexaenoic acid; *FADS*: Fatty Acid Desaturase; SDMT: Symbol Digit
 428 Modalities Test; tHcy: total homocysteine. *p*= level of significance obtained from logistic
 429 regression mixed model; Bold: *p*<0.05

430

431 4. Discussion

432 This study was performed to analyze the long-term effects of prenatal
 433 supplementation, as well as maternal *FADS* and *MTHFR* genetic polymorphisms, on
 434 processing speed in healthy school-age children. Our results suggest that neither FO

435 nor folate prenatal supplementation predicted high processing speed scores at
436 school-age children. However, our secondary exploratory analyses seem to indicate
437 that maternal AA/DHA ratio and *FADS1* rs174556 SNPs, were positively associated
438 with later processing speed in their offspring up to 9 years, while tHcy concentrations
439 in maternal plasma at delivery showed a negatively effect on child processing speed.

440 Prenatal folic acid supplementation has been related to better neurodevelopment
441 in offspring, in terms of reducing the risk of behavioral problems [45], language delay
442 [46], inattention [24], hyperactivity and peer problems [47,48]. However, their
443 potential effects on cognitive and mental performance during development are
444 inconsistent, partly due to the very limited number of studies published [49]. Folic
445 acid acts as methyl donor in the metabolic conversion of homocysteine (Hcy) to
446 methionine [50]. As consequence, folate deficit, alone or in combination with others
447 B-vitamins, attenuates this metabolic pathway, which subsequently increases total
448 Hcy levels. There is evidence that higher maternal Hcy ($\geq 8.3 \mu\text{mol/L}$) may not only
449 negatively influence placental development, birth weight and pregnancy outcomes
450 [51], but also are related to cytotoxic- and oxidative stress-dependent endothelial cell
451 impairment and apoptosis of placental trophoblast [52,53]. Interestingly, our results
452 suggest a negative predictive role of maternal tHcy on child's cognitive function. In
453 fact, children born to mothers with high tHcy levels during pregnancy showed a
454 decrease in *SDMT* and *SCWT* hits, as well as lower likelihood to be in the upper
455 percentiles of the *WRST* and *CNST*. Because tHcy concentrations are considered as
456 functional indicator of folate status, use of supplements containing folic acid during
457 pregnancy must be considered to avoid congenital malformations during fetal
458 development [54], while at the same time enhancing neurodevelopment and healthy
459 outcomes at childhood stage.

460 On the other hand, it is also clear that fetal LC-PUFAs, including DHA and AA
461 levels, are strongly related to maternal LC-PUFAs status during pregnancy, playing a
462 major role for an optimal brain development [20,55]. In this regard, DHA is related to
463 synaptogenesis, nerve growth factor expression and neuronal differentiation [56].
464 Furthermore, AA is involved in several synaptic signaling pathways [57], synthesis of
465 eicosanoids, prostaglandins and leukotrienes [11,12], growth-related early gene
466 expression and cell growth [58]. However, there is no consistent evidence for
467 long-term beneficial effects of *n*-3 or *n*-6 LC-PUFAs supplementation during
468 pregnancy or lactation on child's neurodevelopment [6,17,31,59-61]. As a
469 consequence, there is growing interest to analyze the long-term effects of AA/DHA
470 ratio on child neurodevelopment, which reflects both its endogenous synthesis and
471 exogenous supply. Moreover, because both FAs compete for the same enzymatic
472 pathways to convert them into biologically active eicosanoids, AA/DHA ratio is
473 strongly influenced by the prevalence of genetic predisposition for *FADS* and elongase
474 genes [56]. Recently, higher DHA/AA ratio and higher DHA concentrations in cord
475 blood have been considered favorable for infant visual, cognitive and motor
476 development in Arctic Inuit exposed to high intakes of seafood and *n*-3 LC-PUFAs
477 [62]. According to these findings, we did not find clear associations between type of

478 prenatal supplementation and processing speed development, except for beneficial
479 effects of prenatal FO supplementation on *CCTT-1* elapsed time at 9 years. However,
480 higher maternal AA/DHA ratio seems to be a positive and long-term modulator of
481 processing speed (mainly on *SDMT*, *CCTT-1* and *CNST*) in the offspring, indicating
482 the importance not only of DHA, but also its equilibrium with AA. Interestingly, at 9
483 years, children whose mothers were heterozygotes for *FADS1* rs174556 performed
484 better the processing speed tasks respect to those born to mothers with homozygous
485 major alleles. Our findings are also consistent with PUFAs' role on myelination and
486 white matter integrity shown in animal studies [63-65]. In this regard, DHA may
487 increase processing speed by changing the physical-chemical and structural properties
488 of membrane [66]. Moreover, Peters *et al.* [67] not only demonstrated that erythrocyte
489 membrane PUFAs concentrations in young adults seem to be robustly related to white
490 matter integrity, but also showed that these associations were mostly related to AA
491 levels. So, as the connection between white matter integrity and processing speed in
492 cognitive tasks is consistently established, our results show positive and strong
493 long-term effects of perinatal LC-PUFAs, in terms of adequate AA/DHA ratio and
494 *FADS1* polymorphism, on cognitive development, suggesting an increase of white
495 matter volume and better integrity.

496 The major strength of the present study is the long-term follow-up, from
497 pregnancy to 9years, allowing us to obtain better evaluation of long-term effects of
498 prenatal supplementation with FO, 5-MTHF or FO+5-MTHF on child's cognitive
499 abilities. Moreover, the NUHEAL study was conducted in three different countries
500 (Spain, Germany, and Hungary) with distinct eating habits; due to country of origin
501 has been eliminated as confounder, our data reinforces the idea that long-term effects
502 observed on processing speed are independent of the women's diet. In this regard, we
503 highlight the influence of the cultural level of the mothers on the processing speed of
504 their children, which increases the need to take into account the different
505 socio-environmental factors during early life that may influence on later speed
506 processing capacities. Finally, neuropsychological tests used to evaluate processing
507 speed were administered by different technicians in each country, although all of them
508 received a common training to reduce the examiner and cultural influences on the
509 results.

510 Our results have some limitations. First, the number of children who belong to
511 each study group was homogeneous but relatively low. However, after combining the
512 data from children born to mothers who were supplemented during pregnancy
513 ($n=103$), the effects of supplement combinations were significant with respect to
514 children whose mothers received placebo. Secondly, the effects of FO, 5-MTHF or
515 FO+5-MTHF supplementation were not evaluated at different time-points of
516 administration. Moreover, our study has been conducted only in a selected age range
517 (7.5-9 years). Thus, future studies will be necessary to evaluate whether our findings
518 can be extended to other times of administration or at different ages during
519 development. Finally, conversion of homocysteine to methionine is largely based on

520 both folate and vitamin B12 levels, which act as substrate and cofactor, respectively.
521 However, the status of vitamin B12 level in our study is largely unknown.

522 Findings obtained in this study should be interpreted with caution. NUHEAL
523 women belonging to FO and FO+5-MTHF groups received fish oil preparation, alone
524 or in combination with folate, at a dose of 500 mg DHA+150 mg EPA from week 20
525 until delivery, which are higher than current international recommendations (200-300
526 mg of DHA/day) [12,68]. In addition, study participants followed their usual eating
527 patterns, including PUFAs rich food. Therefore, it is of utmost importance to
528 determine the timing, necessary duration and dosage of DHA+EPA supplementation
529 (in equilibrium to AA) during pregnancy, for obtaining the best cognitive
530 development in the offspring. Interestingly, the mixed supplementation including FO
531 and 5-MTHF had no effect on processing speed up to age 9 years. Thus, we propose
532 that maternal supplementation based on folate, DHA and EPA should be
533 individualized, taking into account diet, habits, folate status and maternal *FADS1*
534 genetic variant rs174556 G/A, and perhaps not together at the same time during
535 pregnancy.

536 **5. Conclusions**

537 In summary, herewith we report that maternal AA/DHA ratio at delivery and
538 mothers who were heterozygote for *FADS1* genetic variant rs174556 seem to have
539 positive long-term effects on processing speed in the offspring up to 9 years.
540 Processing speed tasks, in terms of less time to solve *CCTT-1* task time, was also better
541 in the offspring of mothers who received prenatal FO supplementation. Our results
542 also suggest that the increase of tHcy levels can be considered as an important factor at
543 perinatal time predicting worse speed processing development at 9 years. Thus,
544 maternal LC-PUFAs and folate requirements should be within normal ranges till the
545 end of pregnancy to avoid undesirable long-term effects. Finally, we suggest that data
546 obtained from this study might be useful for designing new studies to assess the
547 effects of increased folic acid, DHA and AA consumption at certain times during
548 pregnancy and early life to improve cognition and mental performance in children.

549

550 **Supplementary Materials:** The following are available online at www.mdpi.com/xxx/s1, Figure
551 S1: title, Table S1: title, Video S1: title.

552 **Author Contributions:** conceptualization, C.C., M.P-G.; methodology, C.C., J.D.L and M.P-G.;
553 formal analysis, C.C., H.A., MC.R-T, A.M., J.D.L; investigation, F.J.T-E., C.M-Z., G.H., E.G.; ;
554 writing—original draft preparation, C.C.; writing—review and editing, C.C., J.A.G-S, H.D., E.R.,
555 P.R., M. P-G.; supervision, C.C., T.D., B.K; project administration, C.C., T.D., B.K.; funding
556 acquisition, C.C., T.D., B.K. C.C., B.K. and T.D. were coordinators of the NUHEAL study at
557 Granada, Germany and Hungary, respectively. All authors critically revised the manuscript for
558 important intellectual content and approved the final version.

559 **Funding:** This work was supported by the Commission of the European Community's 7th
560 Framework Program (FP7/2008-2013), Grant agreement no. 212652 (NUTRIMENTHE Project);
561 within the 6th Framework Program, Contract no. 007036 (EARNEST Project); and supported in
562 part by the Commission of the European Community within the 5th Framework Program,
563 Contract no. QLK1-CT-1999-00888 (NUHEAL EU Project). This publication is the work of the
564 authors and does not necessarily reflect the views of the Commission of the European
565 Community. The work of B.K. is supported by the European Research Council Advanced Grant
566 ERC-2012-AdG – no.322605 META-GROWTH. Funders had no role in the design, analysis or
567 writing of this article.

568

569 **Acknowledgments:** The authors wish to acknowledge the parents and children who
570 participated in the study, an also the pediatricians and technicians belonging to NUHEAL team
571 from University of Munich, University of Granada and University of Pécs for their contribution.

572 **Conflicts of Interest:** The authors declare no conflict of interest

573 **Statement:** The results of this article are likely to be included in the Doctoral Thesis of Hatim
574 Azaryah in the context of the Epidemiology and Public Health Doctoral Program at the
575 University of Granada.

576

577

578 **References**

- 579 1. Rabbitt, P.; Scott, M.; Lunn, M.; Thacker, N.; Lowe, C.; Pendleton, N.; Horan, M.; Jackson,
580 A. White matter lesions account for all age-related declines in speed but not in intelligence.
581 *Neuropsychology* **2007**, *21*, 363-370, doi: 10.1037/0894-4105.21.3.363.
- 582 2. Cheatham, C.L.; Nerhammar, A.S.; Afferhoj, M.; Michaelsen, K.F.; Lauritzen, L. Fish oil
583 supplementation during lactation: effects on cognition and behavior at 7 years of age.
584 *Lipids* **2011**, *46*, 637-645, doi: 10.1007/s11745-011-3557-x.
- 585 3. Salthouse, T.A. Aging and measures of processing speed. *Biol. Psychol* **2000**, *54*, 35-54, doi
586 :S0301051100000521.
- 587 4. Kochunov, P.; Coyle, T.; Lancaster, J.; Robin, D.A.; Hardies, J.; Kochunov, V.; Bartzokis, G.;
588 Stanley, J.; Royall, D.; Schlosser, A.E., et al. Processing speed is correlated with cerebral
589 health markers in the frontal lobes as quantified by neuroimaging. *Neuroimage* **2010**, *49*,
590 1190-1199, doi: 10.1016/j.neuroimage.2009.09.052.
- 591 5. Penke, L.; Muñoz, M.S.; Murray, C.; Gow, A.J.; Hernández, M.C.; Clayden, J.D.; Starr, J.M.;
592 Wardlaw, J.M.; Bastin, M.E.; Deary, I.J. A general factor of brain white matter integrity
593 predicts information processing speed in healthy older people. *J. Neurosci* **2010**, *30*,
594 7569-7574, doi: 10.1523/JNEUROSCI.1553-10.2010.
- 595 6. Campoy, C.; Escolano-Margarit, M.V.; Anjos, T.; Szajewska, H.; Uauy, R. Omega 3 fatty
596 acids on child growth, visual acuity and neurodevelopment. *Br. J. Nutr* **2012**, *107 Suppl 2*,
597 S85-106, doi: 10.1017/S0007114512001493 .
- 598 7. Koletzko, B.; Boey, C.C.; Campoy, C.; Carlson, S.E.; Chang, N.; Guillermo-Tuazon, M.A.;
599 Joshi, S.; Prell, C.; Quak, S.H.; Sjarif, D.R., et al. Current information and Asian
600 perspectives on long-chain polyunsaturated fatty acids in pregnancy, lactation, and
601 infancy: systematic review and practice recommendations from an early nutrition
602 academy workshop. *Ann. Nutr. Metab* **2014**, *65*, 49-80, doi: 10.1159/000365767.
- 603 8. Georgieff, M.K. Nutrition and the developing brain: nutrient priorities and measurement.
604 *Am. J. Clin. Nutr* **2007**, *85*, 614S-620S, doi: 85/2/614S .
- 605 9. McNamara, R.K.; Carlson, S.E. Role of omega-3 fatty acids in brain development and
606 function: potential implications for the pathogenesis and prevention of psychopathology.
607 *Prostaglandins Leukot. Essent. Fatty Acids* **2006**, *75*, 329-349, doi: 10.1016/j.plefa.2006.07.010.
- 608 10. Chevalier, N.; Kurth, S.; Doucette, M.R.; Wiseheart, M.; Deoni, S.C.; Dean, D.C., III;
609 O'Muircheartaigh, J.; Blackwell, K.A.; Munakata, Y.; LeBourgeois, M.K. Myelination Is
610 Associated with Processing Speed in Early Childhood: Preliminary Insights. *PLoS. One*
611 **2015**, *10*, e0139897, doi: 10.1371/journal.pone.0139897.
- 612 11. Delgado-Noguera, M.F.; Calvache, J.A.; Bonfill, C. X. Supplementation with long chain
613 polyunsaturated fatty acids (LCPUFA) to breastfeeding mothers for improving child

- 614 growth and development. *Cochrane Database Syst Rev* **2010**, CD007901, doi:
615 10.1002/14651858.CD007901.pub2.
- 616 12. Koletzko, B.; Cetin, I.; Brenna, J.T. Dietary fat intakes for pregnant and lactating women.
617 *Br. J. Nutr* **2007**, 98, 873-877, doi: 10.1017/S0007114507764747.
- 618 13. Simmer, K.; Patole, S.K.; Rao, S.C. Long-chain polyunsaturated fatty acid supplementation
619 in infants born at term. *Cochrane Database Syst Rev* **2008**, CD000376,
620 doi:10.1002/14651858.CD000376.pub2.
- 621 14. Carlson, S.E. Docosahexaenoic acid supplementation in pregnancy and lactation. *Am. J.
622 Clin. Nutr* **2009**, 89, 678S-684S, doi:10.3945/ajcn.2008.26811E.
- 623 15. Lattka, E.; Klopp, N.; Demmelmair, H.; Klingler, M.; Heinrich, J.; Koletzko, B. Genetic
624 variations in polyunsaturated fatty acid metabolism--implications for child health? *Ann.
625 Nutr. Metab* **2012**, 60 Suppl 3, 8-17, doi: 10.1159/000337308.
- 626 16. Simmer, K.; Patole, S.K.; Rao, S.C. Long-chain polyunsaturated fatty acid supplementation
627 in infants born at term. *Cochrane Database Syst Rev* **2011**, CD000376,
628 doi:10.1002/14651858.CD000376.pub3.
- 629 17. De Giuseppe R.; Roggi, C.; Cena, H. n-3 LC-PUFA supplementation: effects on infant and
630 maternal outcomes. *Eur. J. Nutr* **2014**, 53, 1147-1154, doi:10.1007/s00394-014-0660-9.
- 631 18. Scholtz, S.A.; Kerling, E.H.; Shaddy, D.J.; Li, S.; Thodosoff, J.M.; Colombo, J.; Carlson, S.E.
632 Docosahexaenoic acid (DHA) supplementation in pregnancy differentially modulates
633 arachidonic acid and DHA status across FADS genotypes in pregnancy. *Prostaglandins
634 Leukot. Essent. Fatty Acids* **2015**, 94, 29-33, doi: 10.1016/j.plefa.2014.10.008.
- 635 19. Judge, M.P.; Cong, X.; Harel, O.; Courville, A.B.; Lammi-Keefe, C.J. Maternal consumption
636 of a DHA-containing functional food benefits infant sleep patterning: an early
637 neurodevelopmental measure. *Early Hum. Dev* **2012**, 88, 531-537, doi:
638 10.1016/j.earlhumdev.2011.12.016.
- 639 20. Mulder, K.A.; Elango, R.; Innis, S.M. Fetal DHA inadequacy and the impact on child
640 neurodevelopment: a follow-up of a randomised trial of maternal DHA supplementation
641 in pregnancy. *Br. J. Nutr* **2018**, 119, 271-279, doi: 10.1017/S0007114517003531.
- 642 21. Kohlboeck, G.; Glaser, C.; Tiesler, C.; Demmelmair, H.; Standl, M.; Romanos, M.; Koletzko,
643 B.; Lehmann, I.; Heinrich, J. Effect of fatty acid status in cord blood serum on children's
644 behavioral difficulties at 10 y of age: results from the LISApplus Study. *Am. J. Clin. Nutr*
645 **2011**, 94, 1592-1599, doi: 10.3945/ajcn.111.015800.
- 646 22. Koletzko, B.; Carlson, S.E.; van Goudoever, J.B. Should Infant Formula Provide Both
647 Omega-3 DHA and Omega-6 Arachidonic Acid? *Ann. Nutr. Metab* **2015**, 66, 137-138, doi:
648 10.1159/000377643.

- 649 23. Steer, C.D.; Lattka, E.; Koletzko, B.; Golding, J.; Hibbeln, J.R. Maternal fatty acids in
650 pregnancy, FADS polymorphisms, and child intelligence quotient at 8 y of age. *Am. J. Clin.*
651 *Nutr* **2013**, *98*, 1575-1582, doi: 10.3945/ajcn.112.051524.
- 652 24. Julvez, J.; Fortuny, J.; Mendez, M.; Torrent, M.; Ribas-Fito, N.; Sunyer, J. Maternal use of
653 folic acid supplements during pregnancy and four-year-old neurodevelopment in a
654 population-based birth cohort. *Paediatr. Perinat. Epidemiol* **2009**, *23*, 199-206, doi:
655 10.1111/j.1365-3016.2009.01032.x.
- 656 25. Marques, A.H.; O'Connor, T.G.; Roth, C.; Susser, E.; Bjørke-Monsen, A.L. The influence of
657 maternal prenatal and early childhood nutrition and maternal prenatal stress on offspring
658 immune system development and neurodevelopmental disorders. *Front Neurosci* **2013**, *7*,
659 120, doi: 10.3389/fnins.2013.00120.
- 660 26. Veena, S.R.; Krishnaveni, G.V.; Srinivasan, K.; Wills, A.K.; Muthayya, S.; Kurpad, A.V.;
661 Yajnik, C.S.; Fall, C.H. Higher maternal plasma folate but not vitamin B-12 concentrations
662 during pregnancy are associated with better cognitive function scores in 9- to 10- year-old
663 children in South India. *J. Nutr* **2010**, *140*, 1014-1022, doi: 10.3945/jn.109.118075.
- 664 27. Villamor, E.; Rifas-Shiman, S.L.; Gillman, M.W.; Oken, E. Maternal intake of methyl-donor
665 nutrients and child cognition at 3 years of age. *Paediatr. Perinat. Epidemiol* **2012**, *26*, 328-335,
666 doi: 10.1111/j.1365-3016.2012.01264.x.
- 667 28. Suren, P.; Roth, C.; Bresnahan, M.; Haugen, M.; Hornig, M.; Hirtz, D.; Lie, K.K.; Lipkin,
668 W.I.; Magnus, P.; Reichborn-Kjennerud, T., et al. Association between maternal use of folic
669 acid supplements and risk of autism spectrum disorders in children. *JAMA* **2013**, *309*,
670 570-577, doi: 10.1001/jama.2012.155925.
- 671 29. Lu, P.H.; Lee, G.J.; Raven, E.P.; Tingus, K.; Khoo, T.; Thompson, P.M.; Bartzikis, G.
672 Age-related slowing in cognitive processing speed is associated with myelin integrity in a
673 very healthy elderly sample. *J. Clin. Exp. Neuropsychol* **2011**, *33*, 1059-1068, doi:
674 10.1080/13803395.2011.595397.
- 675 30. Carlson, S.E. Early determinants of development: a lipid perspective. *Am. J. Clin. Nutr*
676 **2009**, *89*, 1523S-1529S, doi: 10.3945/ajcn.2009.27113G.
- 677 31. Campoy, C.; Escolano-Margarit, M.V.; Ramos, R.; Parrilla-Roure, M.; Csabi, G.; Beyer, J.;
678 Ramirez-Tortosa, M.C.; Molloy, A.M.; Decsi, T.; Koletzko, B.V. Effects of prenatal fish-oil
679 and 5-methyltetrahydrofolate supplementation on cognitive development of children at
680 6.5 y of age. *Am. J. Clin. Nutr* **2011**, *94*, 1880S-1888S, doi: 10.3945/ajcn.110.001107.
- 681 32. Krauss-Etschmann, S.; Shadid, R.; Campoy, C.; Hoster, E.; Demmelmair, H.; Jiménez, M.;
682 Gil, A.; Rivero, M.; Veszpremi, B.; Decsi, T., et al. Effects of fish-oil and folate
683 supplementation of pregnant women on maternal and fetal plasma concentrations of
684 docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter
685 trial. *Am. J. Clin. Nutr* **2007**, *85*, 1392-1400, doi:85/5/1392.

- 686 33. Escribano, J.; Luque, V.; Canals-Sans, J.; Ferré, N.; Koletzko, B.; Grote, V.; Weber, M.;
687 Grusfeld, D.; Szott, K.; Verduci, E., et al. Mental performance in 8-year-old children fed
688 reduced protein content formula during the 1st year of life: safety analysis of a randomised
689 clinical trial. *Br. J. Nutr.* **2016**, 1-9, doi: 10.1017/S0007114515000768.
- 690 34. Smith, A. Symbol digit modalities test: Manual. *Western Psychological Corporation* **2002**.
- 691 35. Llorente, A.M.; Voigt, R.G.; Williams, J.; Frailey, J.K.; Satz, P.; D'Elia, L.F. Children's Color
692 Trails Test 1 & 2: test-retest reliability and factorial validity. *Clin. Neuropsychol* **2009**, 23,
693 645-660, doi: 10.1080/13854040802427795.
- 694 36. Van der Elst, W.; Van Boxtel, M.P.; Van Breukelen, G.J.; Jolles, J. The Stroop color-word
695 test: influence of age, sex, and education; and normative data for a large sample across the
696 adult age range. *Assessment* **2006**, 13, 62-79, doi: 10.1177/1073191105283427.
- 697 37. Peña-Casanova, J.; Quiñones-Ubeda, S.; Gramunt-Fombuena, N.; Quintana, M.; Aguilar,
698 M; Molinuevo, J.L.; Serradell, M.; Robles, A.; Barquero, M.S.; Payno, M., et al. Spanish
699 Multicenter Normative Studies (NEURONORMA Project): norms for the Stroop
700 color-word interference test and the Tower of London-Drexel. *Arch. Clin. Neuropsychol.*
701 **2009**, 24, 413-429.
- 702 38. Strauss, E.; Sherman, E.M.S.; Spreen, O. A. Compendium of Neuropsychological Tests:
703 Administration, Norms, and Commentary. *Oxford University Press*. **2006**.
- 704 39. Kolarovic, L.; Fournier, N.C. A comparison of extraction methods for the isolation of
705 phospholipids from biological sources. *Anal. Biochem* **1986**, 156, 244-250, doi:
706 0003-2697(86)90179-X.
- 707 40. Jakobik, V.; Burus, I.; Decsi, T. Fatty acid composition of erythrocyte membrane lipids in
708 healthy subjects from birth to young adulthood. *Eur. J. Pediatr* **2009**, 168, 141-147,
709 doi:10.1007/s00431-008-0719-9.
- 710 41. Molloy, A.M.; Scott, J.M. Microbiological assay for serum, plasma, and red cell folate using
711 cryopreserved, microtiter plate method. *Methods Enzymol* **1997**, 281, 43-53,
712 doi:S0076-6879(97)81007-5.
- 713 42. García-Minguillán, C.J.; Fernández-Ballart, J.D.; Ceruelo, S.; Ríos, L.; Bueno, O.;
714 Berrocal-Zaragoza, M.I.; Molloy, A.M.; Ueland, P.M.; Meyer, K.; Murphy, M.M. Riboflavin
715 status modifies the effects of methylenetetrahydrofolate reductase (MTHFR) and
716 methionine synthase reductase (MTRR) polymorphisms on homocysteine. *Genes Nutr*
717 **2014**, 9, 435, doi:10.1007/s12263-014-0435-1.
- 718 43. Mills, J.L.; McPartlin, J.M.; Kirke, P.N.; Lee, Y.J.; Conley, M.R.; Weir, D.G.; Scott, J.M.
719 Homocysteine metabolism in pregnancies complicated by neural-tube defects. *Lancet* **1995**,
720 345, 149-151, doi: S0140-6736(95)90165-5.

- 721 44. Klerk, M.; Verhoef, P.; Clarke, R.; Blom, H.J.; Kok, F.J.; Schouten, E.G.. MTHFR 677C->T
722 polymorphism and risk of coronary heart disease: a meta-analysis. *JAMA* **2002**, *288* (16),
723 2023-2031.
- 724 45. Roza, S.J.; van Batenburg-Eddes, T.; Steegers, E.A.; Jaddoe, V.W.; Mackenbach, J.P.;
725 Hofman, A.; Verhulst, F.C.; Tiemeier, H. Maternal folic acid supplement use in early
726 pregnancy and child behavioural problems: The Generation R Study. *Br. J. Nutr* **2010**, *103*,
727 445-452, doi: 10.1017/S0007114509991954.
- 728 46. Roth, C.; Magnus, P.; Schjolberg, S.; Stoltenberg, C.; Suren, P.; McKeague, I.W.; Davey,
729 S.G.; Reichborn-Kjennerud, T.; Susser, E. Folic acid supplements in pregnancy and severe
730 language delay in children. *JAMA* **2011**, *306*, 1566-1573, doi: 10.1001/jama.2011.1433.
- 731 47. del Río, G.C.; Torres-Sánchez, L.; Chen, J.; Schnaas, L.; Hernández, C; Osorio, E; Portillo,
732 M.G.; López-Carillo, L. Maternal MTHFR 677C>T genotype and dietary intake of folate
733 and vitamin B(12): their impact on child neurodevelopment. . *Nutr Neurosci*. **2009**, *12* (1),
734 13-20.
- 735 48. Schlotz, W.; Jones, A.; Phillips, D.I.; Gale, C.R.; Robinson, S.M.; Godfrey, K.M. Lower
736 maternal folate status in early pregnancy is associated with childhood hyperactivity and
737 peer problems in offspring. *J. Child Psychol. Psychiatry* **2010**, *51*, 594-602, doi:
738 10.1111/j.1469-7610.2009.02182.x.
- 739 49. Chmielewska, A.; Dziechciarz, P.; Gieruszczak-Bialek, D.; Horvath, A.; Piesik-Lech, M.;
740 Ruszczynski, M.; Skorka, A.; Szajewska, H. Effects of prenatal and/or postnatal
741 supplementation with iron, PUFA or folic acid on neurodevelopment: update. *Br. J. Nutr*
742 **2016**, 1-6, doi: 10.1017/S0007114514004243.
- 743 50. Skorka, A.; Gieruszczak-Bialek, D.; Piesik, M.; Szajewska, H. Effects of prenatal and/or
744 postnatal (maternal and/or child) folic acid supplementation on the mental performance of
745 children. *Crit Rev. Food Sci. Nutr* **2012**, *52*, 959-964, doi: 10.1080/10408398.2010.515042.
- 746 51. Bergen, N.E.; Jaddoe, V.W.; Timmermans, S.; Hofman, A.; Lindemans, J.; Russcher, H.;
747 Raat, H.; Steegers-Theunissen, R.P.; Steegers, E.A. Homocysteine and folate concentrations
748 in early pregnancy and the risk of adverse pregnancy outcomes: the Generation R Study.
749 *BJOG* **2012**, *119*, 739-751, doi: 10.1111/j.1471-0528.2012.03321.x .
- 750 52. Di Simone, N.; Maggiano, N.; Caliandro, D.; Riccardi, P.; Evangelista, A.; Carducci, B.;
751 Caruso, A. Homocysteine induces trophoblast cell death with apoptotic features. *Biol.
752 Reprod* **2003**, *69*, 1129-1134, doi:10.1095/biolreprod.103.015800.
- 753 53. van Mil, N.H.; Oosterbaan, A.M.; Steegers-Theunissen, R.P. Teratogenicity and underlying
754 mechanisms of homocysteine in animal models: a review. *Reprod. Toxicol* **2010**, *30*, 520-531,
755 doi: 10.1016/j.reprotox.2010.07.002.

- 756 54. Wald, N.J.; Morris, J.K.; Blakemore, C. Public health failure in the prevention of neural
757 tube defects: time to abandon the tolerable upper intake level of folate. *Public Health Rev*
758 **2018**, *39*, 2, doi: 10.1186/s40985-018-0079-6 .
- 759 55. Escolano-Margarit, M.V.; Campoy, C.; Ramírez-Tortosa, M.C.; Demmelmair, H.; Miranda,
760 M.T.; Gil, A.; Decsi, T.; Koletzko, B. Effects of fish oil supplementation on the fatty acid
761 profile in erythrocyte membrane and plasma phospholipids of pregnant women and their
762 offspring: a randomised controlled trial. *Br. J. Nutr* **2013**, *109*, 1647-1656, doi:
763 10.1017/S0007114512003716.
- 764 56. Davis-Bruno, K.; Tassinari, M.S. Essential fatty acid supplementation of DHA and ARA
765 and effects on neurodevelopment across animal species: a review of the literature. *Birth
766 Defects Res. B Dev. Reprod. Toxicol* **2011**, *92*, 240-250, doi: 10.1002/bdrb.20311.
- 767 57. Friesen, R.W.; Innis, S.M. Linoleic acid is associated with lower long-chain n-6 and n-3
768 fatty acids in red blood cell lipids of Canadian pregnant women. *Am. J. Clin. Nutr* **2010**, *91*,
769 23-31, doi: 10.3945/ajcn.2009.28206.
- 770 58. Sellmayer, A.; Danesch, U.; Weber, P.C. Effects of different polyunsaturated fatty acids on
771 growth-related early gene expression and cell growth. *Lipids* **1996**, *31 Suppl*, S37-S40.
- 772 59. Anjos, T.; Altmae, S.; Emmett, P.; Tiemeier, H.; Closa-Monasterolo, R.; Luque, V.;
773 Wiseman, S.; Pérez-García, M.; Lattka, E.; Demmelmair, H., et al. Nutrition and
774 neurodevelopment in children: focus on NUTRIMENTHE project. *Eur. J. Nutr* **2013**, *52*,
775 1825-1842, doi:10.1007/s00394-013-0560-4.
- 776 60. Dunstan, J.A.; Simmer, K.; Dixon, G.; Prescott, S.L. Cognitive assessment of children at age
777 2(1/2) years after maternal fish oil supplementation in pregnancy: a randomised controlled
778 trial. *Arch. Dis. Child Fetal Neonatal Ed* **2008**, *93*, F45-F50, doi: 10.1136/adc.2006.099085 .
- 779 61. Makrides, M.; Gibson, R.A.; McPhee, A.J.; Yelland, L.; Quinlivan, J.; Ryan, P. Effect of DHA
780 supplementation during pregnancy on maternal depression and neurodevelopment of
781 young children: a randomized controlled trial. *JAMA* **2010**, *304*, 1675-1683, doi:
782 10.1001/jama.2010.1507.
- 783 62. Jacobson, J.L.; Jacobson, S.W.; Muckle, G.; Kaplan-Estrin, M.; Ayotte, P.; Dewailly, E.
784 Beneficial effects of a polyunsaturated fatty acid on infant development: evidence from the
785 inuit of arctic Quebec. *J. Pediatr* **2008**, *152*, 356-364, doi: 10.1016/j.jpeds.2007.07.008.
- 786 63. Figueroa, J.D.; Cordero, K.; Baldeosingh, K.; Torrado, A.I.; Walker, R.L.; Miranda, J.D.;
787 Leon, M.D. Docosahexaenoic acid pretreatment confers protection and functional
788 improvements after acute spinal cord injury in adult rats. *J. Neurotrauma* **2012**, *29*, 551-566,
789 doi:10.1089/neu.2011.2141.
- 790 64. Haubner, L.; Sullivan, J.; Ashmeade, T.; Saste, M.; Wiener, D.; Carver, J. The effects of
791 maternal dietary docosahexaenoic acid intake on rat pup myelin and the auditory startle
792 response. *Dev. Neurosci* **2007**, *29*, 460-467, doi: 10.1159/000107047.

- 793 65. Ward, R.E.; Huang, W.; Curran, O.E.; Priestley, J.V.; Michael-Titus, A.T. Docosahexaenoic
794 acid prevents white matter damage after spinal cord injury. *J. Neurotrauma* **2010**, *27*,
795 1769-1780, doi: 10.1089/neu.2010.1348.
- 796 66. Stillwell, W.; Wassall, S.R. Docosahexaenoic acid: membrane properties of a unique fatty
797 acid. *Chem. Phys. Lipids* **2003**, *126*, 1-27, doi: S0009308403001014.
- 798 67. Peters, B.D.; Machielsen, M.W.; Hoen, W.P.; Caan, M.W.; Malhotra, A.K.; Szczesko, P.R.;
799 Duran, M.; Olabarriaga, S.D.; de, H.L. Polyunsaturated fatty acid concentration predicts
800 myelin integrity in early-phase psychosis. *Schizophr. Bull.* **2013**, *39*, 830-838, doi:
801 10.1093/schbul/sbs089.
- 802 68. Koletzko, B.; Lien, E.; Agostoni, C.; Bohles, H.; Campoy, C.; Cetin, I.; Decsi, T.;
803 Dudenhausen, J.W.; Dupont, C.; Forsyth, S., et al. The roles of long-chain polyunsaturated
804 fatty acids in pregnancy, lactation and infancy: review of current knowledge and
805 consensus recommendations. *J. Perinat. Med* **2008**, *36*, 5-14, doi: 10.1515/JPM.2008.001.
- 806
- 807
- 808
- 809
- 810
- 811
- 812
- 813
- 814
- 815
- 816
- 817
- 818

1 *Supplemental Methods*

2 **Long-chain polyunsaturated fatty acids,**
3 **homocysteine at birth and fatty acid**
4 **desaturase gene cluster polymorphisms are**
5 **associated with children's processing speed**
6 **up to age 9 years.**

7
8
9 *SNP selection and genotyping*

10 Genotyping of SNPs (single-nucleotide polymorphisms) from *FADS* gene cluster
11 was performed with the iPLEX method (Sequenom, San Diego, CA, USA) (see main
12 text for more information). Initially, seventeen SNPs from the *FADS1* (rs174548,
13 rs174556 and rs174561), *FADS2* (rs174570, rs174574, rs174575, rs174576, rs174578,
14 rs174579, rs174602, rs498793, rs968567, rs2727271 and rs3834458) and *FADS3*
15 (rs174448, rs174449 and rs174455) gene cluster from the NUHEAL mothers were
16 genotyped .Specific SNPs, including rs174556, rs174561, rs3834458, rs174548, rs174574
17 and rs174578, were selected due to its relation with FA levels [1,2], while 11 SNPs
18 remain were included according to its localization in *FADS* gene cluster on
19 chromosome 11. Based on the linkage disequilibrium data from Lewontin's D'
20 ($D'>0.9$) and pairwise-squared correlations r^2 ($r^2>0.7$), 4 SNPs out of the initial 17 SNPs
21 (*FADS1* rs174556 and rs174561, *FADS2* rs174575 and rs3834458) were considered for
22 further analyses (**Supplemental Figure 1**). Hardy-Weinberg (H-W) equilibrium for the
23 genotypes was calculated using the statistical software R (Version 3.2.2, package
24 "genetics"). Deviations from the H-W equilibrium were analyzed by Fisher's exact test
25 (**Supplemental Table 1**), where *FADS1* rs174561 was discarded due to its low
26 significance ($p= 0.016$). To test the linkage disequilibrium, Lewontin's D' and pairwise
27 squared correlations r^2 were also performed (**Supplemental Table 3**). Finally, we have
28 selected the *FADS1* rs174556 as a representative of the block and were included in our
29 following analysis.


30
31
32
33
34
35

36 **Supplemental Table 1.** Characteristics of the 4 selected variants in *FADS 1/2* gene from the
 37 initial 17 SNPs analyzed in the NUHEAL population

SNP	Supplementation group	Alleles (Major/Minor) and Frequency 0/1	Number (%) of subjects with Genotype			<i>p</i>
			0	1	2	
<i>FADS1</i> rs174556		G/A(0.74/0.26)	80(0.57)	47(0.34)	13(0.09)	0.127
	FO	G/A(0.67/0.33)	22(0.41)	13(0.52)	4(0.07)	0.671
	5-MTHF	G/A(0.66/0.34)	12(0.38)	12(0.56)	5(0.06)	0.591
	FO+5-MTFH	G/A(0.73/0.27)	22(0.68)	10(0.27)	-	0.538
	Placebo	G/A(0.79/0.21)	24(0.62)	12(0.35)	4(0.04)	1
<i>FADS1</i> rs174561		A/G(0.76/0.24)	81(0.61)	38(0.29)	13(0.10)	0.016
	FO	A/G(0.68/0.32)	22(0.43)	12(0.50)	4(0.07)	0.671
	5-MTHF	A/G(0.67/0.13)	12(0.40)	10(0.53)	5(0.07)	0.616
	FO+5-MTFH	A/G(0.75/0.25)	23(0.68)	7(0.32)	0	1
	Placebo	A/G(0.80/0.20)	24(0.64)	9(0.32)	4(0.04)	1
<i>FADS2</i> rs174575		C/G(0.71/0.29)	74(0.52)	53(0.37)	15(0.11)	0.230
	FO	C/G(0.71/0.29)	21(0.48)	14(0.45)	5(0.07)	0.274
	5-MTHF	C/G(0.75/0.25)	12(0.45)	14(0.45)	3(0.10)	1
	FO+5-MTFH	C/G(0.73/0.27)	20(0.50)	11(0.45)	3(0.05)	0.385
	Placebo	C/G(0.75/0.25)	21(0.54)	14(0.42)	4(0.04)	0.448
<i>FADS2</i> rs3834458		T/Z(0.68/0.32)	68(0.49)	55(0.39)	17(0.12)	0.249
	FO	T/Z(0.64/0.34)	18(0.38)	15(0.55)	2(0.07)	0.413
	5-MTHF	T/Z(0.66/0.34)	11(0.38)	13(0.56)	5(0.06)	0.591
	FO+5-MTFH	T/Z(0.75/0.25)	19(0.55)	2(0.41)	2(0.05)	1
	Placebo	T/Z(0.73/0.27)	20(0.50)	15(0.46)	5(0.04)	0.631

38 0= Homozygous major; 1= Heterozygous; 2=Homozygous minor; 5-MTHF:
 39 5-Methyltetrahydrofolate; *FADS*: Fatty Acid Desaturase; FO: Fish-oil; *p*: level of significance
 40 obtained from Hardy-Weinberg Equilibrium Test; Bold: *p* <0.05

42 **Supplemental Figure 1.** Pairwise LD measured in D' (a) and r² (b) for selected maternal FADS
 43 SNPs



44
 45
 46
 47 **Supplemental Table 2.** Power calculation obtained for processing speed evaluation in
 48 NUHEAL children
 49

Speed processing tasks at 75 years	Pooled		
	Intervention group (FO+5MTHF+MIX)	Placebo group Mean(SD)	z
		Mean(SD)	
SDMT-hits	2287(622)	2466(638)	0.80
CCTT-1(sc)	86.12(41.12)	99.88(50.77)	0.80
STROOPTest-hits-1(Word-Reading)	60.13(14.85)	59.34(16.41)	0.80
STROOPTest-hits-2(Color-Naming)	41.30(8.12)	41.95(8.41)	0.80

50 Values expressed as mean (standard deviation); 5-MTHF:
 51 5-Methyltetrahydrofolate; CCTT: Children Color Trails test; FO: Fish-oil;
 52 MIX: FO + 5-MTHF; SDMT: Symbol Digit Modalities test; z= power
 53 calculation

54
 55
 56 Interestingly, power calculation for genetic study was also calculated using the
 57 package "powerEQTL v0.1.3" (R software). For this purpose, we considered an

58 one-way unbalanced ANOVA with different ranges of sample size (50, 100, our-case
 59 143, 200, 250 and 300), α value of 0.05 and 17 analyzed SNPs in *FADS* 1/2/3 gene
 60 cluster. As show in **and Supplemental Table 2 and 3**, a statistical power of 90% was
 61 obtained for analyzed SNPs, except for rs174570 and rs2727271.

62

63 **Supplemental Table 3.** Power calculation obtained for genetic study in NUHEAL children

SNPs	Possible Functional Region	Alleles Frequency (Major/Minor)	Power Calculation
rs174548	<i>FADS1</i>	G/C (0.73/0.27)	>0.90
rs174556	<i>FADS1</i>	G/A (0.74/0.26)	>0.90
rs174561	<i>FADS1</i>	A/G (0.75/0.25)	>0.90
rs174570	<i>FADS2</i>	C/T (0.90/0.10)	>0.80
rs174574	<i>FADS2</i>	C/A (0.68/0.32)	>0.90
rs174575	<i>FADS2</i>	C/G (0.73/0.27)	>0.90
rs174576	<i>FADS2</i>	C/A (0.68/0.32)	>0.90
rs174578	<i>FADS2</i>	T/A (0.67/0.33)	>0.90
rs174579	<i>FADS2</i>	C/T (0.81/0.19)	>0.90
rs174602	<i>FADS2</i>	T/C (0.77/0.23)	>0.90
rs498793	<i>FADS2</i>	C/T (0.55/0.45)	>0.90
rs968567	<i>FADS2</i>	C/T (0.83/0.17)	>0.90
rs2727271	<i>FADS2</i>	A/T (0.89/0.11)	>0.80
rs3834458	<i>FADS2</i>	T/Z (0.70/0.30)	>0.90
rs174448	<i>FADS3</i>	T/C (0.69/0.31)	>0.90
rs174449	<i>FADS3</i>	T/C (0.69/0.31)	>0.90
rs174455	<i>FADS3</i>	T/C (0.68/0.32)	>0.90

64 *FADS*: Fatty Acid Desaturase; SNP: Single-Nucleotide polymorphism.

65

66

67 **Supplemental References**

1. Koletzko, B.; Lattka, E.; Zeilinger, S.; Illig, T.; Steer, C. Genetic variants of the fatty acid desaturase gene cluster predict amounts of red blood cell docosahexaenoic and other polyunsaturated fatty acids in pregnant women: findings from the Avon Longitudinal Study of Parents and Children. *Am J ClinNutr* 2011, 93(1), 211-219.
2. Lattka, E.; Koletzko, B.; Zeilinger, S.; Hibbeln, J.R.; Klopp, N.; Ring, S.M.; Steer, C. Umbilical cord PUFA are determined by maternal and child fatty acid desaturase (*FADS*) genetic variants in the Avon Longitudinal Study of Parents and Children (ALSPAC). *Br J Nutr* 2013, 109(7), 1196-210.

- 76 3. Chow, S.; Shao, J.; Wang, H. Sample size calculations in clinical research. 2nd Ed. Chapman &
77 Hall/CRC Biostatistics Series. 2008, page 8

78
79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

ESTUDIO 3

“Effects of Maternal Fish Oil and/or 5-Methyl-Tetrahydrofolate Supplementation during Pregnancy on Offspring Brain Resting-State at 10 Years Old: A Follow-up Study from the NUHEAL Randomized Controlled Trial”

Hatim Azaryah, Juan Verdejo-Román, Cristina Martín-Pérez, José Antonio García-Santos, Cristina Martínez-Zaldívar, Francisco J. Torres-Espínola, Daniel Campos, Berthold Koletzko, Miguel Pérez-García , Andrés Catena y Cristina Campoy. Nutrients 2020, 12, 2701; doi:10.3390/nu12092701. IF: 4.546

Effects of Maternal Fish Oil and/or 5-Methyl-Tetrahydrofolate Supplementation during Pregnancy on Offspring Brain Resting-State at 10 Years Old: A Follow-up Study from the NUHEAL Randomized Controlled Trial

Hatim Azaryah ^{1,2,†}, Juan Verdejo-Román ^{3,†}, Cristina Martín-Pérez ³,
José Antonio García-Santos ^{1,2,4}, Cristina Martínez-Zaldívar ^{1,2}, Francisco J.
Torres-Espínola ^{1,2}, Daniel Campos ^{1,2}, Berthold Koletzko ⁵, Miguel
Pérez-García ³, Andrés Catena ³ and Cristina Campoy ^{1,2,4,6,*}

¹ Department of Paediatrics, School of Medicine, University of Granada, Avda. Investigación 11,
18016 Granada, Spain; rifappstudio@gmail.com (H.A.); joseantonio_gsantos@outlook.es
(J.A.G.-S.); mcriszald@ugr.es (C.M.-Z.); fjespinola@yahoo.es (F.J.T.-E.); dconsu@ugr.es
(D.C.)

² EURISTIKOS Excellence Centre for Paediatric Research, Biomedical Research Centre,
University of Granada, 18016 Granada, Spain

³ Mind, Brain and Behaviour International Research Centre (CIMCYC), University of
Granada,
18011 Granada, Spain; j.verdejo@gmail.com (J.V.-R.); crmartinperez@gmail.com (C.M.-P.);
mperezg@ugr.es (M.P.-G.); acatena@ugr.es (A.C.)

⁴ Instituto de Investigación Biosanitaria de Granada (Ibs-GRANADA), Health Sciences
Technological Park, 18012 Granada, Spain

⁵ Ludwig-Maximilians-Universität München, Dr. von Hauner Children's Hospital,
University of Munich Hospitals, 80337 Munich, Germany;
Berthold.Koletzko@med.uni-muenchen.de

⁶ Spanish Network of Biomedical Research in Epidemiology and Public Health (CIBERESP),
Granada's node, Institute of Health Carlos III, 28029 Madrid, Spain

* Correspondence: ccampoy@ugr.es; Tel.: +34-629308695

† Equal contribution.

Received: 16 July 2020; Accepted: 02 September 2020; Published: 04 September 2020

Abstract: Recent studies have shown that maternal supplementation with folate and long-chain polyunsaturated fatty acids (LC-PUFAs) during pregnancy may affect children's brain development. We aimed at examining the potential long-term effect of maternal supplementation with fish oil (FO) and/or 5-methyl-tetrahydrofolate (5-MTHF) on the brain functionality of offspring at the age of 9.5–10 years. The current study was conducted as a follow-up of the Spanish participants belonging to the Nutraceuticals for a Healthier Life (NUHEAL) project; 57 children were divided into groups according to mother's supplementation and assessed through functional magnetic resonance imaging (fMRI) scanning and neurodevelopment testing. Independent component analysis and double regression methods were implemented to investigate plausible associations. Children born to mothers supplemented with FO (FO and FO + 5-MTHF groups, n = 33) showed weaker functional connectivity in the default mode (DM) (angular gyrus), the sensorimotor (SM) (motor and somatosensory cortices) and the fronto-parietal (FP) (angular gyrus) networks compared to the No-FO group (placebo and 5-MTHF groups, n = 24) ($P_{FWE} < 0.05$). Furthermore, no differences were found regarding the neuropsychological tests, except for a trend of better results in an object recall (memory) test. Considering the No-FO group, the aforementioned networks were associated negatively with attention and speed-processing functions. Mother's FO supplementation during pregnancy seems to be able to shape resting-state network functioning in their children at school age and appears to produce long-term effects on children's cognitive processing.

Keywords: fish oil; folate; pregnancy; brain function; resting-state functional neuroimaging; neurodevelopment; children

1. Introduction

The key role of nutrition during the “first 1000 days” (from conception to 2 years after birth) on optimal brain development in later life is well established. Rather than a homogenous organ, the human brain is formed by distinct regions and processes, each of which differs in its developmental trajectory and nutritional needs. In this line, fetal life has been established as a “critical” timeframe where deficiencies of some nutrients may lead to long-lasting or irreversible effects for later neurodevelopment in offspring [1].

Maternal intake during pregnancy of certain nutrients, including long-chain polyunsaturated fatty acids (LC-PUFAs), folic acid, and other B-group vitamins, is needed for fetal nervous system development, but also for the normal development of specific brain regions (i.e., the hippocampus, striatum, retina or cortex) and to establish the neural architecture and its underlying circuitry (synaptogenesis, neuronal pruning, and myelination) that supports major brain functions [2–5].

In fact, the links between LC-PUFAs (contained in fish oil) and the function of these networks underpinning cognition in children are well established. DHA

supplementation has been associated with cortical circuit maturation in children [6] and increased pre-frontal activation during sustained attention [7]. Low DHA concentrations have been associated with anomalies such as reduced indices in cortical integrity in the anterior cingulate (which implies a slower reaction time during sustained attention) [8], and increased risk for developing affective or bipolar disorders [9]. Regarding folic acid, there are consistent indications that prenatal supplements during the first 12 weeks of pregnancy not only prevent neural tube defects [10], but also affect apoptosis, neurogenesis, and overall nervous system development [11,12]. Cerebral 5-methyl-tetrahydrofolate (5-MTHF) deficiency could be associated with disturbed folate transportation or increased turnover from the central nervous system, which could lead to atrophy of fronto-temporal regions and periventricular demyelination, as can be observed in some neuroimaging studies [13].

Resting-state functional magnetic resonance imaging (rsfMRI) has been identified as a useful tool to explore brain function in the absence of task-demanding stimuli [14]. The rsfMRI allows for identification of the intrinsic brain networks implicated in primary (i.e., sensorimotor or visual networks) and high-order functions (i.e., fronto-parietal or default mode networks), such as executive functions or attention networks [15]. Despite the relevance of nutritional supplementation on brain structure, little is known about the effects of these nutrients on brain functioning in humans. A previous study has shown associations between PUFAs and the functional connectivity in areas within the default mode network, and the visual and limbic systems in elderly adults [16].

Recently, in a previous publication from the Nutraceuticals for a Healthier Life (NUHEAL) project, a long-term early nutrition programming effect of maternal folate and omega-3 fatty acid supplementation on offspring metabolism has been suggested [17]. To the best of our knowledge, no other study has explored the early nutrition programming effects on brain resting-state in school children at 10 years old. Due to the lack of research in this field, in the present study, we hypothesized that maternal prenatal supplementation with fish oil (FO) and/or 5-methyl-tetrahydrofolate (5-MTHF) might have a long-term effect on the brain resting-state networks of offspring at the age of 9.5–10 years. Furthermore, we will also explore the association between functional connectivity and children's mental processing.

2. Materials and Methods

2.1. Study Design

The current study was conducted as a follow-up of the Spanish children enrolled in the NUHEAL double-blind randomized trial www.ClinicalTrials.gov Identifier NCT01180933). A detailed study design, subject recruitment, and population characteristics have been described elsewhere [18]. Briefly, NUHEAL is a multicenter, randomized, double-blind, 2x2 factorial placebo-controlled trial designed to assess the effects of n-3 LC-PUFAs and 5-MTHF-supplementation during the second half of pregnancy on infant development. Healthy pregnant women were recruited before the 20th weeks of gestation and were randomly assigned to four different groups.

From week 20 to delivery, they received a daily supplement consisting of fish oil (FO: 500 mg of docosahexaenoic acid (DHA) + 150 mg eicosapentaenoic acid (EPA)), 400 µg 5-MTHF, both, or placebo, together with vitamins and minerals following European recommendations for pregnant women. All children were born at term and with birth weight appropriate for gestational age. At the age of 9 years, a total of 154 NUHEAL children were assessed by the NUTRIMENTHE neuropsychological battery (NNB) [19], and 85 of them also underwent an MR-scanning session at the age of 9.5–10 years.

The study was approved by the Ethics Committees for human research of the Universidad de Granada (Grant agreement number: 212652) and conducted in accordance with the Helsinki Declaration for human research studies in 2013 [20]. Written informed consent forms were obtained from all participants at the beginning of the study and before the magnetic resonance session.

2.2. Sample Size

A total of 85 Spanish children underwent an MR-scanning session at the age of 9.5–10 years. Twenty-eight of the datasets were discarded due to excessive motion, previous head injuries, claustrophobia and implanted ferromagnetic objects; therefore, a total of 57 children had valid data for all NNB and resting-state functional magnetic resonance imaging (rsfMRI) and were included in the analyses. From these children, 19 were born to mothers who received FO, 10 whose mothers were supplemented with 5-MTHF, 14 whose mothers received placebo and 14 were born to mothers supplemented with FO + 5-MTHF during pregnancy (Figure 1). All participants met the inclusion and exclusion criteria established for this study.




Figure 1. Participant flowchart. FO= fish oil, 5-MTHF = 5-methyl-tetrahydrofolate. Discards, D₁= excessive motion, D₂= previous head injuries, D₃ = claustrophobia, D₄ = implanted ferromagnetic object.

To achieve a statistical power of 80%, a medium-to-large effect size (0.7–0.9) between study groups, and considering a significance level as 0.05, the minimum sample size required is 20 per group [21]. Due to a high number of discards, future clustering of our original groups will be made to reach the minimum sample size required for a robust and reliable neuroimaging analysis.

2.3. Resting-State fMRI Experimental Procedure (Primary Outcome)

Before starting the fMRI acquisition, children were trained by a master's degree psychologist to lie down on the patient table, keep calm and close their eyes during the scanner session. They were instructed to think about nothing in particular, but not to fall asleep during the resting-state acquisition. Resting-state brain images were acquired for a total time of 6 min.

2.3.1. Independent Component Analyses

Independent component analyses (ICA) was carried out using the probabilistic independent component analysis [22] as implemented in MELODIC (Multivariate Exploratory Linear Decomposition into Independent Components) version 3.14, part of FSL (FMRIB Software Library). Pre-processed data were whitened and projected onto a 40-dimensional subspace using probabilistic principal component analysis. The forty components were visually checked and identified. Components that represent well-known artifacts as motion, high-frequency noise, or venous pulsation [23,24] or those not located mainly in the gray matter [25] were identified and not taken into account in the following analyses. Fourteen components were discarded because of the previous reason; and the remaining twenty-six resting-state networks (RSNs) were labeled based on the overlap with the Harvard–Oxford cortical and subcortical structural atlases available in FSL.

2.3.2. Imaging Data Acquisition and Pre-Processing

fMRI data were collected with a 3T Philips Intera Achieva System (Philips Medical Systems, Eindhoven, The Netherlands) equipped with an eight-channel phased-array head coil. A T2*-weighted echo-planar imaging (EPI) sequence was acquired with the following parameters: repetition time (TR) = 2000 ms; echo time (TE) = 30 ms; flip angle = 78°; field of view = 230 × 230 mm; number of slices = 23; voxel dimension = 3 × 3 × 4 mm; gap, 1 mm. Structural images were also obtained as an isotropic T1-weighted turbo-gradient-echo sequence in the sagittal plane (TR = 8.3 ms; TE = 3.8 ms; flip angle = 8°; FOV (Field Of View) = 240 × 240 mm; number of slices = 160; slice thickness = 1 mm; voxel dimension = 1 × 1 × 1 mm). Prior to specific resting-state preprocessing, motion during acquisition was estimated using the realign tool implemented in statistical parametric mapping (SPM8) software (Wellcome Department of Cognitive Neurology, Institute of Neurology, Queen Square, London). Subjects with motion parameters exceeding 3 mm or 3 degrees were excluded from the subsequent processing and analyses.

Resting-state functional imaging pre-processing was performed using Functional MRI of the Brain (FMRIB) Software Library (v5.0.9, FSL,

<http://fsl.fmrib.ox.ac.uk/fsl/fslwiki>). Pre-processing steps included the removal of the ten first volumes, high-pass temporal filtering (120s), motion correction using the MCFLIRT tool [26], brain extraction using BET (Smith, 200), spatial smoothing using a Gaussian kernel of FWHM (Full Width at Half Maximum) = 8 mm, registration to a T1-weighted standard template using the FSL linear registration tool (FLIRT) with 12 degrees of freedom (DOF) and finally resampling to a 4 mm resolution.

2.4. Neuropsychological Assessment (Secondary Outcome)

Children's neurocognitive development was assessed using a NUTRIMENTHE neuropsychological battery (NNB), a comprehensive neuropsychological battery specifically developed for the NUTRIMENTHE project [19,27,28]. For the present study, NNB was used to evaluate long-term effects of prenatal supplementation on the whole spectrum of neuropsychological functioning in children. The NNB consists of fifteen cognitive tests to assess seven different neuropsychological domains: processing speed, perception, motor, memory, attention, language, and executive functions, which are described briefly in Table 1 (a full description was already published elsewhere [19]).

Table 1. NUTRIMENTHE neuropsychological battery description [19,28,29].

Domain	Function	Test
Memory	Visual Episodic Memory	Recall of Objects Test (ROT)
	Verbal Memory	Rey Auditory Verbal Learning Test (RAVLT)
Attention	Sustained and Focused Attention	Continuous Performance Test (CPT)
	Spatial Attention	Pair Cancellation Test (W-M)
Motor	Visio-Motor Coordination	Grooved Pegboard Test (GPT)
Perception	Visio-Perceptual Integration	Hooper Visual Organization Test (HVOT)
Language	Semantic Fluency	Categorical Fluency Test (F-A-S-Animals)
	Verbal Comprehension	Token Test II (NEPSY-II)
Processing Speed	Processing Speed	Symbol Digit Modalities Test (SDMT)
Executive Functions	Impulsivity/Inhibition	Stroop Color and Word Test
	Update	Reversal Digits Subtest
	Flexibility/Shifting	Matrix Analogies Test-(K-ABC-II)
	Decision Making	Children's Color Trail Test (CCTT)

2.5. Statistical Analyses

2.5.1. Resting-State fMRI

A dual regression method, described elsewhere [30], was implemented in FSL, followed by two-group t-tests, to compare brain maps across groups. Briefly, subject-specific statistical brain maps were created and collapsed in a 4D file for each resting-state network. In the first stage of the dual regression method, the spatial components generated during the ICA analysis were regressed into each subject's resting-state data to give a set of subject-specific time courses for each component. In the second stage, those time courses were regressed into the resting-state data to obtain subject-specific spatial brain maps for each component. Then, those subject-specific brain maps were used to compare each brain network between groups. These comparisons were tested voxel-wise for differences between groups using nonparametric permutation testing (5000 permutations) [31]. For each RSN, the resulting statistical maps had a threshold at $p < 0.05$ (threshold-free cluster enhancement-corrected for family-wise errors).

2.5.2. Neuropsychological Outcomes

The normality of variables was assessed for both RSN scores and neurodevelopment outcomes with Shapiro-Wilk's method. NNB outcomes were represented as mean (standard errors), and significant differences were assessed through Student t and Kruskal-Wallis tests. Pearson and Spearman correlations between RSN scores and NNB tests were carried out, taking into account the normality of variables.

3. Results

The general characteristics of the study population obtained at the study entry before the fMRI session are shown in Table 2.

Table 2. Sociodemographic characteristics of the study population by study group.

	FO (n = 19)	5-MTHF (n = 10)	Placebo (n = 14)	FO + 5-MTHF (n = 14)
Mothers' characteristics				
Age, years	29.68 (4.73)	34.15 (5.77)	31.86 (3.25)	30.68 (4.81)
BMI (20 w), kg/m ²	25.96 (3.67)	24.87 (2.13)	25.63 (2.47)	26.40 (2.89)
BMI (30 w), kg/m ²	28.47 (4.19)	26.64 (2.07)	27.50 (2.50)	28.46 (2.59)
BMI (delivery), kg/m ²	29.98 (4.58)	27.81 (2.05)	29.08 (3.08)	29.39 (2.86)
Weight gain, kg	10.64 (3.65)	7.67 (3.31)	8.86 (3.16)	7.25 (4.61)
Relative weight gain, %	15.45 (5.14)	12.08 (6.30)	13.49 (5.15)	10.99 (7.33)
Education *				
Mother	8 (42.1)	2 (50.00)	4 (50.00)	4 (44.45)
Father	11 (57.9)	2 (50.00)	4 (50.00)	5 (55.55)
Parity, n (%)				
0	13 (68.42)	5 (50.0)	7 (50.0)	6 (42.86)
≥1	6 (31.58)	5 (50.0)	7 (50.0)	8 (57.14)
Smoking (20 w), n (%)	5 (26.32)	1 (10.0)	0 (0.0)	4 (28.57)

Gravidity risk at 20 w, n (%)				
No risk factors	3 (15.79)	3 (30.0)	5 (38.46)	3 (21.43)
≥1 risk factor	16 (84.21)	7 (70.0)	8 (61.54)	11 (78.57)
Delivery risk				
No risk factors	6 (31.58)	4 (40.0)	7 (53.85)	5 (35.71)
≥1 risk factor	13 (68.42)	6 (60.0)	6 (46.15)	9 (64.29)
Children's characteristics				
Age, years	9.67 (0.26)	9.76 (0.20)	9.75 (0.19)	9.69 (0.22)
BMI, kg/m ²	19.45 (4.22)	17.64 (2.60)	17.76 (2.87)	19.08 (2.87)
Sex, n (%)				
Female	8 (42.11)	7 (70.0)	3 (21.43)	6 (42.86)
Male	11 (57.89)	3 (30.0)	11 (78.57)	8 (57.14)

FO: fish oil; 5-MTHF: 5-methyl-tetrahydrofolate; BMI: body mass index. * Attained general qualification level for university entrance or university degree. For qualitative variables (frequency (percentage)); for quantitative variables (mean (standard deviation)).

3.1. Resting-State fMRI Results

To assess the effect of prenatal FO supplementation, participants were clustered into two groups: (i) 33 children from the FO group (FO or FO + 5-MTHF), and (ii) 24 children from the No-FO group (5-MTHF alone or placebo). Three resting-state networks showed significant differences between the study groups. Specifically, children from No-FO group showed strong functional connectivity in the default mode (DM) (angular gyrus), the sensorimotor (SM) (motor and somatosensory cortices) and the fronto-parietal (FP) (angular gyrus) networks compared to the FO group ($P_{FWE} < 0.05$) (see Figure 2 and Table 3).

Alternatively, to assess the effect of folate supplementation during pregnancy, participants were divided into the following: (i) 24 children born to mothers supplemented with 5-MTHF or FO + 5-MTHF and (ii) 33 children whose mothers were supplemented during pregnancy only with FO or placebo. We found no significant differences in brain networks during resting-state between children supplemented with or without 5-MTHF.




Figure 2. Children's resting-state functional magnetic resonance imaging (fMRI). Voxel-wise significant differences between maternal supplementation or not with FO during pregnancy. Color bars represent t-value. Warm colors represent the whole brain colors represented over the networks show the brain areas with significant differences between groups. (a) Default mode network, si gyrus; (b) sensorimotor network, significant areas: postcentral gyrus, precentral (left and right) gyrus and putamen; (c) fronto-parietal area: angular gyrus. (FO: fish oil, 5-MTHF : 5-methyl-tetrahydrofolate). ** PFWE < 0.05.

Table 3. Brain regions showing differences between groups ($P_{FWE} < 0.05$).

Side	MNI Coordinates			Volume (mm ³)	t-Value
	X	Y	Z		
Default Mode Network					
Angular Gyrus	R	50	-62	20	176
Sensorimotor Network					
Postcentral Gyrus	L	-26	-50	60	2792
Precentral Gyrus	L	-18	2	44	760
Precentral Gyrus	R	22	-2	68	672
Putamen	L	-22	10	12	336
Fronto-Parietal Network					
Angular Gyrus	R	46	-58	28	296

MNI: Montreal Neurological Institute; X Y and Z: Axis; R: Right, L: Left.

3.2. Neuropsychological Outcomes and RSN Scores

No significant differences were found between the FO and the No-FO groups regarding the neuropsychological test results (see Table 4), except for a trend of children belonging to the FO group performing better in the Recall of Objects (ROT) test (memory domain) ($p = 0.065$).

In Table 5, correlations established between RSN scores and neuropsychological results are shown, considering the FO or No-FO groups. No significant results were found between the default mode network (DMN) and the NNB scores. The No-FO group showed a negative association between the angular gyrus within the fronto-parietal network (FPN) regarding SDMT hits (speed-processing domain) and CT hits (attention domain) (See Figure 3). In addition, the No-FO group presented a negative correlation between the precentral (right) and postcentral gyrus within the SMN (sensorimotor network) and CT hits (attention domain) (See Figure 3).

Table 4. Hits, timing and scores obtained by school children in the neuropsychological assessment depending on their mothers' fish oil supplementation during pregnancy.

NNB	FO Group (FO and FO + 5-MTHF)	No-FO Group (5-MTHF + Placebo)	<i>p</i> -Value
	<i>n</i> = 33	<i>n</i> = 24	
SDMT Hits	24.74 (0.96)	24.38 (1.38)	0.812
Grooved DH	45.03 (2.51)	40.25 (2.41)	0.162
Grooved NDH	54.77 (4.87)	45.17 (3.42)	0.101
HVOT Hits	16.06 (0.59)	16.62 (0.61)	0.512
CT Hits	74.12 (2.7)	72.33 (2.76)	0.654
CPT BL7 OMI	9.35 (1.43)	9.25 (1.39)	0.962
ROT Immediate Hits	5.81 (0.4)	4.83 (0.34)	0.065
ROT Delayed Hits	0.34 (0.15)	0.25 (0.09)	0.589
RAVLT Hits Trial 1	4.61 (0.25)	4.5 (0.42)	0.795
RAVLT Hits Trial 1–5	10.29 (0.35)	9.71 (0.49)	0.344
RAVLT Delayed Trial	13.13 (0.3)	12.83 (0.39)	0.562
Animals Total Hits	12.38 (0.63)	12.5 (0.65)	0.875
Token Test Total Hits	20.78 (0.37)	21.58 (0.58)	0.255
Stroop Interference	-1.57 (0.87)	-1.47 (1.18)	0.514
Reversal Digits, Hits	9.12 (0.41)	9.46 (0.63)	0.652
K-ABC-II	12.75 (0.46)	13.46 (0.88)	0.451
CCTT Part 1(s)	107.94 (5.8)	108.71 (10.13)	0.352
HDT Total Hits	0.81 (3.96)	0.27 (3.45)	0.114

NNB: NUTRIMENTHE neuropsychological battery; SDMT, Symbol Digit Modalities Test (total hits); DH, dominant hand; NDH, non-dominant hand; HVOT, Hooper Visual Organization Test (total hits); CT, Cancellation Test (total hits); CPT BL7, continuous performance test (total hits), Block7; OMI, omissions; ROT, Recall of Objects test (immediate and delayed recalled pictures); RAVLT, Rey Auditory Verbal Learning Test (recalled words in trial 1, trial 1–5 and delayed (hits)); K-ABC-II, Matrix Analogies Test (total hits); CCTT, Children's Color Trail Test (time, part 1(s)); HDT, Hungry Donkey Task (total score); (s), seconds. FO : fish oil; 5-MTHF : 5-methyl-tetrahydrofolate. Data are expressed by mean (standard errors). *P*-value from Student t-test or Kruskal-Wallis test depending on normality.

Table 5. Correlations between resting-state network (RSN) scores and neuropsychological battery (NNB) tests for each supplemen

NNB	Default Mode Network				Sensorimotor Network				Frontal Lobe	
	Angular Gyrus		Postcentral Gyrus		Precentral Gyrus (L)		Precentral Gyrus (R)		Putamen	
	FO	No-FO	FO	No-FO	FO	No-FO	FO	No-FO	FO	No-FO
SDMT hits ^s	0.055	-0.110	0.180	-0.245	0.130	-0.300	-0.005	-0.225	0.147	-0.211
Grooved DH ^s	-0.144	0.046	-0.244	0.210	-0.114	0.411	0.160	0.350	0.044	0.250
Grooved NDH ^s	0.043	-0.079	-0.349	0.082	-0.189	0.240	-0.197	0.183	0.066	0.161
HVOT Hits ^s	-0.044	0.092	0.221	-0.033	-0.077	-0.236	-0.224	-0.001	-0.154	-0.056
CT Hits ^s	-0.147	-0.332	0.040	-0.489 *	0.109	-0.228	-0.26	-0.491 *	-0.042	-0.164
CPT BL7 OMI ^s	0.106	-0.137	0.201	-0.044	0.214	0.063	0.355	-0.05	0.144	-0.221
ROT Immediate Hits ^s	0.219	-0.138	0.237	-0.231	-0.114	-0.274	-0.067	-0.282	-0.224	0.026
ROT Delayed Hits ^s	0.084	-0.108	-0.077	-0.152	0.470	-0.026	0.095	-0.219	0.180	-0.167
RAVLT Hits Trial-1 ^p	-0.285	-0.206	-0.076	-0.136	0.007	-0.108	-0.025	-0.159	-0.379	0.162
RAVLT Hits Trial-1-5 ^s	-0.166	-0.031	0.084	-0.042	-0.111	-0.021	0.425	-0.095	-0.497	0.175
RAVLT Delayed Trial ^s	0.145	-0.233	-0.043	0.138	0.022	0.228	-0.198	0.155	-0.121	0.357
Animals Total Hits ^s	0.072	-0.209	-0.271	-0.206	0.112	0.151	-0.503	-0.147	-0.019	0.439
Token Test Total Hits ^p	-0.037	-0.190	0.163	-0.153	-0.312	-0.222	-0.161	-0.069	-0.045	0.04
Stroop Interference ^p	0.267	-0.253	0.369	-0.315	0.042	-0.394	0.017	-0.200	0.120	-0.247
Reversal Digits, Hits ^p	-0.221	0.139	-0.081	-0.038	-0.108	-0.188	-0.149	-0.118	-0.165	0.011
K-ABC-II ^s	0.124	-0.276	0.124	-0.221	-0.035	-0.187	-0.147	-0.302	0.201	-0.160
CCTT Part 1(sec) ^p	0.087	0.119	0.101	0.155	-0.214	0.003	0.054	0.339	0.292	0.005
HDT Total Hits ^s	-0.041	0.084	0.259	0.232	0.017	0.122	0.478	0.258	0.214	0.283

NNB: NUTRIMENTHE neuropsychological battery; SDMT, Symbol Digit Modalities Test(total hits); DH, dominant hand; NDH, non-dominant hand; HVOT, Hooper Visual Organization Test (total hits); CT, Cancellation Test (total hits); CPT BL7, continuous performance test; Block7; OMI, omissions; ROT, Recall of Objects test (immediate and delayed recalled pictures); RAVLT, Rey Auditory Verbal Learning Test (recalled words in trial 1, trial 1-5 and delayed (hits)); K-ABC-II, Matrix Analogies Test (total hits); CCTT, Children's Color Test (total score); CCTT Part 1(s); HDT, Hungry Donkey Task (total score); (s), seconds; FO = fish oil. Data are expressed as r correlation coefficient from Pearson or Spearman, * $p < 0.05$.




Figure 3. Spearman correlations between NNB and RSN scores; R = correlation coefficient; p = p -value; CT = Cancellation Test (total hits) from the attention domain; SDMT = Symbol Digit Modalities Test (total hits) from the speed-processing domain.

4. Discussion

This is the first study to examine the long-term effect of maternal supplementation with FO and/or 5-MTHF on the RSNs of the offspring at school age. We found that FO, but not 5-MTHF, supplementation during the second half of pregnancy is associated with decreased functional connectivity of children's brain networks at 9.5–10 years of age. Specifically, the default mode, the sensorimotor and the fronto-parietal networks displayed weaker functional connectivity in children born to mothers supplemented with FO or FO + 5-MTHF. Furthermore, after

correlating the resting-state scores and NNB tests, we found that children born to mothers who did not take FO supplements performed poorly regarding speed processing and attention tests.

Weak functional connectivity does not necessarily indicate poor cognitive neurodevelopment; in fact, some studies have shown for instance that the variance in IQ levels within a heterogeneous population was mostly explained by the distributed communication efficiency of brain networks built using moderately weak, long-distance connections, with only a smaller contribution of stronger connections [32]. In this study, children exposed to prenatal FO did not show any functional disadvantage but tended to have better memory. Another example is the weaker brain resting-state of bilingual subjects compared to monolingual ones [33,34], where the strength of resting-state functional connectivity correlated inversely with behavioral performance.

Considering the main brain area differences found in the present study, the angular gyrus is a cross-modal region which might act as a “connector hub” for the global processing of information [35], but also as a shifting area between internal (DMN) and external/salient (FPN) information [36]. These functions are competing but complementary [37] and could mask a high intrinsic relationship between functional connectivity and neurodevelopment. Indeed, the children born to mothers not supplemented with FO showed that the angular gyrus activity within the FPN was negatively related to the performance in attention and processing speed, suggesting an FO-related conjoint alteration between the most relevant brain network related to cognition (FPN) and the performance in important cognitive processes.

Regarding several alterations in the sensorimotor network (SMN), both somatosensory (postcentral) and motor (putamen and precentral gyrus) areas are involved in pre-mediated state of readiness to perform/coordinate a motor task [38], and their alterations in healthy subjects might lead to a maladaptive coordination of movements and motor learning, as proposed by previous animal studies [38]. However, this brain network’s function is not limited to motor execution. Indeed, it also mediates action execution programs [39], and its activity is known to be more related to attention to external stimuli in comparison with internal attentional processes [40]. Those children born to mothers not supplemented with FO showed a negative correlation between SMN and the performance in neuropsychological tasks related to attention; these results support the previously studied association between attentional and speed-processing processes and the SMN function [40]. It is well established that motor performance, visual-motor coordination [41] and attention [3] start to develop during gestation, especially at the second and third trimester of pregnancy; thus, these domains may be affected by nutritional interventions during this critical period of neurodevelopment, noting that omega-3 polyunsaturated fatty acids are essential due to their role in neurogenesis, fluidity and membrane fatty acid composition [42].

To date, clinical literature focused on neurodevelopmental effects of key nutrients is broadly based on nutrient deficiencies or deprivation, but optimal nutrient doses and potential long-term effects at different developmental ages remain unclear [1,43]. Some studies suggest that prenatal or postnatal dietary interventions based on

LC-PUFAs could have long-term effects on late child neurodevelopment, mainly on sustained attention, language, and processing speed [44–47]. For instance, children whose mothers received fish oil supplementation performed significantly better than the placebo group regarding the communication domain at the ages of 4 and 6 months [48], eye and hand coordination at 2.5 years [49], and sustained attention at 5 years [44]. However, there is no conclusive RCT evidencing long-term benefits of LC-PUFA supplementation during early life on neurodevelopment in healthy term infants [50–52], reflecting differences in terms of timing of supplementation, doses, and combination with other micronutrients. In relation to folic acid, some epidemiological studies [53] and a previous EEG/ERP (Electroencephalography/Event-Related Potential) research from the NUHEAL project [54] have reported that prenatal folate supplementation improves neurodevelopmental performance (mainly in attention system) in offspring at school age. However, there is no clear or robust evidence to support the use of multivitamin-containing folic acid supplementation during pregnancy on mental performance later in life [55,56]. Interestingly, these contradictory results come from the evaluation of mental performance as a global measure or an inappropriate timeframe for targeted neuropsychological domains, which could mask specific effects of a nutritional intervention during “critical periods” of brain development on long-term neurodevelopment. We must keep in mind that our No-FO group comprehends not only the 5-MTHF subgroup, but also the placebo subgroup, and the results of this study are directed to enforce the protective role of maternal LC-PUFA supplementation on children’s brain development and function.

The main strengths of this study are in relation to its long term follow-up and monitoring, brain imaging to assess functional connectivity, and the use of an extensive neuropsychological batteries of tests to measure different brain domains. This novel approach has facilitated the study of associations between early nutrition, brain networks, and mental performance. The results provided in this manuscript provide more insight into the impact of FO supplementation during pregnancy on children’s neurodevelopment and brain functioning. A large number of validated techniques have been used to assess our hypothesis, and the data come from a well-established cohort.

The main limitation of this study is the relatively small sample size in combination with multiple outcomes. Due to a large number of participants being excluded from the study (32.9%), mainly due to excessive movement during the rsfMRI session, we were required to cluster our four initial groups into two. In this case, we were able to guarantee 80% of statistical power (minimum required $n = 20$ for each group) and to detect a medium-to-large effect size (0.7–0.9). Furthermore, to avoid false positives regarding our neuroimaging analysis, the TFCE (threshold-free cluster enhancement) is one of the most reliable approaches, which, in our case, involves 5000 permutations to control for the family-wise error rate. –We believe that large differences between study groups are considerably rare and unlikely. All subjects eligible for this study are within the normal range of cognitive capabilities with no previous neuropathology diagnosed.. Nevertheless, the results obtained here can be interpreted as preliminary data and cannot be considered generalizable.

Further research in this area is needed to optimize the recommendations regarding LC-PUFAs and folic acid supplements during pregnancy.

5. Conclusions

This study further elucidates how maternal FO supplementation during pregnancy may be able to shape the resting-state network functioning of children at school age and as a consequence to produce effects on children's cognitive processing; these results reinforce the idea of an early nutrition programming effect on brain functioning during childhood.

Author Contributions All authors helped in the interpretation of results and contributed to manuscript preparation. H.A. wrote the first draft. C.C. and B.K. designed the study and were coordinators of the study at University of Granada and Ludwig-Maximilians-Universität Munich, respectively. C.C. also wrote part of the manuscript and B.K. supervised it; C.M.-Z., F.J.T.-E. and D.C. performed the children examinations; M.P.-G. designed the NNB and reviewed the manuscript; H.A., J.V.-R., C.M.-P., A.C. and J.A.G.-S. performed the data analysis and interpretation.

Funding: This work was supported by the Commission of the European Community's 7th Framework Program (FP7/2008–2013), Grant agreement no. 212652 (NUTRIMENTHE Project); within the 6th Framework Program, Contract no. 007036 (EARNEST Project); and supported in part by the Commission of the European Community within the 5th Framework Program, Contract no. QLK1-CT-1999-00888 (NUHEAL EU Project). This publication is the work of the authors and does not necessarily reflect the views of the Commission of the European Community. The work of B.K. is supported by the European Research Council Advanced Grant ERC-2012-AdG-no.322605 META-GROWTH. JVR is supported by a grant from the Spanish Ministry of Science, Innovation and Universities (FJCI-2017-33396). The funders had no role in the design, analysis or writing of this article.

Acknowledgments: The results reported in this article are likely to be included in the Doctoral Thesis of H.A. at the University of Granada, PhD Program in Epidemiology and Public Health.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

5-MTHF	5-methyl-tetrahydrofolate
CCTT	Children's Colors Trail Test
CPTBL7	Continuous Performance Test Block7
CT	Cancellation Test
DHA	Docosahexanoic acid
DH	Dominant Hand
DMN	Default Mode Network
EPA	Eicosapentaenoic acid
FO	Fish Oil
FPN	Fronto-Parietal Network
HDT	Hungry Donkey Task
HVOT	Hooper Visual Organization Test

K-ABC-II	Matrix Analogies Test
LC-PUFAs	long-chain polyunsaturated fatty acids
NDH	Non Dominant Hand
NNB	NUTRIMENTHE Neuropsychological Battery
NUHEAL	NUtraceuticals for a HEALthier life
RAVLT	Rey Auditory Verbal Learning Test
ROT	Recall of Object Test
rsfMRI	Resting-state functional magnetic resonance imaging
RSN	Resting-State Network
SDMT	Symbol Digit Modalities Test
SMN	SensoriMotor Network

References

1. Cusick, S.E.; Georgieff, M.K. The role of nutrition in brain development: The Golden opportunity of the "first 1000 days." *J. Pediatr.* **2016**, *175*, 16–21.
2. Wachs, T.D.; Georgieff, M.; Cusick, S.; McEwen, B.S. Issues in the timing of integrated early interventions: Contributions from nutrition, neuroscience, and psychological research. *Ann. N. Y. Acad. Sci.* **2014**, *1308*, 89–106. –
3. Georgieff, M.K.; Ramel, S.E.; Cusick, S.E. Nutritional influences on brain development. *Acta Paediatr. Int. J. Paediatr.* **2018**, *107*, 1310–1321.
4. Elmadafa, I.; Meyer, A.L. Vitamins for the first 1000 days: Preparing for life. *Int. J. Vitam. Nutr. Res.* **2012**, *82*, 342–347.
5. Cheng, G.; Sha, T.; Gao, X.; Wu, X.; Tian, Q.; Yang, F.; Yan, Y. Effects of maternal prenatal multi-micronutrient supplementation on growth and development until 3 years of age. *Int. J. Environ. Res. Public Health* **2019**, *16*, 2744, doi:10.3390/ijerph16152744.
6. Almeida, D.M.; Jandacek, R.J.; Weber, W.A.; McNamara, R.K. Docosahexaenoic acid biostatus is associated with event-related functional connectivity in cortical attention networks of typically developing children. *Nutr. Neurosci.* **2016**, *20*, 246–254, doi:10.1179/1476830515y.0000000046..
7. McNamara, R.K.; Able, J.; Jandacek, R.; Rider, T.; Tso, P.; Eliassen, J.C.; Alfieri, D.; Weber, W.; Jarvis, K.; Delbello, M.P.; et al. Docosahexaenoic acid supplementation increases prefrontal cortex activation during sustained attention in healthy boys: A placebo-controlled, dose-ranging, functional magnetic resonance imaging study. *Am. J. Clin. Nutr.* **2010**, *91*, 1060–1067.
8. McNamara, R.K.; Jandacek, R.; Tso, P.; Weber, W.; Chu, W.J.; Strakowski, S.M.; Adler, C.M.; Delbello, M.P. Low docosahexaenoic acid status is associated with reduced indices in cortical integrity in the anterior cingulate of healthy male children: A 1 MRS study. *Nutr. Neurosci.* **2013**, *16*, 183–190.
9. McNamara, R.K.; Jandacek, R.; Tso, P.; Blom, T.J.; Welge, J.A.; Strawn, J.R.; Adler, C.M.; Strakowski, S.M.; Delbello, M.P. Adolescents with or at ultra-high risk for bipolar disorder exhibit erythrocyte docosahexaenoic acid and eicosapentaenoic acid deficits: A candidate prodromal risk biomarker. *Early Interv. Psychiatry* **2016**, *10*, 203–211.
10. Crider, K.S.; Devine, O.; Hao, L.; Dowling, N.F.; Li, S.; Molloy, A.M.; Li, Z.; Zhu, J.; Berry, R.J. Population red blood cell folate concentrations for prevention of neural tube defects: Bayesian model. *BMJ* **2014**, *349*, g4554, doi:10.1136/bmj.g4554.

11. Mattson, M.P.; Shea, T.B. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. *Trends Neurosci.* **2003**, *26*, 137–146.
12. Pérez-Dueñas, B.; Ormazábal, A.; Toma, C.; Torrico, B.; Cormand, B.; Serrano, M.; Sierra, C.; Grandis, E.D.; Marfa, M.P.; García-Cazorla, A.; et al. Cerebral folate deficiency syndromes in childhood: Clinical, analytical, and etiologic aspects. *Arch. Neurol.* **2011**, *68*, 615–621.
13. Ramaekers, V.T.; Blau, N. Cerebral folate deficiency. *Dev. Med. Child Neurol.* **2004**, *46*, 843–851.
14. Raichle, M.E. The restless brain: How intrinsic activity organizes brain function. *Philos. Trans. R. Soc. B Biol. Sci.* **2015**, *370*, 20140172, doi:10.1098/rstb.2014.0172.
15. Damoiseaux, J.S.; Rombouts, S.A.R.B.; Barkhof, F.; Scheltens, P.; Stam, C.J.; Smith, S.M.; Beckmann, C.F. Consistent resting-state networks across healthy subjects. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 13848–13853.
16. Talukdar, T.; Zamroziewicz, M.K.; Zwilling, C.E.; Barbey, A.K. Nutrient biomarkers shape individual differences in functional brain connectivity: Evidence from omega-3 PUFAs. *Hum. Brain Mapp.* **2019**, *40*, 1887–1897.
17. Martínez-Zaldívar, C.; Azaryah, H.; García-Santos, J.A.; Demmelmaier, H.; Altmäe, S.; Reischl, E.; Rzehak, P.; Koletzko, B.; Campoy, C. Early nutrition in combination with polymorphisms in fatty acid desaturase gene cluster modulate fatty acid composition of cheek cells' glycerophospholipids in school-age children. *Br. J. Nutr.* **2019**, *122*, S68–S79.
18. Krauss-Etschmann, S.; Shadid, R.; Campoy, C.; Hoster, E.; Demmelmaier, H.; Jiménez, M.; Gil, A.; Rivero, M.; Veszprémi, B.; Decsi, T.; et al. Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: A European randomized multicenter trial. *Am. J. Clin. Nutr.* **2007**, *85*, 1392–1400.
19. Pérez-García, M.; Luna, J.D.D.; Torres-Espínola, F.J.; Martínez-Zaldívar, C.; Anjos, T.; Steenweg-De Graaff, J.; Weber, M.; Grote, V.; Gruszfeld, D.; Verduci, E.; et al. Cultural effects on neurodevelopmental testing in children from six European countries: An analysis of nutrimenthe global database. *Br. J. Nutr.* **2019**, *122*, S59–S67.
20. World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects. *JAMA J. Am. Med. Assoc.* **2013**, *310*, 2191–2194.
21. Poldrack, R.A.; Baker, C.I.; Durnez, J.; Gorgolewski, K.J.; Matthews, P.M.; Munafò, M.R.; Nichols, T.E.; Poline, J.B.; Vul, E.; Yarkoni, T. Scanning the horizon: Towards transparent and reproducible neuroimaging research. *Nat. Rev. Neurosci.* **2017**, *18*, 115–126.
22. Beckmann, C.F.; Smith, S.M. Probabilistic Independent Component analysis for functional magnetic resonance imaging. *IEEE Trans. Med. Imaging* **2004**, *23*, 137–152.
23. Beckmann, C.F.; Deluca, M.; Devlin, J.T.; Smith, S.M. Decomposing fMRI data using ICA. *Magn. Reson. Imaging* **2005**, *1*, 1–16.
24. Luca, M.D.; Beckmann, C.F.; Stefano, N.D.; Matthews, P.M.; Smith, S.M. fMRI resting state networks define distinct modes of long-distance interactions in the human brain. *Neuroimage* **2006**, *29*, 1359–1367.
25. Martino, F.D.; Gentile, F.; Esposito, F.; Balsi, M.; Salle, F.D.; Goebel, R.; Formisano, E. Classification of fMRI independent components using IC-fingerprints and support vector machine classifiers. *Neuroimage* **2007**, *34*, 177–194.
26. Jenkinson, M.; Beckmann, C.F.; Behrens, T.E.J.; Woolrich, M.W.; Smith, S.M. Review FSL. *Neuroimage* **2012**, *62*, 782–790.

27. Escribano, J.; Luque, V.; Canals-Sans, J.; Ferré, N.; Koletzko, B.; Grote, V.; Weber, M.; Grusfeld, D.; Szott, K.; Verduci, E.; et al. Mental performance in 8-year-old children fed reduced protein content formula during the 1st year of life: Safety analysis of a randomised clinical trial. *Br. J. Nutr.* **2019**, *122*, S22–S30.
28. Gispert-Llaurado, M.; Perez-Garcia, M.; Escribano, J.; Closa-Monasterolo, R.; Luque, V.; Grote, V.; Weber, M.; Torres-Espínola, F.J.; Czech-Kowalska, J.; Verduci, E.; et al. Fish consumption in mid-childhood and its relationship to neuropsychological outcomes measured in 7–9 year old children using a nutrimenthe neuropsychological battery. *Clin. Nutr.* **2016**, *35*, 1301–1307.
29. Anjos, T.; Altmäe, S.; Emmett, P.; Tiemeier, H.; Closa-Monasterolo, R.; Luque, V.; Wiseman, S.; Pérez-García, M.; Lattka, E.; Demmelmair, H.; et al. Nutrition and neurodevelopment in children: Focus on nutrimenthe project. *Eur. J. Nutr.* **2013**, *52*, 1825–1842.
30. Filippini, N.; MacIntosh, B.J.; Hough, M.G.; Goodwin, G.M.; Frisoni, G.B.; Smith, S.M.; Matthews, P.M.; Beckmann, C.F.; Mackay, C.E. Distinct patterns of brain activity in young carriers of the APOE-ε4 allele. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 7209–7214.
31. Nichols, T.E.; Holmes, A.P. Nonparametric permutation tests for functional neuroimaging: A primer with examples. *Hum. Brain Mapp.* **2002**, *15*, 1–25.
32. Santarecchi, E.; Galli, G.; Polizzotto, N.R.; Rossi, A.; Rossi, S. Efficiency of weak brain connections support general cognitive functioning. *Hum. Brain Mapp.* **2014**, *35*, 4566–4582.
33. Li, L.; Abutalebi, J.; Zou, L.; Yan, X.; Liu, L.; Feng, X.; Wang, R.; Guo, T.; Ding, G. Bilingualism alters brain functional connectivity between “control” regions and “language” regions: Evidence from bimodal bilinguals. *Neuropsychologia* **2015**, *71*, 236–247.
34. Sun, X.; Li, L.; Ding, G.; Wang, R.; Li, P. Effects of language proficiency on cognitive control: Evidence from resting-state functional connectivity. *Neuropsychologia* **2019**, *129*, 263–275.
35. Pasquale, F.d.; Penna, S.D.; Snyder, A.Z.; Marzetti, L.; Pizzella, V.; Romani, G.L.; Corbetta, M. A cortical core for dynamic integration of functional networks in the resting human brain. *Neuron* **2012**, *74*, 753–764.
36. Gottlieb, J. From thought to action: The parietal cortex as a bridge between perception, action, and cognition. *Neuron* **2007**, *53*, 9–16, doi:10.1016/j.neuron.2006.12.009.
37. Chand, G.B.; Wu, J.; Hajjar, I.; Qiu, D. Interactions of the salience network and its subsystems with the default-mode and the central-executive networks in normal aging and mild cognitive impairment. *Brain Connect.* **2017**, *7*, 401–412.
38. Chenji, S.; Jha, S.; Lee, D.; Brown, M.; Seres, P.; Mah, D.; Kalra, S. Investigating default mode and sensorimotor network connectivity in amyotrophic lateral sclerosis. *PLoS ONE* **2016**, *11*, e0157443, doi:10.1371/journal.pone.0157443.
39. Smith, S.M.; Fox, P.T.; Miller, K.L.; Glahn, D.C.; Fox, P.M.; Mackay, C.E.; Filippini, N.; Watkins, K.E.; Toro, R.; Laird, A.R.; et al. Correspondence of the brain’s functional architecture during activation and rest. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 13040–13045.
40. Milnik, A.; Nowak, I.; Müller, N.G. Attention-dependent modulation of neural activity in primary sensorimotor cortex. *Brain Behav.* **2013**, *3*, 54–66.
41. Afif, A.; Trouillas, J.; Mertens, P. Development of the sensorimotor cortex in the human fetus: A morphological description. *Surg. Radiol. Anat.* **2015**, *37*, 153–160.
42. Mulder, K.A.; Elango, R.; Innis, S.M. Fetal DHA inadequacy and the impact on child neurodevelopment: A follow-up of a randomised trial of maternal DHA supplementation in pregnancy. *Br. J. Nutr.* **2018**, *119*, 271–279.

43. Rosales, F.J.; Reznick, J.S.; Zeisel, S.H. Understanding the role of nutrition in the brain and behavioral development of toddlers and preschool children: Identifying and addressing methodological barriers. *Nutr. Neurosci.* **2009**, *12*, 190–202.
44. Jensen, C.L.; Voigt, R.G.; Llorente, A.M.; Peters, S.U.; Prager, T.C.; Zou, Y.L.; Rozelle, J.C.; Turcich, M.R.; Fraley, J.K.; Anderson, R.E.; et al. Effects of early maternal docosahexaenoic acid intake on neuropsychological status and visual acuity at five years of age of breast-fed term infants. *J. Pediatr.* **2010**, *157*, 900–905.
45. Helland, I.B.; Smith, L.; Saarem, K.; Saugstad, O.D.; Drevon, C.A. Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children's IQ at 4 years of age. *Pediatrics* **2003**, *111*, e39–e44, doi:10.1542/peds.111.1.e39.
46. Lauritzen, L.; Jorgensen, M.H.; Olsen, S.F.; Straarup, E.M.; Michaelsen, K.F. Maternal fish oil supplementation in lactation: Effect on developmental outcome in breast-fed infants. *Reprod. Nutr. Dev.* **2005**, *45*, 535–547.
47. Cheatham, C.L.; Nerhammer, A.S.; Asserhøj, M.; Michaelsen, K.F.; Lauritzen, L. Fish oil supplementation during lactation: Effects on cognition and behavior at 7 years of age. *Lipids* **2011**, *46*, 637–645.
48. Ostadrahimi, A.; Mohammad-Alizadeh, S.; Mirghafourvand, M.; Farshbaf-Khalili, S.; Jafarilar-Agdam, N.; Farshbaf-Khalili, A. The effect of fish oil supplementation on maternal and neonatal outcomes: A triple-blind, randomized controlled trial. *J. Perinat. Med.* **2017**, *45*, 1069–1077.
49. Dunstan, J.A.; Simmer, K.; Dixon, G.; Prescott, S.L. Cognitive assessment of children at age 2 1/2 years after maternal fish oil supplementation in pregnancy: A randomised controlled trial. *Arch. Dis. Child. Fetal Neonatal Ed.* **2008**, *93*, 45–50.
50. Makrides, M.; Gibson, R.A.; McPhee, A.J.; Yell, L.; Quinlivan, J.; Ryan, P. Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: A randomized controlled trial. *Obstet. Gynecol. Surv.* **2011**, *66*, 79–81.
51. Brei, C.; Stecher, L.; Brunner, S.; Ensenauer, R.; Heinen, F.; Wagner, P.D.; Hermsdörfer, J.; Hauner, H. Impact of the n-6: N-3 long-chain PUFA ratio during pregnancy and lactation on offspring neurodevelopment: 5-year follow-up of a randomized controlled trial. *Eur. J. Clin. Nutr.* **2017**, *71*, 1114–1120.
52. Meldrum, S.; Dunstan, J.A.; Foster, J.K.; Simmer, K.; Prescott, S.L. Maternal fish oil supplementation in pregnancy: A 12 year follow-up of a randomised controlled trial. *Nutrients* **2015**, *7*, 2061–2067.
53. Ars, C.L.; Nijs, I.M.; Marroun, H.E.; Muetzel, R.; Schmidt, M.; Graaff, J.S.-D.; Lugt, A.V.D.; Jaddoe, V.W.; Hofman, A.; Steegers, E.A.; et al. Prenatal folate, homocysteine and Vitamin B12 levels and child brain volumes, cognitive development and psychological functioning: The Generation R Study. *Br. J. Nutr.* **2019**, *122*, S1–S9.
54. Catena, A.; Angela Muñoz-Machicao, J.; Torres-Espínola, F.J.; Martínez-Zaldívar, C.; Diaz-Piedra, C.; Gil, A.; Haile, G.; Gyorei, E.; Molloy, A.M.; Decsi, T.; et al. Folate and long-chain polyunsaturated fatty acid supplementation during pregnancy has long-term effects on the attention system of 8.5-y-old offspring: A randomized controlled trial. *Am. J. Clin. Nutr.* **2016**, *103*, 115–127.
55. Dobó, M.; Czeizel, A.E. Long-term somatic and mental development of children after periconceptional multivitamin supplementation. *Eur. J. Pediatr.* **1998**, *157*, 719–723.

56. Tamura, T.; Goldenberg, R.L.; Chapman, V.R.; Johnston, K.E.; Ramey, S.L.; Nelson, K.G. Folate status of mothers during pregnancy and mental and psychomotor development of their children at five years of age. *Pediatrics* **2005**, *116*, 703–708.

DISCUSIÓN

DISCUSIÓN

Las técnicas de minería de datos han resultado de vital importancia a la hora de extraer conocimiento útil de la base de datos global de NUTRIMENTHE, teniendo en cuenta las complejidades intrínsecas asociadas, como es el caso de la imperfección de datos y el gran número de variables con las que se cuenta. En el caso de los **estudios 1 y 2**, gracias a las reglas de asociación, se ha conseguido extraer de una manera simple y sin apenas esfuerzo, la relación vigente entre el tabaquismo materno durante el embarazo, y los problemas conductuales externalizantes en sus hijos en edad escolar. Así mismo, se ha comprobado la asociación entre el índice AA/DHA en la madre en el momento del parto y la velocidad de procesamiento en los niños. Utilizando sólo técnicas de estadística clásica dicha tarea habría sido ardua, tediosa y difícil de demostrar teniendo en cuenta la hipótesis inicial del estudio (suplementación y con FO y/o 5-MTHF y neurodesarrollo).

Considerando los resultados obtenidos en el **estudio 3**, la técnica de minería de datos ICA (Análisis de Componentes Independientes), ha permitido descubrir las diferencias de conectividad cerebral entre los grupos de estudio mediante análisis complejos de neuroimágenes, mientras que las técnicas de

aprendizaje supervisado (randomForest) y selección de características (caret) ha facilitado demostrar la asociación entre la conectividad funcional cerebral y la expresión clínica del neurodesarrollo en los niños, tras el descarte de un gran número variables potenciales que realmente proporcionaban poca o nula información.

A continuación se justifican por separado los resultados obtenidos en cada uno de los estudios.

ESTUDIO 1 : “Maternal smoking during pregnancy and child behavior problems: A multicenter study from the NUTRIMENTHE EU Project.”

Este estudio observacional realizado en niños de entre 7 y 8 años, procedentes de 3 cohortes diferentes y de 6 países europeos, se ha llevado a cabo con el objetivo de investigar una posible asociación entre el tabaquismo materno durante la gestación, y el perfil conductual de los hijos en edad escolar evaluados mediante el CBCL. Se obtuvieron datos de las parejas de madre-hijo participantes en el proyecto Europeo NUTRIMENTHE. En general, los resultados muestran que los niños nacidos de madres fumadoras tienen un mayor riesgo de **externalizar problemas de comportamiento** respecto a los niños

nacidos de madres no fumadoras, incluso después de ajustar por variables de confusión (*cohorte y país de origen, nivel educativo materno y paterno y lactancia materna al menos durante tres meses*). Los problemas de internalización / externalización en la niñez parecen predecir los resultados negativos posteriores de salud conductual, emocional, cognitiva y física de adolescentes y adultos [121].

Los problemas de internalización se refieren a conductas negativas enfocadas hacia el interior, como ansiedad, depresión y síntomas somáticos, mientras que los problemas de externalización se refieren a conductas negativas enfocadas hacia el exterior, como hiperactividad, agresión, conducta disruptiva y uso de sustancias psicotrópicas [122,123].

También vale la pena mencionar que la educación de los padres y la lactancia materna parecen modular los efectos del tabaquismo materno en los problemas de pensamiento y atención, respectivamente. Está bien establecido el papel protector de la lactancia materna frente a los problemas de internalización y externalización del comportamiento y a una alteración del desarrollo cognitivo en la infancia [124].

Los resultados obtenidos concuerdan con otros estudios publicados previamente [125–127], donde se han comprobado problemas de comportamiento en niños expuestos al tabaquismo materno durante la gestación. Se han encontrado trastornos de conducta y del comportamiento asociados con frecuencia a la exposición prenatal al tabaco, en niños de tan solo 18-24 meses y en niños mayores (6-16 años) [128]. Sin embargo, otros investigadores no han encontrado una asociación causal entre el tabaquismo materno durante el embarazo y el TDAH, utilizando estudios de gemelos, cohortes de fertilización in vitro o enfoques de epidemiología genética [129,130], que apoyan la idea de que la asociación entre el tabaquismo materno durante el embarazo y el TDAH de la descendencia no se debe a efectos prenatales causales, sino que refleja una confusión no medida [21]. Otros autores sugieren que el efecto del tabaquismo sobre el comportamiento es pequeño y menos importante que el encontrado en estudios previos, y la influencia puede deberse a factores familiares estables en el tiempo, tales como factores ambientales y genéticos [40]. Por otro lado, otros investigadores han encontrado cambios en las cortezas frontal y parietal superiores

y volúmenes cerebrales globales más pequeños en niños de 6 a 8 años que estuvieron expuestos prenatalmente al tabaco, incluso después de ajustar por factores confusores socioeconómicos [131].

No obstante, existe un amplio consenso acerca de los efectos perniciosos del humo del tabaco durante el embarazo, que se produce en el contexto de un conjunto de circunstancias socioeconómicas que colocan al niño en un mayor riesgo de desarrollo, pero que pueden no estar relacionadas causalmente con el comportamiento del niño [126].

La asociación del tabaquismo materno con los problemas de comportamiento de los niños podría verse fuertemente afectada por las características sociodemográficas. Se ha visto anteriormente que las madres fumadoras durante el embarazo tienen, en promedio, un nivel de ingresos más bajo y menos educación [132]. En el presente estudio, las madres del grupo de fumadoras también presentan niveles educativos entre medio y bajo, mientras que las madres no fumadoras tienen un nivel educativo superior. Además, el país de origen se ha sugerido previamente como un factor confusor importante en los estudios que miden el rendimiento neuropsicológico [29], teniendo

siempre en cuenta la fuerte relación que prevalece con los resultados conductuales.

Una de las limitaciones del presente estudio es la carencia de datos disponibles sobre el tabaquismo paterno. El tabaquismo materno se basó únicamente en cuestionarios, no se disponía de datos sobre la duración del tabaquismo de las madres ni sobre el número de cigarrillos fumados al día. Esto puede implicar un riesgo de *bias* y excluye la posibilidad de evaluar una posible relación dosis-respuesta. Por otro lado, el período de tabaquismo abarca un período prolongado (antes, durante y después del embarazo), lo que determina que las conclusiones se refieran a los probables efectos del tabaco tanto durante el periodo prenatal como tras el parto. Algunos investigadores han señalado que los niños expuestos prenatalmente al tabaco eran más propensos a exhibir comportamientos anormales en comparación con los niños expuestos solo durante el período posnatal [133], enfatizando así que la gestación es un período crítico en el desarrollo de trastornos conductuales. Otra limitación del presente estudio es la carencia de datos sobre posibles problemas psicológicos maternos, que pudieran afectar la percepción materna de sus

hijos, ni la influencia del entorno social familiar. En ese sentido, la depresión y los problemas psicopatológicos fueron más comunes en las madres que fumaron durante el embarazo que en las madres no fumadoras [134].

Los resultados obtenidos en el presente estudio demuestran la necesidad de incrementar los esfuerzos de control del tabaco y reducir las tasas de tabaquismo en mujeres jóvenes y en edad de procrear, en embarazadas y en los hogares con niños pequeños. La comprensión de este fenómeno tiene el potencial de facilitar el reconocimiento, la prevención y la mitigación de los problemas de conducta infantil relacionados con los factores de riesgo en la vida precoz, así como las consecuencias negativas para la salud a largo plazo.

ESTUDIO 2: “Long-chain polyunsaturated fatty acids, homocysteine at birth and fatty acid desaturase gene cluster polymorphisms are associated with children’s processing speed up to age 9 years.”

Este estudio se realizó para analizar los efectos a largo plazo de la suplementación prenatal con FO y/o 5-MTHF, así como el impacto de los polimorfismos genéticos maternos de las

FADS y MTHFR, sobre la velocidad de procesamiento en niños sanos en edad escolar. Nuestros resultados sugieren que ni la suplementación prenatal con FO ni con 5-MTFH predijeron puntuaciones altas de velocidad de procesamiento en niños en edad escolar. Sin embargo, los análisis exploratorios secundarios indican que la proporción de AA/DHA maternos y la heterocigosis de FADS1 en el SNP rs174556 se asocian positivamente con el desarrollo de la velocidad de procesamiento de los niños hasta los 9 años. Sin embargo, las concentraciones de tHcy en el plasma materno en el momento del parto mostraron un efecto negativo sobre la velocidad de procesamiento del niño en edad escolar.

La suplementación prenatal con ácido fólico se ha relacionado con un mejor desarrollo neurológico en la descendencia, en términos de reducción del riesgo de problemas de comportamiento [135], retraso del lenguaje [136], falta de atención [36], hiperactividad y problemas con los compañeros [137]. Sin embargo, los efectos del ácido fólico potenciales sobre el rendimiento cognitivo y mental durante el desarrollo son inconsistentes, en parte debido al número muy

limitado de estudios publicados [138]. El ácido fólico actúa como donante de grupos metilo en la conversión metabólica de homocisteína (Hcy) a metionina [138]. Como consecuencia, el déficit de folatos, sólo o en combinación con otras vitaminas B, atenúa esta vía metabólica, aumentando posteriormente los niveles totales de Hcy. Existe evidencia científica de que una tHcy materna más alta ($\geq 8,3 \mu\text{mol/L}$) puede no sólo influir negativamente en el desarrollo placentario, el peso al nacimiento y los resultados del embarazo [139], sino que también se relaciona con el deterioro de las células endoteliales dependientes del estrés oxidativo, citotóxico y de la apoptosis del trofoblasto placentario [140,141]. Curiosamente, nuestros resultados sugieren un papel predictor negativo de la tHcy materna en la función cognitiva del niño. De hecho, los niños nacidos de madres con altos niveles de tHcy durante el embarazo muestran una disminución en los aciertos en el SDMT y SCWT, así como una menor probabilidad de estar en los percentiles superiores de WRST y CNST. Debido a que las concentraciones de tHcy se consideran un indicador funcional del estado de folatos, se recomienda el uso de suplementos que contienen ácido fólico durante el primer trimestre de la

gestación para evitar malformaciones congénitas durante el desarrollo fetal [142], y mantener un adecuado estado nutricional de esta vitamina durante todo el embarazo para la optimizar el desarrollo neurológico.

Por otro lado, también está claro que las concentraciones de LC-PUFAs fetales, incluidos los niveles de DHA y AA, están fuertemente relacionados con el estado materno de los LC-PUFAs durante el embarazo, desempeñando un papel importante en el desarrollo cerebral [143] [144]. En este sentido, el DHA está relacionado con la sinaptogénesis, la expresión del factor de crecimiento nervioso y la diferenciación neuronal [145]. Además, el AA está involucrado en varias vías de señalización sináptica [146], síntesis de eicosanoides, prostaglandinas y leucotrienos, y expresión génica temprana relacionada con el desarrollo antropométrico y crecimiento celular [147]. Sin embargo, no existe evidencia consistente de los efectos beneficiosos a largo plazo de la suplementación con CL-PUFAs n-3 o n-6 durante el embarazo o la lactancia en el desarrollo neurológico de los niños [3,55,148]. Como consecuencia, existe un interés creciente por analizar los efectos a largo plazo de la relación AA/DHA sobre el desarrollo

neurológico infantil, que refleja tanto su síntesis endógena como su suministro exógeno [144]. Además, debido a que ambos ácidos grasos compiten por las mismas vías enzimáticas, la proporción AA/DHA está fuertemente influida por la prevalencia de polimorfismos genéticos de las FADS y de elongasas (ELOV1, ELOV2, ELOV3) [145]. Recientemente, una proporción más alta del índice DHA/AA y concentraciones más altas de DHA en la sangre del cordón umbilical se han asociado a un mejor desarrollo visual, cognitivo y motor del bebé en los inuit árticos expuestos a ingestas elevadas de mariscos y LC-PUFAs n-3 [149]. De acuerdo con estos hallazgos, no encontramos asociaciones claras entre el tipo de suplementación prenatal y el desarrollo de la velocidad de procesamiento, excepto por los efectos beneficiosos de la suplementación con FO sobre el tiempo transcurrido de CCTT-1 a los 9 años. Sin embargo, un índice AA/DHA materno más elevado parece ser un modulador positivo a largo plazo de la velocidad de procesamiento (principalmente en SDMT, CCTT-1) en la descendencia, lo que indica la importancia no solo del DHA, sino también de su equilibrio con el AA. Curiosamente, a los 9 años, los niños cuyas madres eran heterocigotas para FADS1 rs174556 realizaron mejor

las tareas de velocidad de procesamiento con respecto a los nacidos de madres con alelos mayores homocigotos. Nuestros hallazgos también son consistentes con el papel de los LC-PUFAs en la mielinización y la integridad de la materia blanca mostrado en estudios con animales [150–152]. En este sentido, el DHA puede aumentar la velocidad de procesamiento al cambiar las propiedades físico-químicas y estructurales de la membrana [153]. Además, Peters et al. [154] no solo demostró que las concentraciones de PUFAs en la membrana de los eritrocitos en adultos jóvenes parecen estar fuertemente relacionadas con la integridad de la sustancia blanca, sino que también mostró que estas asociaciones estaban relacionadas principalmente con los niveles de AA. Así pues, como la conexión entre la integridad de la materia blanca y la velocidad de procesamiento en las tareas cognitivas se establece de manera consistente, nuestros resultados muestran efectos positivos y fuertes a largo plazo de los LC-PUFAs perinatales, (adecuado índice AA/DHA) y los polimorfismos FADS1, sobre el desarrollo cognitivo, lo que sugiere un aumento del volumen de materia blanca y una mejor integridad.

La mayor fortaleza del presente estudio es el seguimiento a largo plazo, desde el embarazo hasta los 9 años, lo que nos permite obtener una mejor evaluación de los efectos a largo plazo de la suplementación prenatal con FO, 5-MTHF o FO+5-MTHF en las capacidades cognitivas del niño. Además, el estudio NUHEAL se realizó en tres países diferentes (España, Alemania y Hungría) con hábitos alimentarios distintos; debido a que el país de origen se ha eliminado como factor de confusión, nuestros datos refuerzan la idea de que los efectos a largo plazo observados en la velocidad de procesamiento son independientes de la dieta de la mujer. En este sentido, destacamos la influencia del nivel cultural de las madres en la velocidad de procesamiento de sus hijos, lo que aumenta la necesidad de tener en cuenta los diferentes factores socioambientales durante la vida temprana que pueden influir en la velocidad de procesamiento posterior. Finalmente, las pruebas neuropsicológicas utilizadas para evaluar la velocidad de procesamiento fueron administradas por diferentes técnicos en cada país, aunque todos recibieron una formación común para reducir la influencia de los examinadores y las diferencias culturales en los resultados.

Los resultados obtenidos tienen algunas limitaciones. Primero, el número de niños que pertenecen a cada grupo de estudio fue homogéneo pero relativamente bajo. Sin embargo, después de combinar los datos de los niños nacidos de madres que recibieron suplementos durante el embarazo ($n = 103$), los efectos de las combinaciones de suplementos fueron significativos con respecto a los niños cuyas madres recibieron placebo. En segundo lugar, los efectos de la suplementación con FO, 5-MTHF o FO+5-MTHF no se evaluaron en diferentes puntos temporales de administración. Además, nuestro estudio se ha realizado solo en un rango de edad seleccionado (7,5 a 9 años). Por lo tanto, serán necesarios estudios futuros para evaluar si nuestros hallazgos se pueden extender a otros momentos de administración o en diferentes edades durante el desarrollo. Finalmente, la conversión de homocisteína en metionina se basa en gran medida en los niveles de ácido fólico y vitamina B12, que actúan como sustrato y cofactor, respectivamente.

Los resultados obtenidos en este estudio deben interpretarse con precaución. Los participantes del estudio

siguieron sus patrones de alimentación habituales, incluidos los alimentos ricos en PUFAs. Por tanto, es de suma importancia determinar el momento, la duración necesaria y la dosificación de la suplementación de DHA + EPA (en equilibrio con AA) durante el embarazo, y la suplementación de las embarazadas con ácido fólico, para obtener el mejor desarrollo cognitivo de la descendencia. Curiosamente, la suplementación mixta que incluye FO y 5-MTHF no tuvo ningún efecto sobre la velocidad de procesamiento hasta los 9 años, indicando un efecto de interacción de estos dos nutrientes. Por lo tanto, proponemos que la suplementación materna basada en ácido fólico, DHA y EPA debe individualizarse, teniendo en cuenta la dieta, los hábitos, el estado de folato y la variante genética materna FADS1 rs174556 G/A, y tal vez se deban recomendar en distintos momentos de la gestación.

ESTUDIO 3: “Effects of Maternal Fish Oil and/or 5-Methyl-Tetrahydrofolate Supplementation during Pregnancy on Offspring Brain Resting-State at 10 Years Old: A Follow-up Study from the NUHEAL Randomized Controlled Trial”

Este es el primer estudio que examina el efecto a largo plazo de la suplementación materna con FO y/o 5-MTHF en las RSN de los niños en edad escolar. Encontramos que la suplementación con FO, pero no con 5-MTHF, durante la segunda mitad del embarazo se asocia con una menor conectividad funcional de las redes cerebrales de los niños entre los 9,5 y los 10 años de edad. Específicamente, las redes DMN, SMN y FPN mostraron una conectividad funcional más débil en los niños nacidos de madres suplementadas con FO o FO+5-MTHF. Además, después de correlacionar las RSN con las pruebas de NNB, encontramos que en el grupo NO-FO, los niños tuvieron un rendimiento peor en cuanto a pruebas de atención y velocidad de procesamiento.

El hecho de tener una conectividad funcional débil no necesariamente indica un desarrollo neurológico cognitivo deficiente, de hecho, algunos estudios han demostrado, por ejemplo, que la variación en los niveles del cociente intelectual dentro de una población heterogénea se explica principalmente por la eficiencia de la comunicación distribuida de las redes cerebrales usando conexiones moderadamente débiles de larga distancia, con solo una contribución menor de

conexiones más fuertes [155]. En este estudio, los niños expuestos a FO prenatal no mostraron ninguna desventaja funcional pero tendieron a tener mejor memoria. Otro ejemplo de conectividad funcional débil está en los sujetos bilingües en comparación con los monolingües [156,157], donde la fuerza de la conectividad funcional se correlacionó inversamente con el rendimiento conductual.

Teniendo en cuenta las principales diferencias del área del cerebro encontradas en el presente estudio, el *angular gyrus* es una región intermodal que podría actuar como un "centro conector" para el procesamiento global de la información [158], pero también como un área de intercambio entre el DMN y el FPN [159]. Estas funciones son competitivas pero complementarias [160] y podrían enmascarar una relación intrínseca entre la conectividad funcional y el neurodesarrollo. De hecho, los niños nacidos de madres no suplementadas con FO mostraron que la actividad del *angular gyrus* dentro del FPN se relacionó negativamente con el rendimiento en atención y velocidad de procesamiento, lo que sugiere una alteración conjunta relacionada con FO entre la red cerebral más relevante asociada a la cognición (FPN) y el desempeño en

importantes procesos de la inteligencia. Con respecto a varias alteraciones en la red sensoriomotora (SMN), tanto las áreas somatosensoriales (poscentral) como las motoras (*putamen* y *precentral gyrus*) están involucradas en un estado pre-mediado de disposición para realizar y/o coordinar una tarea motora [83], y sus alteraciones pueden conducir a una descoordinación de movimientos y dificultad de aprendizaje, tal y como lo proponen estudios previos en animales [83]. Sin embargo, la función de esta red cerebral no se limita a la ejecución motora. De hecho, también está presente en los procesos ejecutivos [161], y se sabe que su actividad está más relacionada con la atención a los estímulos externos en comparación con los procesos de atención internos [40]. Los hijos de madres no suplementadas con FO presentaron correlación negativa entre SMN y el desempeño en tareas neuropsicológicas relacionadas con la atención; estos resultados apoyan la asociación previamente estudiada entre los procesos de atención y de procesamiento de velocidad y la función SMN [162].

Se sabe que el motor, la coordinación visomotora [163] y la atención [164] comienzan a desarrollarse durante la gestación, especialmente en el segundo y tercer trimestre del

embarazo; por lo tanto, estos dominios pueden verse afectados por intervenciones nutricionales durante este período crítico de neurodesarrollo, teniendo en cuenta que los ácidos grasos poliinsaturados omega-3 son esenciales debido a su papel en la neurogénesis, la fluidez y la composición de ácidos grasos de la membrana [165]. Algunos estudios sugieren que las intervenciones dietéticas prenatales o posnatales basadas en LC-PUFAs podrían tener efectos a largo plazo en el desarrollo neurológico tardío del niño, principalmente en la atención sostenida, el lenguaje y la velocidad de procesamiento [56,75,166,167]. Sin embargo, no existe ningún estudio concluyente que demuestre los beneficios a largo plazo de la suplementación con LC-PUFAs durante las primeras etapas de la vida sobre el desarrollo neurológico en nutrientes en niños sanos.

En relación al ácido fólico, algunos estudios epidemiológicos [64] y una investigación previa de EEG/ERP del proyecto NUHEAL [66] han sugerido que la suplementación prenatal con folato mejora el rendimiento del neurodesarrollo (principalmente en el sistema de atención) en los niños en edad escolar. Sin embargo, al igual que pasaba con los LC-PUFAs, no existe evidencia clara o sólida que respalde el uso de

suplementos de ácido fólico durante el embarazo y un mejor neurodesarrollo en los niños [168,169]. Debemos tener en cuenta que el grupo No-FO comprende no solo el subgrupo 5-MTHF, sino también el subgrupo placebo, y los resultados de este estudio están dirigidos a reforzar el papel protector de la suplementación materna con LC-PUFAs en el desarrollo y función cerebral de los niños.

Las principales fortalezas de este estudio en el seguimiento a largo plazo, rs-fMRI para evaluar la conectividad funcional y el uso de la NNB para medir diferentes dominios cerebrales. Este nuevo enfoque ha facilitado el estudio de las asociaciones entre la nutrición prenatal, conectoma y el rendimiento cognitivo. Los resultados proporcionados en este manuscrito brindan más información sobre el impacto de la suplementación con LC-PUFAS durante el embarazo en el neurodesarrollo y el funcionamiento cerebral de los niños. Se ha utilizado una gran cantidad de técnicas validadas para evaluar nuestra hipótesis y los datos provienen de una cohorte bien establecida.

La principal limitación de este estudio es el tamaño de la muestra relativamente pequeño en combinación con múltiples resultados. Debido a que un gran número de participantes

fueron excluidos del estudio (32,9%), principalmente debido a un exceso de movimiento durante la sesión de rs-fMRI, se requirió agrupar nuestros cuatro grupos iniciales en dos. En este caso, pudimos garantizar el 80% de la potencia estadística (mínimo requerido n=20 para cada grupo) y para detectar un effect size de 0.7 a 0.9. Además, para evitar falsos positivos con respecto a al análisis de neuroimagen realizado, el TFCE es uno de los enfoques más fiables, que, en nuestro caso, implica 5000 permutaciones para controlar la tasa de error.

Los resultados obtenidos en el presente estudio pueden interpretarse como datos preliminares y no se deben generalizar.

CONCLUSIONES

CONCLUSIONES

1. Las técnicas de minería de datos resultan de vital importancia a la hora de descubrir conocimiento oculto en una base de datos de grandes dimensiones, teniendo en cuenta que la adquisición de datos ha conllevado un gran esfuerzo, así como la cantidad de recursos destinados a dicha labor.
2. Gracias al uso de reglas de asociación, se justifica el hecho de que el tabaquismo materno durante la gestación puede influir en el desarrollo conductual de los niños en edad escolar, incluso considerando otros factores confusores, como es el caso de país de origen, educación de los padres y lactancia materna. Por lo tanto, resulta de vital importancia fomentar la políticas anti-tabaco especialmente para concienciar a las mujeres en edad de concebir y embarazadas.
3. Los niños cuyas madres recibieron aceite de pescado (FO: 500 mg de DHA/día + 150 mg EPA/día) durante la gestación mostraron una mayor velocidad de

procesamiento en la resolución de las tareas del CCTT1. El índice AA/DHA materno al final de la gestación, y la heterocigosis de la variante genética rs174556 de la FADS1 ejercen un efecto beneficioso a largo plazo sobre la velocidad de procesamiento que muestran los niños a los 9 años de edad. El incremento de la Homocisteína total durante la gestación predice una menor velocidad de procesamiento cognitivo en los hijos a los 9 años de edad.

4. Gracias a la técnica de análisis de componentes independientes, la suplementación materna con aceite de pescado durante el embarazo parece tener efectos a largo plazo sobre la conectividad funcional cerebral de los niños en edad escolar, que se asocia a un mejor desarrollo del procesamiento cognitivo.
5. Se refuerza la hipótesis de la posibilidad de una programación nutricional precoz (*Early Nutrition Programming*) que determina efectos a muy largo plazo sobre el funcionamiento cerebral en los hijos.

BIBLIOGRAFÍA

BIBLIOGRAFÍA

1. Liu, Y.; Scirica, B.M.; Stultz, C.M.; Guttag, J. V. Beatquency domain and machine learning improve prediction of cardiovascular death after acute coronary syndrome. *Sci. Rep.* **2016**, *6*.
2. Marvdashti, T.; Duan, L.; Aasi, S.Z.; Tang, J.Y.; Ellerbee Bowden, A.K. Classification of basal cell carcinoma in human skin using machine learning and quantitative features captured by polarization sensitive optical coherence tomography. *Biomed. Opt. Express* **2016**, *7*, 3721.
3. Anjos, T.; Altmäe, S.; Emmett, P.; Tiemeier, H.; Closa-Monasterolo, R.; Luque, V.; Wiseman, S.; Pérez-García, M.; Lattka, E.; Demmelmair, H.; et al. Nutrition and neurodevelopment in children: Focus on NUTRIMENTHE project. *Eur. J. Nutr.* **2013**, *52*, 1825–1842.
4. Agarwal, S. Data mining: Data mining concepts and techniques. In Proceedings of the Proceedings - 2013 International Conference on Machine Intelligence Research and Advancement, ICMIRA 2013; 2014; pp. 203–207.
5. Buschgens, C.J.M.; Swinkels, S.H.N.; Van Aken, M.A.G.; Ormel, J.; Verhulst, F.C.; Buitelaar, J.K. Externalizing behaviors in preadolescents: Familial risk to externalizing behaviors, prenatal and perinatal risks, and their interactions. *Eur. Child Adolesc. Psychiatry* **2009**, *18*, 65–74.
6. Orlebeke, J.F.; Knol, D.L.; Verhulst, F.C. Child Behavior Problems Increased by Maternal Smoking During Pregnancy. *Arch. Environ. Health* **1999**, *54*, 15–19.
7. Sood, B.; Delaney-Black, V.; Covington, C.; Nordstrom-Klee, B.; Ager, J.; Templin, T.; Janisse, J.; Martier, S.; Sokol, R.J. Prenatal alcohol exposure and childhood behavior at age 6 to 7 years: I. dose-response effect. *Pediatrics* **2001**, *108*.

8. Goldschmidt, L.; Day, N.L.; Richardson, G.A. Effects of prenatal marijuana exposure on child behavior problems at age 10. *Neurotoxicol. Teratol.* **2000**, *22*, 325–336.
9. Kwok, M.K.; Leung, G.M.; Schooling, C.M. Breast feeding and early adolescent behaviour, self-esteem and depression: Hong Kong's "Children of 1997" birth cohort. *Arch. Dis. Child.* **2013**, *98*, 887–894.
10. Cardona, D.A.; Hernández Cobos, J.S. Desarrollo organizacional. *Saber, Cienc. y Lib.* **2010**, *5*, 83–94.
11. Ekblad, M.; Korkeila, J.; Lehtonen, L. Smoking during pregnancy affects foetal brain development. *Acta Paediatr. Int. J. Paediatr.* **2015**, *104*, 12–18.
12. Banderali, G.; Martelli, A.; Landi, M.; Moretti, F.; Betti, F.; Radaelli, G.; Lassandro, C.; Verduci, E. Short and long term health effects of parental tobacco smoking during pregnancy and lactation: A descriptive review. *J. Transl. Med.* **2015**, *13*.
13. Blencowe, H.; Cousens, S.; Oestergaard, M.Z.; Chou, D.; Moller, A.B.; Narwal, R.; Adler, A.; Vera Garcia, C.; Rohde, S.; Say, L.; et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: A systematic analysis and implications. *Lancet* **2012**, *379*, 2162–2172.
14. Flenady, V.; Koopmans, L.; Middleton, P.; Frøen, J.F.; Smith, G.C.; Gibbons, K.; Coory, M.; Gordon, A.; Ellwood, D.; McIntyre, H.D.; et al. Major risk factors for stillbirth in high-income countries: A systematic review and meta-analysis. *Lancet* **2011**, *377*, 1331–1340.
15. Leonardi-Bee, J.; Smyth, A.; Britton, J.; Coleman, T. Environmental tobacco smoke and fetal health: Systematic review and meta-analysis. *Arch. Dis. Child. Fetal Neonatal Ed.* **2008**, *93*.
16. Pineles, B.L.; Hsu, S.; Park, E.; Samet, J.M. Systematic review and meta-analyses of

- perinatal death and maternal exposure to tobacco smoke during pregnancy. *Am. J. Epidemiol.* 2016, **184**, 87–97.
17. Zhang, K.; Wang, X. Maternal smoking and increased risk of sudden infant death syndrome: A meta-analysis. *Leg. Med.* **2013**, *15*, 115–121.
18. Gupta, P.C.; Sreevidya, S. Smokeless tobacco use, birth weight, and gestational age: Population based, prospective cohort study of 1217 women in Mumbai, India. *Br. Med. J.* **2004**, *328*, 1538–1540.
19. Inamdar, A.S.; Croucher, R.E.; Chokhandre, M.K.; Mashyakhy, M.H.; Marinho, V.C.C. Maternal smokeless tobacco use in pregnancy and adverse health outcomes in newborns: A systematic review. *Nicotine Tob. Res.* 2015, **17**, 1058–1066.
20. Duby, J.C.; Langkamp, D.L. *Journal of Pediatrics*. 2015, pp. 224–225.
21. Gustavson, K.; Ystrom, E.; Stoltenberg, C.; Susser, E.; Suren, P.; Magnus, P.; Knudsen, G.P.; Smith, G.D.; Langley, K.; Rutter, M.; et al. Smoking in pregnancy and child ADHD. *Pediatrics* **2017**, *139*, e20162509.
22. Malanchini, M.; Smith-Woolley, E.; Ayorech, Z.; Rimfeld, K.; Krapohl, E.; Vuoksimaa, E.; Korhonen, T.; Bartels, M.; Van Beijsterveldt, T.C.E.M.; Rose, R.J.; et al. Aggressive behaviour in childhood and adolescence: The role of smoking during pregnancy, evidence from four twin cohorts in the EU-ACTION consortium. *Psychol. Med.* 2019, **49**, 646–654.
23. Grossi, E.; Migliore, L.; Muratori, F. Pregnancy risk factors related to autism: An Italian case-control study in mothers of children with autism spectrum disorders (ASD), their siblings and of typically developing children. *J. Dev. Orig. Health Dis.* **2018**, *9*, 442–449.
24. Mackay, D.F.; Anderson, J.J.; Pell, J.P.; Zammit, S.; Smith, D.J. Exposure to tobacco smoke in utero or during early childhood and risk of hypomania: Prospective birth

- cohort study. *Eur. Psychiatry* **2017**, *39*, 33–39.
25. Kristjansson, A.L.; Thomas, S.; Lilly, C.L.; Thorisdottir, I.E.; Allegranter, J.P.; Sigfusdottir, I.D. Maternal smoking during pregnancy and academic achievement of offspring over time: A registry data-based cohort study. *Prev. Med. (Baltim.)*. **2018**, *113*, 74–79.
26. Key, A.P.F.; Ferguson, M.; Molfese, D.L.; Peach, K.; Lehman, C.; Molfese, V.J. Smoking during pregnancy affects speech-processing ability in newborn infants. *Environ. Health Perspect.* **2007**, *115*, 623–629.
27. Motlagh, M.G.; Sukhodolsky, D.G.; Landeros-Weisenberger, A.; Katsovich, L.; Thompson, N.; Scahill, L.; King, R.A.; Peterson, B.S.; Schultz, R.T.; Leckman, J.F. Adverse effects of heavy prenatal maternal smoking on attentional control in children with ADHD. *J. Atten. Disord.* **2011**, *15*, 593–603.
28. Behl, M.; Rao, D.; Aagaard, K.; Davidson, T.L.; Levin, E.D.; Slotkin, T.A.; Srinivasan, S.; Wallinga, D.; White, M.F.; Walker, V.R.; et al. Evaluation of the association between maternal smoking, childhood obesity, and metabolic disorders: A national toxicology program workshop review. *Environ. Health Perspect.* **2013**, *121*, 170–180.
29. Pérez-García, M.; Luna, J.D.D.; Torres-Espínola, F.J.; Martínez-Zaldívar, C.; Anjos, T.; Steenweg-De Graaff, J.; Weber, M.; Grote, V.; Grusfeld, D.; Verduci, E.; et al. Cultural effects on neurodevelopmental testing in children from six European countries: An analysis of NUTRIMENTHE Global Database. *Br. J. Nutr.* **2019**, *122*, S59–S67.
30. Cusick, S.E.; Georgieff, M.K. The Role of Nutrition in Brain Development: The Golden Opportunity of the “First 1000 Days.” *J. Pediatr.* **2016**, *175*, 16–21.
31. Kolb, B.; Fantie, B.D. Development of the Child’s Brain and Behavior. In *Handbook of Clinical Child Neuropsychology*; 2009; pp. 19–46.
32. Kakooza-Mwesige, A.; Mohammed, A.H.; Kristensson, K.; Juliano, S.L.; Lutwama, J.J. Emerging viral infections in Sub-Saharan Africa and the developing nervous system: A

- mini review. *Front. Neurol.* 2018, 9.
33. Paus, T. A primer for brain imaging: A tool for evidence-based studies of nutrition? *Nutr. Rev.* **2010**, *68*.
34. Egan, B.; Gage, H.; Williams, P.; Brands, B.; Györei, E.; López-Robles, J.C.; Campoy, C.; Decsi, T.; Koletzko, B.; Raats, M. The effect of diet on the physical and mental development of children: Views of parents and teachers in four European countries. *Br. J. Nutr.* **2019**, *122*, S31–S39.
35. World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects. *JAMA - J. Am. Med. Assoc.* **2013**, *310*, 2191–2194.
36. Julvez, J.; Fortuny, J.; Mendez, M.; Torrent, M.; Ribas-Fitó, N.; Sunyer, J. Maternal use of folic acid supplements during pregnancy and four-year-old neurodevelopment in a population-based birth cohort. *Paediatr. Perinat. Epidemiol.* **2009**, *23*, 199–206.
37. Elmadafa, I.; Meyer, A.L. Vitamins for the first 1000 days: Preparing for life. *Int. J. Vitam. Nutr. Res.* **2012**, *82*, 342–347.
38. Cheng, G.; Sha, T.; Gao, X.; Wu, X.; Tian, Q.; Yang, F.; Yan, Y. Effects of maternal prenatal multi-micronutrient supplementation on growth and development until 3 years of age. *Int. J. Environ. Res. Public Health* **2019**, *16*.
39. Koletzko, B.; Demmelmair, H.; Schaeffer, L.; Illig, T.; Heinrich, J. Genetically determined variation in polyunsaturated fatty acid metabolism may result in different dietary requirements. In Proceedings of the Nestle Nutrition Workshop Series: Pediatric Program; 2008; Vol. 62, pp. 35–44.
40. Calder, P.C. Functional Roles of Fatty Acids and Their Effects on Human Health. *J. Parenter. Enter. Nutr.* **2015**, *39*, 18S-32S.
41. Lee, J.M.; Lee, H.; Kang, S.B.; Park, W.J. Fatty acid desaturases, polyunsaturated fatty acid regulation, and biotechnological advances. *Nutrients* **2016**, *8*.

42. Cetin, I.; Alvino, G.; Cardelluccio, M. Long chain fatty acids and dietary fats in fetal nutrition. In Proceedings of the Journal of Physiology; 2009; Vol. 587, pp. 3441–3451.
43. Calder, P.C. Polyunsaturated fatty acids, inflammation, and immunity. *Lipids* **2001**, *36*, 1007–1024.
44. Rotstein, N.P.; Aveldaño, M.I.; Politi, L.E. Essentiality of docosahexaenoic acid in retina photoreceptor cell development. In Proceedings of the Lipids; 1999; Vol. 34.
45. Malcolm, C.A.; McCulloch, D.L.; Montgomery, C.; Shepherd, A.; Weaver, L.T. Maternal docosahexaenoic acid supplementation during pregnancy and visual evoked potential development in term infants: A double blind, prospective, randomised trial. *Arch. Dis. Child. Fetal Neonatal Ed.* **2003**, *88*.
46. Koletzko, B.; Lien, E.; Agostoni, C.; Böhles, H.; Campoy, C.; Cetin, I.; Decsi, T.; Dudenhausen, J.W.; Dupont, C.; Forsyth, S.; et al. The roles of long-chain polyunsaturated fatty acids in pregnancy, lactation and infancy: Review of current knowledge and consensus recommendations. *J. Perinat. Med.* **2008**, *36*, 5–14.
47. Sprecher, H.; Luthria, D.L.; Mohammed, B.S.; Baykousheva, S.P. Reevaluation of the pathways for the biosynthesis of polyunsaturated fatty acids. *J. Lipid Res.* **1995**, *36*, 2471–2477.
48. Jump, D.B. Dietary polyunsaturated fatty acids and regulation of gene transcription. *Curr. Opin. Lipidol.* **2002**, *13*, 155–164.
49. Ailhaud, G.; Guesnet, P.; Cunnane, S.C. An emerging risk factor for obesity: Does disequilibrium of polyunsaturated fatty acid metabolism contribute to excessive adipose tissue development? *Br. J. Nutr.* **2008**, *100*, 461–470.
50. Korotkova, M.; Gabrielsson, B.; Lönn, M.; Hanson, L.Å.; Strandvik, B. Leptin levels in rat offspring are modified by the ratio of linoleic to α-linolenic acid in the maternal diet. *J. Lipid Res.* **2002**, *43*, 1743–1749.

51. Lombardo, Y.B.; Chicco, A.G. Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review. *J. Nutr. Biochem.* 2006, **17**, 1–13.
52. Isaacs, E.B.; Gadian, D.G.; Sabatini, S.; Chong, W.K.; Quinn, B.T.; Fischl, B.R.; Lucas, A. The effect of early human diet on caudate volumes and IQ. *Pediatr. Res.* **2008**, *63*, 308–314.
53. Hibbeln, J.R.; Davis, J.M.; Steer, C.; Emmett, P.; Rogers, I.; Williams, C.; Golding, J. Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood (ALSPAC study): an observational cohort study. *Lancet* **2007**, *369*, 578–585.
54. Ostadrahimi, A.; Mohammad-Alizadeh, S.; Mirghafourvand, M.; Farshbaf-Khalili, S.; Jafarilar-Agdam, N.; Farshbaf-Khalili, A. The effect of fish oil supplementation on maternal and neonatal outcomes: A triple-blind, randomized controlled trial. *J. Perinat. Med.* **2017**, *45*, 1069–1077.
55. Dunstan, J.A.; Simmer, K.; Dixon, G.; Prescott, S.L. Cognitive assessment of children at age 2 1/2 years after maternal fish oil supplementation in pregnancy: A randomised controlled trial. *Arch. Dis. Child. Fetal Neonatal Ed.* **2008**, *93*.
56. Jensen, C.L.; Voigt, R.G.; Llorente, A.M.; Peters, S.U.; Prager, T.C.; Zou, Y.L.; Rozelle, J.C.; Turcich, M.R.; Fraley, J.K.; Anderson, R.E.; et al. Effects of early maternal docosahexaenoic acid intake on neuropsychological status and visual acuity at five years of age of breast-fed term infants. *J. Pediatr.* **2010**, *157*, 900–905.
57. Makrides, M.; Gibson, R.A.; McPhee, A.J.; Yell, L.; Quinlivan, J.; Ryan, P. Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: A randomized controlled trial. *Obstet. Gynecol. Surv.* **2011**, *66*, 79–81.
58. Brei, C.; Stecher, L.; Brunner, S.; Ensenauer, R.; Heinen, F.; Wagner, P.D.;

- Hermsdörfer, J.; Hauner, H. Impact of the n-6: N-3 long-chain PUFA ratio during pregnancy and lactation on offspring neurodevelopment: 5-year follow-up of a randomized controlled trial. *Eur. J. Clin. Nutr.* **2017**, *71*, 1114–1120.
59. Meldrum, S.; Dunstan, J.A.; Foster, J.K.; Simmer, K.; Prescott, S.L. Maternal fish oil supplementation in pregnancy: A 12 year follow-up of a randomised controlled trial. *Nutrients* **2015**, *7*, 2061–2067.
60. Crider, K.S.; Devine, O.; Hao, L.; Dowling, N.F.; Li, S.; Molloy, A.M.; Li, Z.; Zhu, J.; Berry, R.J. Population red blood cell folate concentrations for prevention of neural tube defects: Bayesian model. *BMJ* **2014**, *349*.
61. Mattson, M.P.; Shea, T.B. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. *Trends Neurosci.* **2003**, *26*, 137–146.
62. Pérez-Dueñas, B.; Ormazábal, A.; Toma, C.; Torrico, B.; Cormand, B.; Serrano, M.; Sierra, C.; De Grandis, E.; Marfa, M.P.; García-Cazorla, A.; et al. Cerebral folate deficiency syndromes in childhood: Clinical, analytical, and etiologic aspects. *Arch. Neurol.* **2011**, *68*, 615–621.
63. Ramaekers, V.T.; Blau, N. Cerebral folate deficiency. *Dev. Med. Child Neurol.* **2004**, *46*, 843–851.
64. Ars, C.L.; Nijs, I.M.; Marroun, H.E.; Muetzel, R.; Schmidt, M.; Steenweg-De Graaff, J.; Van Der Lugt, A.; Jaddoe, V.W.; Hofman, A.; Steegers, E.A.; et al. Prenatal folate, homocysteine and Vitamin B12 levels and child brain volumes, cognitive development and psychological functioning: The Generation R Study. *Br. J. Nutr.* **2019**, *122*, S1–S9.
65. White, T.; Muetzel, R.L.; El Marroun, H.; Blanken, L.M.E.; Jansen, P.; Bolhuis, K.; Kocevska, D.; Mous, S.E.; Mulder, R.; Jaddoe, V.W.V.; et al. Paediatric population neuroimaging and the Generation R Study: the second wave. *Eur. J. Epidemiol.* **2018**,

- 33, 99–125.
66. Catena, A.; Angela Muñoz-Machicao, J.; Torres-Espínola, F.J.; Martínez-Zaldívar, C.; Diaz-Piedra, C.; Gil, A.; Haile, G.; Gyorei, E.; Molloy, A.M.; Decsi, T.; et al. Folate and long-chain polyunsaturated fatty acid supplementation during pregnancy has long-term effects on the attention system of 8.5-y-old offspring: A randomized controlled trial. *Am. J. Clin. Nutr.* **2016**, *103*, 115–127.
67. Morales, E.; Bustamante, M.; Gonzalez, J.R.; Guxens, M.; Torrent, M.; Mendez, M.; Garcia-Estebar, R.; Julvez, J.; Forns, J.; Vrijheid, M.; et al. Genetic variants of the FADS gene cluster and ELOVL gene family, colostrums LC-PUFA levels, breastfeeding, and child cognition. *PLoS One* **2011**, *6*.
68. Laanpere, M.; Altmäe, S.; Stavreus-Evers, A.; Nilsson, T.K.; Yngve, A.; Salumets, A. Folate-mediated one-carbon metabolism and its effect on female fertility and pregnancy viability. *Nutr. Rev.* **2010**, *68*, 99–113.
69. Altmäe, S.; Stavreus-Evers, A.; Ruiz, J.R.; Laanpere, M.; Syvänen, T.; Yngve, A.; Salumets, A.; Nilsson, T.K. Variations in folate pathway genes are associated with unexplained female infertility. *Fertil. Steril.* **2010**, *94*, 130–137.
70. Frosst, P.; Blom, H.J.; Milos, R.; Goyette, P.; Sheppard, C.A.; Matthews, R.G.; Boers, G.J.H.; Den Heijer, M.; Kluijtmans, L.A.J.; van den Heuve, L.P.; et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. *Nat. Genet.* **1995**, *10*, 111–113.
71. Harmon, D.L.; Woodside, J. V.; Yarnell, J.W.G.; McMaster, D.; Young, I.S.; McCrum, E.E.; Gey, K.F.; Whitehead, A.S.; Evans, A.E. The common “thermolabile” variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. *QJM - Mon. J. Assoc. Physicians* **1996**, *89*, 571–577.
72. Pilsner, J.R.; Hu, H.; Wright, R.O.; Kordas, K.; Ettinger, A.S.; Sánchez, B.N.;

- Cantonwine, D.; Lazarus, A.L.; Cantoral, A.; Schnaas, L.; et al. Maternal MTHFR genotype and haplotype predict deficits in early cognitive development in a lead-exposed birth cohort in Mexico City. *Am. J. Clin. Nutr.* **2010**, *92*, 226–234.
73. Schmidt, R.J.; Hansen, R.L.; Hartiala, J.; Allayee, H.; Schmidt, L.C.; Tancredi, D.J.; Tassone, F.; Hertz-Pannier, I. Prenatal vitamins, one-carbon metabolism gene variants, and risk for Autism. *Epidemiology* **2011**, *22*, 476–485.
74. Rabbitt, P.; Scott, M.; Lunn, M.; Thacker, N.; Lowe, C.; Pendleton, N.; Horan, M.; Jackson, A. White matter lesions account for all age-related declines in speed but not in intelligence. *Neuropsychology* **2007**, *21*, 363–370.
75. Cheatham, C.L.; Nerhammar, A.S.; Asserhøj, M.; Michaelsen, K.F.; Lauritzen, L. Fish oil supplementation during lactation: Effects on cognition and behavior at 7 years of age. *Lipids* **2011**, *46*, 637–645.
76. Salthouse, T.A. Aging and measures of processing speed. *Biol. Psychol.* **2000**, *54*, 35–54.
77. Kochunov, P.; Coyle, T.; Lancaster, J.; Robin, D.A.; Hardies, J.; Kochunov, V.; Bartzokis, G.; Stanley, J.; Royall, D.; Schlosser, A.E.; et al. Processing speed is correlated with cerebral health markers in the frontal lobes as quantified by neuroimaging. *Neuroimage* **2010**, *49*, 1190–1199.
78. Penke, L.; Maniega, S.M.; Murray, C.; Gow, A.J.; Valdés Hernández, M.C.; Clayden, J.D.; Starr, J.M.; Wardlaw, J.M.; Bastin, M.E.; Deary, I.J. A general factor of brain white matter integrity predicts information processing speed in healthy older people. *J. Neurosci.* **2010**, *30*, 7569–7574.
79. Biswal, B.B.; Van Kylen, J.; Hyde, J.S. Simultaneous assessment of flow and BOLD signals in resting-state functional connectivity maps. *NMR Biomed.* **1997**, *10*, 165–170.

80. Raichle, M.E. The Brain's Default Mode Network. *Annu. Rev. Neurosci.* **2015**, *38*, 433–447.
81. Greicius, M.D.; Supekar, K.; Menon, V.; Dougherty, R.F. Resting-state functional connectivity reflects structural connectivity in the default mode network. *Cereb. Cortex* **2009**, *19*, 72–78.
82. Buckner, R.L. The serendipitous discovery of the brain's default network. *Neuroimage* **2012**, *62*, 1137–1145.
83. Chenji, S.; Jha, S.; Lee, D.; Brown, M.; Seres, P.; Mah, D.; Kalra, S. Investigating default mode and sensorimotor network connectivity in amyotrophic lateral sclerosis. *PLoS One* **2016**, *11*.
84. Biswal, B.; Zerrin Yetkin, F.; Haughton, V.M.; Hyde, J.S. Functional connectivity in the motor cortex of resting human brain using echo-planar mri. *Magn. Reson. Med.* **1995**, *34*, 537–541.
85. Gong, D.; He, H.; Ma, W.; Liu, D.; Huang, M.; Dong, L.; Gong, J.; Li, J.; Luo, C.; Yao, D. Functional Integration between Salience and Central Executive Networks: A Role for Action Video Game Experience. *Neural Plast.* **2016**, *2016*.
86. Gratton, C.; Sun, H.; Petersen, S.E. Control networks and hubs. *Psychophysiology* **2018**, *55*.
87. Menon, V. Large-scale brain networks and psychopathology: A unifying triple network model. *Trends Cogn. Sci.* **2011**, *15*, 483–506.
88. García, S.; Luengo, J.; Herrera, F. Data Preprocessing in Data Mining. *Intell. Syst. Ref. Libr.* **2015**, *72*.
89. Bolón-Canedo, V.; Sánchez-Marcano, N.; Alonso-Betanzos, A. Feature selection for high-dimensional data. *Prog. Artif. Intell.* **2016**, *5*, 65–75.
90. Beckmann, C.F.; Smith, S.M. Probabilistic Independent Component Analysis for

- Functional Magnetic Resonance Imaging. *IEEE Trans. Med. Imaging* **2004**, *23*, 137–152.
91. Beckmann, C.F.; Deluca, M.; Devlin, J.T.; Smith, S.M. Decomposing fMRI data using ICA. *Magn. Reson. Imaging* **2005**, *1*, 1–16.
92. De Luca, M.; Beckmann, C.F.; De Stefano, N.; Matthews, P.M.; Smith, S.M. fMRI resting state networks define distinct modes of long-distance interactions in the human brain. *Neuroimage* **2006**, *29*, 1359–1367.
93. De Martino, F.; Gentile, F.; Esposito, F.; Balsi, M.; Di Salle, F.; Goebel, R.; Formisano, E. Classification of fMRI independent components using IC-fingerprints and support vector machine classifiers. *Neuroimage* **2007**, *34*, 177–194.
94. Herrera, F.; Carmona, C.J.; González, P.; del Jesus, M.J. An overview on subgroup discovery: Foundations and applications. *Knowl. Inf. Syst.* **2011**, *29*, 495–525.
95. Lordo, R.A. Learning from Data: Concepts, Theory, and Methods. *Technometrics* **2001**, *43*, 105–106.
96. Alcalá-Fdez, J.; Flugy-Pape, N.; Bonarini, A.; Herrera, F. Analysis of the effectiveness of the genetic algorithms based on extraction of association rules. *Fundam. Informaticae* **2010**, *98*, 1–14.
97. Bishop, C.M. Classification and regression. *Handb. Neural Comput.* **2004**.
98. van Buuren, S.; Groothuis-Oudshoorn, K. mice: Multivariate imputation by chained equations in R. *J. Stat. Softw.* **2011**, *45*, 1–67.
99. Schroff, F.; Criminisi, A.; Zisserman, A. Object class segmentation using random forests. *BMVC 2008 - Proc. Br. Mach. Vis. Conf. 2008* **2008**.
100. Barbosa, P.; Kucera, J.; Strobl, P.; Vogt, P.; Camia, A.; San-Miguel-Ayanz, J. European Forest Fire Information System (EFFIS)—rapid damage assessment: Appraisal of burnt area maps in southern Europe using MODIS data (2003–2005). *For. Ecol. Manage.*

- 2006, 234, S218.
101. Langfelder, P.; Horvath, S. WGCNA: An R package for weighted correlation network analysis. *BMC Bioinformatics* **2008**, *9*.
 102. Kursa, M.B.; Rudnicki, W.R. Feature selection with the boruta package. *J. Stat. Softw.* **2010**, *36*, 1–13.
 103. García, Á.M.; Charte, F.; González, P.; Carmona, C.J.; del Jesus, M.J. Subgroup discovery with evolutionary fuzzy systems in r: The SDEFSR package. *R J.* **2016**, *8*, 307–323.
 104. Hennig, C. fpc: Flexible Procedures for Clustering. R package version 2.1-10. *R Packag. version* **2015**, *2*, <https://CRAN.R-project.org/package=fpc>.
 105. Royle, J.A.; Chandler, R.B.; Yackulic, C.; Nichols, J.D. Likelihood analysis of species occurrence probability from presence-only data for modelling species distributions. *Methods Ecol. Evol.* **2012**, *3*, 545–554.
 106. Krauss-Etschmann, S.; Shadid, R.; Campoy, C.; Hoster, E.; Demmelmair, H.; Jiménez, M.; Gil, A.; Rivero, M.; Veszprémi, B.; Decsi, T.; et al. Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: A European randomized multicenter trial. *Am. J. Clin. Nutr.* **2007**, *85*, 1392–1400.
 107. Koletzko, B.; Von Kries, R.; Closa, R.; Escribano, J.; Scaglioni, S.; Giovannini, M.; Beyer, J.; Demmelmair, H.; Grusfeld, D.; Dobrzanska, A.; et al. Lower protein in infant formula is associated with lower weight up to age 2 y: A randomized clinical trial. *Am. J. Clin. Nutr.* **2009**, *89*, 1836–1845.
 108. Jaddoe, V.W.V.; Mackenbach, J.P.; Moll, H.A.; Steegers, E.A.P.; Tiemeier, H.; Verhulst, F.C.; Witteman, J.C.M.; Hofman, A. The Generation R Study: Design and cohort profile. *Eur. J. Epidemiol.* **2006**, *21*, 475–484.

109. Pérez-García, M.; Luna, J.D.D.; Torres-Espínola, F.J.; Martínez-Zaldívar, C.; Anjos, T.; Steenweg-De Graaff, J.; Weber, M.; Grote, V.; Grusfeld, D.; Verduci, E.; et al. Cultural effects on neurodevelopmental testing in children from six European countries: An analysis of NUTRIMENTHE Global Database. *Br. J. Nutr.* **2019**, *122*, S59–S67.
110. Achenbach, T.M.; Becker, A.; Döpfner, M.; Heiervang, E.; Roessner, V.; Steinhausen, H.C.; Rothenberger, A. Multicultural assessment of child and adolescent psychopathology with ASEBA and SDQ instruments: Research findings, applications, and future directions. *J. Child Psychol. Psychiatry Allied Discip.* **2008**, *49*, 251–275.
111. Campoy, C.; Escolano-Margarit, M. V.; Ramos, R.; Parrilla-Roure, M.; Csábi, G.; Beyer, J.; Ramirez-Tortosa, M.C.; Molloy, A.M.; Decsi, T.; Koletzko, B. V. Effects of prenatal fish-oil and 5-methyltetrahydrofolate supplementation on cognitive development of children at 6.5 y of age. In Proceedings of the American Journal of Clinical Nutrition; 2011; Vol. 94.
112. Kolarovic, L.; Fournier, N.C. A comparison of extraction methods for the isolation of phospholipids from biological sources. *Anal. Biochem.* **1986**, *156*, 244–250.
113. Jakobik, V.; Burus, I.; Decsi, T. Fatty acid composition of erythrocyte membrane lipids in healthy subjects from birth to young adulthood. *Eur. J. Pediatr.* **2009**, *168*, 141–147.
114. Molloy, A.M.; Scott, J.M. Microbiological assay for serum, plasma, and red cell folate using cryopreserved, microtiter plate method. *Methods Enzymol.* **1997**, *281*, 43–53.
115. García-Minguillán, C.J.; Fernandez-Ballart, J.D.; Ceruelo, S.; Ríos, L.; Bueno, O.; Berrocal-Zaragoza, M.I.; Molloy, A.M.; Ueland, P.M.; Meyer, K.; Murphy, M.M. Riboflavin status modifies the effects of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) polymorphisms on homocysteine. *Genes Nutr.* **2014**, *9*.

116. Mills, J.L.; Lee, Y.J.; Conley, M.R.; Kirke, P.N.; McPartlin, J.M.; Weir, D.G.; Scott, J.M. Homocysteine metabolism in pregnancies complicated by neural-tube defects. *Lancet* **1995**, *345*, 149–151.
117. Klerk, M.; Verhoef, P.; Clarke, R.; Blom, H.J.; Kok, F.J.; Schouten, E.G.; Abbate, R.; Marcucci, R.; Samani, N.J.; Anderson, J.L.; et al. MTHFR 677C→T polymorphism and risk of coronary heart disease: A meta-analysis. *J. Am. Med. Assoc.* **2002**, *288*, 2023–2031.
118. Durlak, J.A. How to select, calculate, and interpret effect sizes. *J. Pediatr. Psychol.* **2009**, *34*, 917–928.
119. Filippini, N.; MacIntosh, B.J.; Hough, M.G.; Goodwin, G.M.; Frisoni, G.B.; Smith, S.M.; Matthews, P.M.; Beckmann, C.F.; Mackay, C.E. Distinct patterns of brain activity in young carriers of the APOE-ε4 allele. *Proc. Natl. Acad. Sci. U. S. A.* **2009**, *106*, 7209–7214.
120. Nichols, T.E.; Holmes, A.P. Nonparametric permutation tests for functional neuroimaging: A primer with examples. *Hum. Brain Mapp.* **2002**, *15*, 1–25.
121. Tien, J.; Lewis, G.D.; Liu, J. Prenatal risk factors for internalizing and externalizing problems in childhood. *World J. Pediatr.* **2020**, *16*, 341–355.
122. Achenbach, T.M. Achenbach System of Empirically Based Assessment (ASEBA). In *Encyclopedia of Clinical Neuropsychology*; 2018; pp. 26–33.
123. Liu, J. Childhood externalizing behavior: Theory and implications. *J. Child Adolesc. Psychiatr. Nurs.* **2004**, *17*, 93–103.
124. Park, S.; Kim, B.N.; Kim, J.W.; Shin, M.S.; Yoo, H.J.; Cho, S.C. Protective effect of breastfeeding with regard to children's behavioral and cognitive problems. *Nutr. J.* **2014**, *13*.
125. Martin, R.P.; Dombrowski, S.C.; Mullis, C.; Wisenbaker, J.; Huttunen, M.O. Smoking

- during pregnancy: Association with childhood temperament, behavior, and academic performance. *J. Pediatr. Psychol.* **2006**, *31*, 490–500.
126. Roza, S.J.; Verhulst, F.C.; Jaddoe, V.W.V.; Steegers, E.A.P.; Mackenbach, J.P.; Hofman, A.; Tiemeier, H. Maternal smoking during pregnancy and child behaviour problems: The generation R study. *Int. J. Epidemiol.* **2009**, *38*, 680–689.
127. Cornelius, M.D.; De Genna, N.M.; Leech, S.L.; Willford, J.A.; Goldschmidt, L.; Day, N.L. Effects of prenatal cigarette smoke exposure on neurobehavioral outcomes in 10-year-old children of adolescent mothers. *Neurotoxicol. Teratol.* **2011**, *33*, 137–144.
128. Ross, E.J.; Graham, D.L.; Money, K.M.; Stanwood, G.D. Developmental consequences of fetal exposure to drugs: What we know and what we still must learn. *Neuropsychopharmacology* **2015**, *40*, 61–87.
129. Rice, F.; Harold, G.T.; Boivin, J.; Van Den Bree, M.; Hay, D.F.; Thapar, A. The links between prenatal stress and offspring development and psychopathology: Disentangling environmental and inherited influences. *Psychol. Med.* **2010**, *40*, 335–342.
130. Langley, K.; Heron, J.; Smith, G.D.; Thapar, A. Maternal and paternal smoking during pregnancy and risk of ADHD symptoms in offspring: Testing for intrauterine effects. *Am. J. Epidemiol.* **2012**, *176*, 261–268.
131. El Marroun, H.; Tiemeier, H.; Franken, I.H.A.; Jaddoe, V.W.V.; van der Lugt, A.; Verhulst, F.C.; Lahey, B.B.; White, T. Prenatal Cannabis and Tobacco Exposure in Relation to Brain Morphology: A Prospective Neuroimaging Study in Young Children. *Biol. Psychiatry* **2016**, *79*, 971–979.
132. Cornelius, M.D.; Leech, S.L.; Goldschmidt, L. Characteristics of persistent smoking among pregnant teenagers followed to young adulthood. *Nicotine Tob. Res.* **2004**, *6*, 159–169.

133. Rückinger, S.; Rzehak, P.; Chen, C.M.; Sausenthaler, S.; Koletzko, S.; Bauer, C.P.; Hoffmann, U.; Kramer, U.; Berdel, D.; Von Berg, A.; et al. Prenatal and postnatal tobacco exposure and behavioral problems in 10-year-old children: Results from the GINI-plus prospective birth cohort study. *Environ. Health Perspect.* **2010**, *118*, 150–154.
134. Godleski, S.A.; Eiden, R.D.; Schuetze, P.; Colder, C.R.; Huestis, M.A. Tobacco exposure and maternal psychopathology: Impact on toddler problem behavior. *Neurotoxicol. Teratol.* **2016**, *57*, 87–94.
135. Roza, S.J.; Van Batenburg-Eddes, T.; Steegers, E.A.P.; Jaddoe, V.W.V.; MacKenbach, J.P.; Hofman, A.; Verhulst, F.C.; Tiemeier, H. Maternal folic acid supplement use in early pregnancy and child behavioural problems: The Generation R Study. *Br. J. Nutr.* **2010**, *103*, 445–452.
136. Roth, C.; Magnus, P.; Schjølberg, S.; Stoltenberg, C.; Surén, P.; McKeague, I.W.; Smith, G.D.; Reichborn-Kjennerud, T.; Susser, E. Folic acid supplements in pregnancy and severe language delay in children. *JAMA - J. Am. Med. Assoc.* **2011**, *306*, 1566–1573.
137. Schlotz, W.; Jones, A.; Phillips, D.I.W.; Gale, C.R.; Robinson, S.M.; Godfrey, K.M. Lower maternal folate status in early pregnancy is associated with childhood hyperactivity and peer problems in offspring. *J. Child Psychol. Psychiatry Allied Discip.* **2010**, *51*, 594–602.
138. Chmielewska, A.; Dziechciarz, P.; Gieruszczak-Białek, D.; Horvath, A.; Pieścik-Lech, M.; Ruszczyński, M.; Skórka, A.; Szajewska, H. Effects of prenatal and/or postnatal supplementation with iron, PUFA or folic acid on neurodevelopment: Update. *Br. J. Nutr.* **2019**, *122*, S10–S15.
139. Bergen, N.E.; Jaddoe, V.W.V.; Timmermans, S.; Hofman, A.; Lindemans, J.; Russcher, H.; Raat, H.; Steegers-Theunissen, R.P.M.; Steegers, E.A.P. Homocysteine and folate

- concentrations in early pregnancy and the risk of adverse pregnancy outcomes: The generation R study. *BJOG An Int. J. Obstet. Gynaecol.* **2012**, *119*, 739–751.
140. Di Simone, N.; Maggiano, N.; Caliandro, D.; Riccardi, P.; Evangelista, A.; Carducci, B.; Caruso, A. Homocysteine induces trophoblast cell death with apoptotic features. *Biol. Reprod.* **2003**, *69*, 1129–1134.
141. van Mil, N.H.; Oosterbaan, A.M.; Steegers-Theunissen, R.P.M. Teratogenicity and underlying mechanisms of homocysteine in animal models: A review. *Reprod. Toxicol.* **2010**, *30*, 520–531.
142. Wald, N.J.; Morris, J.K.; Blakemore, C. Public health failure in the prevention of neural tube defects: Time to abandon the tolerable upper intake level of folate. *Public Health Rev.* **2018**, *39*.
143. Campoy, C.; Escolano-Margarit, M. V.; Ramos, R.; Parrilla-Roure, M.; Csábi, G.; Beyer, J.; Ramirez-Tortosa, M.C.; Molloy, A.M.; Decsi, T.; Koletzko, B. V. Effects of prenatal fish-oil and 5-methyltetrahydrofolate supplementation on cognitive development of children at 6.5 y of age. In Proceedings of the American Journal of Clinical Nutrition; 2011; Vol. 94.
144. Campoy, C.; Escolano-Margarit, V.; Anjos, T.; Szajewska, H.; Uauy, R. Omega 3 fatty acids on child growth, visual acuity and neurodevelopment. *Br. J. Nutr.* **2012**, *107*.
145. Davis-Bruno, K.; Tassinari, M.S. Essential fatty acid supplementation of DHA and ARA and effects on neurodevelopment across animal species: A review of the literature. *Birth Defects Res. Part B - Dev. Reprod. Toxicol.* **2011**, *92*, 240–250.
146. Friesen, R.W.; Innis, S.M. Linoleic acid is associated with lower long-chain n-6 and n-3 fatty acids in red blood cell lipids of Canadian pregnant women. *Am. J. Clin. Nutr.* **2010**, *91*, 23–31.
147. Danesch, U.; Weber, P.C.; Sellmayer, A. Differential effects of n-6 and n-3

- polyunsaturated fatty acids on cell growth and early gene expression in swiss 3T3 fibroblasts. *J. Cell. Physiol.* **1996**, *168*, 618–624.
148. Makrides, M.; Smithers, L.G.; Gibson, R.A. Role of long-chain polyunsaturated fatty acids in neurodevelopment and growth. In Proceedings of the Nestle Nutrition Workshop Series: Pediatric Program; 2010; Vol. 65, pp. 123–136.
149. Jacobson, J.L.; Jacobson, S.W.; Muckle, G.; Kaplan-Estrin, M.; Ayotte, P.; Dewailly, E. Beneficial Effects of a Polyunsaturated Fatty Acid on Infant Development: Evidence from the Inuit of Arctic Quebec. *J. Pediatr.* **2008**, *152*.
150. Figueroa, J.D.; Cordero, K.; Baldeosingh, K.; Torrado, A.I.; Walker, R.L.; Miranda, J.D.; De Leon, M. Docosahexaenoic acid pretreatment confers protection and functional improvements after acute spinal cord injury in adult rats. *J. Neurotrauma* **2012**, *29*, 551–566.
151. Haubner, L.; Sullivan, J.; Ashmeade, T.; Saste, M.; Wiener, D.; Carver, J. The effects of maternal dietary docosahexaenoic acid intake on rat pup myelin and the auditory startle response. *Dev. Neurosci.* **2007**, *29*, 460–467.
152. Ward, R.E.; Huang, W.; Curran, O.E.; Priestley, J. V.; Michael-Titus, A.T. Docosahexaenoic acid prevents white matter damage after spinal cord injury. *J. Neurotrauma* **2010**, *27*, 1769–1780.
153. Stillwell, W.; Wassall, S.R. Docosahexaenoic acid: Membrane properties of a unique fatty acid. *Chem. Phys. Lipids* **2003**, *126*, 1–27.
154. Peters, B.D.; Machielsen, M.W.J.; Hoen, W.P.; Caan, M.W.A.; Malhotra, A.K.; Szeszko, P.R.; Duran, M.; Olabarriaga, S.D.; De Haan, L. Polyunsaturated fatty acid concentration predicts myelin integrity in early-phase psychosis. *Schizophr. Bull.* **2013**, *39*, 830–838.
155. Santar necchi, E.; Galli, G.; Polizzotto, N.R.; Rossi, A.; Rossi, S. Efficiency of weak brain

- connections support general cognitive functioning. *Hum. Brain Mapp.* **2014**, *35*, 4566–4582.
156. Li, L.; Abutalebi, J.; Zou, L.; Yan, X.; Liu, L.; Feng, X.; Wang, R.; Guo, T.; Ding, G. Bilingualism alters brain functional connectivity between “control” regions and “language” regions: Evidence from bimodal bilinguals. *Neuropsychologia* **2015**, *71*, 236–247.
157. Sun, X.; Li, L.; Ding, G.; Wang, R.; Li, P. Effects of language proficiency on cognitive control: Evidence from resting-state functional connectivity. *Neuropsychologia* **2019**, *129*, 263–275.
158. de Pasquale, F.; Della Penna, S.; Snyder, A.Z.; Marzetti, L.; Pizzella, V.; Romani, G.L.; Corbetta, M. A Cortical Core for Dynamic Integration of Functional Networks in the Resting Human Brain. *Neuron* **2012**, *74*, 753–764.
159. Gottlieb, J. From Thought to Action: The Parietal Cortex as a Bridge between Perception, Action, and Cognition. *Neuron* **2007**, *53*, 9–16.
160. Chand, G.B.; Wu, J.; Hajjar, I.; Qiu, D. Interactions of the Salience Network and Its Subsystems with the Default-Mode and the Central-Executive Networks in Normal Aging and Mild Cognitive Impairment. *Brain Connect.* **2017**, *7*, 401–412.
161. Smith, S.M.; Fox, P.T.; Miller, K.L.; Glahn, D.C.; Fox, P.M.; Mackay, C.E.; Filippini, N.; Watkins, K.E.; Toro, R.; Laird, A.R.; et al. Correspondence of the brain’s functional architecture during activation and rest. *Proc. Natl. Acad. Sci. U. S. A.* **2009**, *106*, 13040–13045.
162. Milnik, A.; Nowak, I.; Müller, N.G. Attention-dependent modulation of neural activity in primary sensorimotor cortex. *Brain Behav.* **2013**, *3*, 54–66.
163. Afif, A.; Trouillas, J.; Mertens, P. Development of the sensorimotor cortex in the human fetus: a morphological description. *Surg. Radiol. Anat.* **2015**, *37*, 153–160.

164. Georgieff, M.K.; Ramel, S.E.; Cusick, S.E. Nutritional influences on brain development. *Acta Paediatr. Int. J. Paediatr.* 2018, **107**, 1310–1321.
165. Mulder, K.A.; Elango, R.; Innis, S.M. Fetal DHA inadequacy and the impact on child neurodevelopment: A follow-up of a randomised trial of maternal DHA supplementation in pregnancy. *Br. J. Nutr.* **2018**, *119*, 271–279.
166. Helland, I.B.; Smith, L.; Saarem, K.; Saugstad, O.D.; Drevon, C.A. Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children's IQ at 4 years of age. *Pediatrics* **2003**, *111*.
167. Lauritzen, L.; Jørgensen, M.H.; Olsen, S.F.; Straarup, E.M.; Michaelsen, K.F. Maternal fish oil supplementation in lactation: Effect on developmental outcome in breast-fed infants. *Reprod. Nutr. Dev.* **2005**, *45*, 535–547.
168. Dobó, M.; Czeizel, A.E. Long-term somatic and mental development of children after periconceptional multivitamin supplementation. *Eur. J. Pediatr.* **1998**, *157*, 719–723.
169. Tamura, T.; Goldenberg, R.L.; Chapman, V.R.; Johnston, K.E.; Ramey, S.L.; Nelson, K.G. Folate status of mothers during pregnancy and mental and psychomotor development of their children at five years of age. *Pediatrics* **2005**, *116*, 703–708.

ANEXO

Publicaciones asociadas a esta tesis doctoral

- **Hatim Azaryah**, José Antonio García-Santos, Francisco J. Torres-Espínola, Berthold Koletzko, Miguel Pérez-García and Cristina Campoy. "**Maternal smoking during pregnancy and child behavior problems: A multicenter study from the NUTRIMENTHE EU Project.**" Submitted - Under Review
- Cristina Campoy, **Hatim Azaryah**, Francisco José Torres-Espínola, Cristina Martínez-Zaldívar , José Antonio García-Santos, Berthold Koletzko and Miguel Pérez-García. "**Long-chain polyunsaturated fatty acids, homocysteine at birth and fatty acid desaturase gene cluster polymorphisms are associated with children's processing speed up to age 9 years.**", Submitted - Under Review
- **Hatim Azaryah**, Juan Verdejo-Román, Cristina Martin-Pérez, José Antonio García-Santos, Cristina Martínez-Zaldívar, Francisco J. Torres-Espínola, Daniel Campos, Berthold Koletzko, Miguel Pérez-García , Andrés Catena and Cristina Campoy. "**Effects of Maternal Fish Oil and/or 5-Methyl-Tetrahydrofolate Supplementation during Pregnancy on Offspring Brain Resting-State at 10 Years Old: A Follow-up Study from the NUHEAL Randomized Controlled Trial**", Nutrients 2020, 12, 2701; doi:10.3390/nu12092701. IF: 4.546

Otras publicaciones relacionadas con la Tesis doctoral

- Cristina Martínez-Zaldívar, **Hatim Azaryah**, José A. García-Santos, Hans Demmelmair, Signe Altmäe, Eva Reischl, Peter Rzehak, Berthold Koletzko, Cristina Campoy and the NUHEAL team. "**Early nutrition in combination with polymorphisms in fatty acid desaturase gen cluster modulate fatty acid composition of**

cheek cells' glycerophospholipids in school-age children".
British Journal of Nutrition, 2019.

Otras colaboraciones en publicaciones durante el periodo de Doctorado

- Daniel Campos, Mireia Escudero-Marín , Camila M. Snitman , Francisco José Torres- Espínola , **Hatim Azaryah**, Andrés Catena ,Cristina Campoy, "The Nutritional Profile of Food Advertising for School- Aged Children Via Television. A Longitudinal Approach". Nutrients, Under Review 2020
- Daniel Campos, Francisco J. Torres-Espínola, **Hatim Azaryah**, Cristina Martínez-Zaldívar, Mireia Escudero Martin, Tamas Decsi, Berthold Koletzko, Cristina Campoy. "**Associations between maternal anthropometry and offspring growth during childhood**", Clinical Nutrition ,2018.
- Tomás Cerdó, Alicia Ruiz, Ruy Jáuregui, **Hatim Azaryah**, Francisco José Torres-Espínola, Luz García-Valdés, M. Teresa Segura, Antonio Suárez, Cristina Campoy. "**Maternal obesity is associated with gut microbial metabolic potential in offspring during infancy**", Journal of physiology and biochemistry, 2017.

Comunicaciones presentadas a Congresos

- Tomás Cerdó, Alicia Ruiz, Francisco José Torres-Espínola, Antonio Suarez y Cristina Campoy **Hatim Azaryah**, "Modelo Predictivo Del Desarrollo Cognitivo Infantil En Función De La Microbiota Intestinal, 66 Congreso de la AEP Junio 2018, Zaragoza
- Daniel Campos, Francisco Ortega Porcel, **Hatim Azaryah**, Cristina Campoy. "**Timing of adiposity rebound and Behaviour Problems in early Childhood**" International Symposium «ACTIVE BRAINS FOR ALL», Junio 2017, Granada